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Abstract 
COPD comprising small airways disease and emphysema is a chronic, debilitating 
often fatal lung condition that approximately 20% of smokers develop.  Current 
therapies mostly target inflammation and airflow obstruction caused by small airways 
disease however there are no current therapies which treat emphysema, the 
pathogenesis of which remains poorly understood.  The microvascular hypothesis of 
COPD is a credible alternative to the classical hypothesis of inflammation and 
protease driven lung destruction, whereby an initial insult to the microvasculature 
leads to loss of alveolar structure which typifies emphysema.  I planned to 
investigate the role of the microvasculature in the pathogenesis of COPD by isolating 
susceptible lung microvascular endothelial cells (LMVECs) from individuals with 
emphysema in an attempt to mimic in vivo conditions more closely.  LMVECs were 
isolated from explanted emphysematous lungs removed at transplantation.  
Following successful isolation (71%) and characterisation of emphysema LMVECs, I 
sought to study cellular responses to cigarette smoke injury, namely apoptosis and 
endothelial to mesenchymal transition.  Apoptosis was investigated on tissue blocks 
via caspase 3 immunohistochemistry and by ex vivo methods including flow 
cytometry (annexin V), TUNEL and live cell imaging for activated caspase 3.  
Unfortunately cigarette smoke extract caused autofluorescence of cells and as all of 
these techniques employed the use of fluorescence for detection, any conclusions 
that can be made as to whether cells underwent apoptosis are limited. Endothelial to 
mesenchymal transition was investigated in response to TGFβ1 and cigarette smoke 
extract.  While there was evidence of down regulation of endothelial markers in 
response to cigarette smoke on confocal imaging there was no convincing evidence 
of upregulation of mesenchymal markers with no corresponding change in protein 
expression via western blotting.  One explanation may be that such changes in cell 
structure and endothelial cell expression may be more in keeping with endothelial 
activation rather than a true phenotypic switch.  In summary, this study presents a 
new model of emphysema, with attempts to gain insight into endothelial injury in the 
pathogenesis of COPD, highlighting the challenges and limitations of working with 
primary diseased cells in response to cigarette smoke injury. 
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Chapter 1: Introduction 
1.1 COPD: Background 
Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death 
worldwide and a major cause of chronic disability which costs the NHS 
approximately £500 million per year [1].  This burden of disease is predicted to 
continue to increase in coming years due to both the aging population and ongoing 
exposure to the major risk factor that is cigarette smoking[2].  COPD is characterised 
by persistent airflow limitation that occurs due to inflammation of the small airways 
(bronchiolitis) and lung parenchyma, with destruction of alveolar septal walls leading 
to permanent abnormal dilation of air spaces (emphysema) [3].  Severity of COPD 
has previously been determined by degree of airflow obstruction as measured by 
FEV1, however there is marked heterogeneity among patients with COPD with poor 
correlation between FEV1, symptoms, quality of life and functional outcomes [4].  
This study however did identify that emphysema and continued smoking were the 
strongest predictors of disease progression.  Furthermore patients with emphysema 
are one of the identified subgroups of COPD who have lower survival rates and have 
higher rates of decline in lung function (as measured by FEV1) [5]–[7]..  Currently 
there are no medical therapies that target emphysema either by slowing the rate of 
septal destruction or allow alveolar regeneration.  Understanding further the complex 
pathophysiological mechanisms which lead to septal destruction may allow the 
identification of novel therapeutic targets which may translate into clinical benefits for 
this large patient population.   
 
Cigarette smoking is the leading cause of COPD, however only 20%[1]- 25%[8] of 
smokers develop this condition.  An individual’s cellular response to smoking injury is 
therefore important in the pathogenesis of emphysema, an example of the 
importance of interaction between the environment and an individual’s genes in the 
development of this condition.  This is further highlighted in susceptible individuals 
who develop COPD, in whom smoking cessation reduces the rate of loss of lung 
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function but often does not alter the natural history of the disease [9][10].  Research 
highlights that the triggered inflammatory response is amplified and persists despite 
smoking cessation [11], [12].  Despite awareness of the health risks associated with 
smoking highlighted by numerous smoking cessation campaigns, many individuals 
continue to smoke, making emphysema an ongoing major global health problem. 
 
1.2 Normal lung structure and function 
In order to understand COPD, it is important to discuss briefly normal adult lung 
structure and function [13].  The lungs are formed by ten anatomically defined 
bronchopulmonary segments which are divided into lobes, three on the right (upper, 
middle and lower) and two on the left (upper and lower).  The bronchial tree 
comprises the trachea, bronchi, bronchioles, alveolar ducts and alveolar sacs and is 
further subdivided into conducting airways (trachea, bronchi and bronchioles >2mm) 
and acinus/terminal respiratory unit (respiratory bronchioles and alveoli) which is the 
site of gas exchange.  Alveoli comprise flattened type I pneumocytes with 
interspersed rounded surfactant producing type II pneumocytes.  In close apposition 
to these specialised alveolar epithelial cells, lies the basement membrane and 
interstitial matrix, comprising elastin fibres.  This matrix provides a supporting 
structure for the alveolar-capillary unit while permitting free exchange of oxygen and 
carbon dioxide to facilitate gas exchange.   
 
The lungs have a dual arterial blood supply, being supplied both by the pulmonary 
arteries and the bronchial arteries which arise from the thoracic aorta and transport 
nutrients to the large airways and vessels [14].  The pulmonary arteries transport 
deoxygenated blood from the right heart to the capillary bed where gas exchange 
takes place.  Blood returns to the left heart via the pulmonary veins.  The pulmonary 
arteries branch similarly to the bronchial tree, with large capacitance vessels, 
muscular conducting vessels and smaller intra-acinar arterioles, which are found in 
close apposition to the respiratory bronchioles, to allow gas exchange.  The 
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pulmonary capillaries are found most distally in the alveolus, and have a vast surface 
area (~75-250m2) to allow effective transfer of oxygen and carbon dioxide[14]. 
 
1.3 COPD: clinical and pathological findings 
COPD was classically described as chronic bronchitis, a clinical diagnosis based 
upon symptoms (cough productive of sputum for 3 consecutive months over 2 
successive years), and emphysema, the histopathological finding of thin, dilated 
alveolar septa [15].  However, chronic bronchitis has almost entirely disappeared 
from the COPD literature, and is now best regarded as a distinct clinical entity which 
can occur in the presence of normal lung function or precede or follow airflow 
obstruction [3].  Small airways disease (bronchiolitis) was subsequently identified as 
the predominant site of airflow obstruction in COPD in 1968 [16].  The mainstay 
treatment options of inhaled corticosteroids, β2 agonists, anti-muscarinics and 
mucolytics attempt to treat the airflow obstruction that occurs predominantly as a 
result of small airway bronchiolitis [17], however there are currently no drug 
therapies for emphysema.  Lung volume reduction surgery, to reduce dynamic 
hyperinflation, and endobronchial techniques, which aim provide local volume 
reduction strategies, are somewhat crude attempts to treat emphysema [18].   
 
A unique proposition would be to abandon the old theories that emphysema is simply 
loss of lung tissue and replace them with the more challenging theory that within 
severely damaged emphysematous lungs there are areas of near normality in close 
proximity to emphysematous areas and also regions of alveolar bed with intense 
attempts to repair and replace lost tissue.  Regarding emphysema as a dynamic 
disease with active attempts at alveolar repair, rather than simply loss of lung tissue, 
allows speculation that these attempts at repair could be exploited and targeted to 
stimulate and allow reversal/ regeneration of emphysematous lung tissue. 
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1.4 Emphysema 
Emphysema, classically defined as abnormal permanent destructive dilation of 
airspaces distal to the terminal bronchioles [15], can be sub classified into four 
radiological and pathological entities [19]–[21].  Centrilobular emphysema is the 
commonest form observed and is that most closely associated with cigarette 
smoking.  As the name suggests it occurs predominantly in the respiratory 
bronchioles in the centre of the lobule.  Panacinar emphysema involves all airspaces 
distal to the terminal bronchioles and is found most commonly, but not exclusively, in 
patients with alpha-one antitrypsin deficiency who develop accelerated emphysema 
in association with cigarette smoking.  Paraseptal emphysema (distal acinar) 
involves the most peripheral air spaces adjacent to the pleura.  If greater than 10mm 
in diameter these are termed bullous.  Irregular emphysema, as the term suggests, 
irregularly affects the respiratory acinus and is found in association with scarring.  
Irregular emphysema does not tend to occur in association with cigarette smoking 
and rather should be considered as gas trapping in association with fibrosis [21].  
These phenotypes are however an oversimplification with most patients with 
advanced COPD displaying a combination of emphysema together with secondary 
traction bronchiectasis/ bronchial dilation and small airway fibrosis.  
 
1.5 Bronchiolitis and small airways disease 
Persistent exposure to cigarette smoke is associated with airway inflammation and 
subsequent tissue remodeling, comprising goblet cell proliferation and hypertrophy, 
airway thickening and luminal narrowing [22].  This involves complex orchestration of 
epithelial cells, endothelial cells, fibroblasts, neutrophils, macrophages and T cells.  
Small airway pathology in COPD was examined and reported by Hogg et al using 
lung tissue from patients at risk of COPD and those diagnosed with COPD (GOLD 
grades 1-IV) [12].  This work demonstrated increasing luminal occlusion with 
increased GOLD grade, increased airways inflammatory cells with increasing GOLD 
grade and increased airway wall thickness with increasing GOLD grade, concluding 
that progression of COPD is associated with luminal narrowing by mucus infiltrates 
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and increasing airway inflammation and was most strongly associated with 
thickening of the airway wall and component parts by a repair or remodeling process.   
 
1.6 Heterogeneity in COPD 
COPD encompasses a broad clinical and pathological spectrum of disease, with the 
majority of patients displaying a heterogeneous combination of emphysema and 
airways disease.  While small airways disease (narrowing and loss of terminal 
bronchioles) has been shown to precede emphysema in COPD [23], some patients 
exhibit marked emphysema without evidence of airflow obstruction and limited small 
airways involvement, highlighting further the broad spectrum of disease.  
 
The development and existence of these two distinct pathological processes 
following the same injury process (i.e. cigarette smoking) highlights the importance 
of regional variation in inflammatory response in determining the resulting pathology 
which leads to COPD in a given individual [22].  Why such disparate processes of 
small airway thickening and destructive emphysema occur in such close proximity 
poses a real challenge to researchers.  Such heterogeneity presents further 
challenges to the study of this disease as effectively the disease witnessed within a 
given individual is unique to them and thus they may not respond to all therapies in a 
predictable manner. The acceptance of the broad heterogeneity and the attempt to 
phenotype patients within the COPD spectrum is thus crucial in order to understand 
and develop new strategies for this condition.  
 
1.7 Classical hypothesis of COPD: Inflammation and Protease/ 
Antiprotease imbalance 
A large proportion of research into COPD has focused on the role of inflammation 
and imbalance between proteases which break down connective tissue elements 
and anti-proteases that protect against this [24], [25].  Chronic exposure to cigarette 
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smoking leads to recruitment of inflammatory cells into the alveolar spaces.  
Neutrophils and macrophages release elastolytic proteinases which cause 
destruction of elastin and the lung extracellular matrix [26].  This hypothesis was 
largely founded upon the observation of accelerated emphysema in individuals with 
alpha-one antitrypsin (A1AT) deficiency, who have reduced levels of the major 
neutrophil elastase inhibitor A1AT.  Individuals with A1AT deficiency tend to, 
although not exclusively, develop panacinar emphysema which differs from the more 
common centrilobular pattern witnessed in smokers with normal levels of A1AT.  
However other proteases and inflammatory cells also play an important role as 
witnessed by the development of very severe emphysema in individuals without 
A1AT deficiency.  A1AT replacement therapy does not altering disease progression 
[27] thus researchers have revisited alternative hypotheses of emphysema. 
 
1.8 Alternative Hypothesis of COPD: The role of the 
microvasculature 
The microvascular hypothesis of COPD dates back to the 1950s when Liebow 
identified paucity of pulmonary capillaries in emphysema and hypothesised that 
reduced blood supply was important in the pathogenesis of this condition [28].  A 
revival of this hypothesis has been based upon an emerging literature on the 
importance of the pulmonary microvasculature in maintaining lung structure and 
function [29], [30].  Damage to endothelial cells via cigarette smoking injury, similar 
to that which occurs in the systemic circulation, initiates a complex injury and repair 
pattern that may lead to emphysema[31]. 
 
Factors which lead to loss of the microvasculature are however unclear.  Cigarette 
smoking causes endothelial dysfunction in the systemic circulation, with imbalance of 
nitric oxide (NO), endothelin-1 (ET-1) and other vasoactive substances, and is 
implicated in the pathogenesis of ischaemic heart disease [32]–[34].  Endothelial 
dysfunction also occurs in the pulmonary microvasculature [14].  In response to a 
chronic injury such as cigarette smoking, cells may undergo necrosis, apoptosis, 
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senescence or a phenotypic change.  In emphysema, apoptosis and a phenotype 
change of endothelial cells into mesenchymal cells (endothelial to mesenchymal 
transition) may explain both the loss of alveolar septal capillaries and alveolar septal 
remodelling that occurs in emphysema.  I therefore planned to investigate apoptosis 
and EnMT in response to cigarette smoke with microvascular endothelial cells 
isolated from patients with emphysema.  
 
The initial stress/injury leading to the development of emphysema is most commonly 
cigarette smoking, however the initiating event in emphysema remains unknown.  
This largely relates to poor understanding of the natural history of this condition.  
Some have proposed inflammation of the respiratory bronchioles (bronchiolitis)[12] 
whereas other have suggested a primary hit to the alveolar bed [35], with secondary 
inflammation.  Liebow was the first to comment that the septa appeared almost 
avascular and further studies have confirmed that there is attenuation of the 
capillaries in this disease[36]. 
 
A major stumbling block to tackling emphysema is the belief that loss of alveoli is a 
terminal event and that neo-angiogenesis and re-alveolarisation are impossible.  
However alveolarisation already occurs in life, albeit in the first 2-3 years of life[37].  
Understanding initial lung development may therefore assist us in understanding of 
how the lung repairs itself and how we may manipulate this knowledge to develop 
therapeutics to target the smoking related lung damage that occurs in emphysema. 
 
1.9 Lung development 
Lung development in utero occurs in five overlapping stages: embryonic, 
pseudoglandular, canalicular, saccular and alveolar [37]–[39].  In the embryonic 
stage the lung primordium is formed from the foregut.  Lobar airways lined with 
endoderm are formed within the surrounding mesenchyme.  The pseudoglandular 
stage follows with the formation of all preacinar airways via branching of epithelial 
8 
 
lined primitive airways.  In the canalicular stage, the most distal airways enlarge with 
thinned epithelial cells which eventually form type I and II pneumocytes.  Surfactant 
is detectable from 24 weeks gestation indicating successful differentiation into type II 
pneumocytes.  During the saccular stage the enlarged distal airways develop crests 
with elastin and muscle which extend to form cup shaped alveoli.  Alveolarisation 
begins at 36 weeks gestation with the formation of secondary septa subdividing 
terminal saccules to form mature alveoli.  This process continues until 2-4 years of 
age, thus highlighting the potential for alveolarisation in adult life and challenging the 
theory that emphysema is an irreversible process. 
 
Furthering the link with the developing lung, alveolar enlargement similar to that in 
emphysema is witnessed in survivors of bronchopulmonary dysplasia (BPD), the 
chronic lung disease that occurs in premature infants (especially those born at less 
than 28 weeks, during the late canalicular or saccular stage of lung development) 
[40].  BPD is thought to occur due to the disruption of alveolar development that 
occurs with premature birth, with survivors attaining reduced maximal airway 
function, with the development of fewer larger alveoli with corresponding smaller 
surface for gas exchange in contrast to the loss of alveoli that occurs in COPD [41].  
Although BPD may appear disparate from COPD, occurring at the extremes of life, 
understanding alveolar development may allow targeted treatments for both of these 
conditions [40].  Investigation of BPD has led researchers to suggest that the 
pulmonary vasculature actively promotes alveolar growth during development and 
may play a crucial role in maintenance in postnatal life, challenging the conventional 
hypotheses that the development of blood vessels in the lung passively follows that 
of airways [42][43].   
 
1.10Endothelial cells and the alveolar interface 
The unique high flow, low pressure pulmonary circulation exists to effectively 
facilitate gas exchange between the air and lungs.  This vast surface area 
(approximately 75-200m2) functions in healthy individuals with large reserve[14].  
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This reserve within capillaries allows the lungs to accept high pulmonary blood flow 
without compromising gas exchange.  High blood flow does however not equate with 
high blood volume as only 10% of total blood volume is within the lungs at any time, 
of which only 10-15% is in the pulmonary capillary bed (less than 100ml)[14].   In 
time of increased demand, such as exercise, there is recruitment of pulmonary 
capillaries as cardiac output increases to accommodate increased flow.  Other 
functions of the pulmonary vascular bed include acting as a filter for blood clots, 
vasoactive substances and as a possible area of leucocyte sequestration.  Loss of 
this vast capillary bed as is thought to occur in emphysema has therefore many 
consequences.  
 
Endothelial cells form a physical barrier to the passage of molecules contained within 
blood to the tissues.   This is however an oversimplified view of the endothelium, 
which should not be regarded as a passive barrier, rather as an active interface 
where important metabolic processes occur which preserve vascular integrity and 
function[14]. The alveolar endothelium is unique in that it functions to allow gas 
exchange efficiently while minimising extravasation of fluid and substances into the 
alveolar bed.  This unique property is made possible by intercellular junctions which 
regulate endothelial cell permeability.  Four types of endothelial cell junctions are 
well described; tight junctions, gap junctions, adherens junctions and 
syndesmos[44].  Tight junctions are formed by occludins, which are a 
transmembrane integral proteins found between endothelial cells[45].  The frequency 
of tight junctions varies according to location in the vascular tree based upon the 
degree of permeability required, for example in large arteries they are numerous 
while in post capillary venules they are almost absent.  Gap junctions are formed by 
transmembrane hydrophilic channels termed connexons which allow exchange of 
ions and small molecules between adjacent cells[44].  Gap junctions tend to 
colocalise with tight junctions and support cellular communication between both 
endothelial cells and their supporting cells.  Adherens junctions are formed by 
cadherins, which are single chain transmembrane calcium proteins[46].  Endothelial 
cells express both specific and nonspecific cadherins.  VE-cadherin is found 
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exclusively on intercellular junctions of all endothelial cells[47].  Cadherins only 
localise at intercellular adherens junctions when cells contact each other.   
 
Platelet endothelial cell adhesion molecule (PECAM-1) also known as cluster of 
differentiation 31 (CD31) is a protein which belongs to the immunoglobulin family that 
is expressed by endothelial cells, platelets and leucocytes[48].  PECAM-1 can form 
homotypic bonds with PECAM-1 from neighbouring cells or can attach to 
glycosaminoglycans, and is widely used in histopathology as an endothelial marker.  
When endothelial cells are confluent, PECAM1 localises to the lateral edge of cells 
and appears to associate with adherens junctions, albeit with less affinity [47].  
PECAM1 is important for angiogenesis, vascular injury repair and control of 
leucocyte extravasation with expression in influenced by the cellular milieu.  For 
example, treatment of endothelial cells with TNFα redistributes PECAM-1 away from 
lateral cell surface borders with transmigration of leucocytes across the 
endothelium[49].  Maintenance of endothelial barrier integrity is critical to tissue 
health with disruption of the alveolar endothelium manifesting acutely as alveolar 
oedema as witnessed in pulmonary oedema and acute lung injury.  Chronic insult to 
the endothelial barrier may lead to hyalinisation, fibrosis or necrosis/apoptosis and is 
the study of this thesis with reference to cigarette smoking injury. 
 
1.11VEGF and the Lung 
Vascular Endothelial Growth Factor (VEGF) is a growth and permeability factor for 
endothelial cells [50].  It has an important role in vascular development in utero, 
underlined by the embryonic lethality of knockout models for the genes encoding 
VEGF and its receptors[51], however its normal biological activity in adult life is 
currently not fully understood.  The lung has comparatively high expression of this 
growth factor and over the last ten years it has emerged that VEGF may play a 
crucial role in maintaining lung structure and function, with a number of pulmonary 
pathologies associated with both reduced and increased levels of VEGF [50].   
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In pulmonary arterial hypertension the typical angioproliferative plexiform lesions 
have very high levels of VEGF which suggests this growth factor may play a pivotal 
role in pathogenesis[52].  Increased levels of plasma VEGF have been found in 
patient with Acute Respiratory Distress Syndrome (ARDS)[53]and may mediate 
barrier dysfunction and endothelial permeability with alveolar engorgement.  In 
emphysema, there appears to be reduced VEGF and VEGFR2[54], however there 
are also reports of increased VEGF within in the airways of patients with chronic 
bronchitis[55], thus within the same disease state regional variations in VEGF may 
exist and may explain the complex pathology witnessed in COPD[56].   
 
Five family members (VEGF (a-d) and Placental Growth Factor (PlGF)) have been 
identified, with VEGFa (referred to as VEGF) the most biologically active member 
that is believed to be of greatest importance[50].  VEGF binds to 2 tyrosine kinase 
receptors, VEGF receptor 1 (FLT1) and VEGF receptor 2 (KDR/FLK1) [57].  These 
receptors are regulated by both autocrine and paracrine mechanisms.  The 
KDR/FLK1 is the most studied which is thought to mediate most of the pro-
angiogenic effects of VEGF.  The FLT1 receptor is believed to play more of a 
modulatory role, acting as a decoy receptor to inhibit excessive proliferation.  VEGF 
is produced by macrophages and type II pneumocytes and acts predominantly on 
endothelial cells and type II cells [50].  Withdrawal of VEGF leads to endothelial cell 
apoptosis in vitro and in vivo[57].  Endothelial cells appear more susceptible to the 
effects of VEGF as cultured type II pneumocytes are exposed to VEGFR blockade 
do not undergo cell death [50].   
 
The gene which encodes VEGF is located on chromosome 6p21.3, with expression 
regulated by several factors including hypoxia, via hypoxia-inducible factor 1 (HIF-1) 
[58].  HIF-1 is a heterodimer composed of 2 subunits HIF-1α and HIF-1β.  Both 
proteins are constitutively expressed, however only HIF-1α responds to changes in 
oxygen tension.  Under normoxic conditions, the half-life of HIF-1α is less than 5 
minutes due to continuous proteolysis through the ubiquitin-proteasome pathway via 
an oxygen-dependant degradation domain (ODD).  Hypoxia slows degradation of 
HIF-1α via reduced proline hydroxylase, making HIF-1α resistant to degradation.  
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Thus in the presence of low oxygen tension, increased HIF-1 binds to a hypoxia-
responsive element (HRE) on the VEGF promoter region to cause induction and 
stabilisation of VEGF mRNA.      
 
VEGF has multiple effects on endothelial cells including activation of endothelial 
Nitric Oxide Synthase (eNOS), via c-Src and phospholipase C γ1, which mediates 
angiogenesis and produces NO with vasorelaxation and maintenance of endothelial 
function [50].  VEGF also leads to increased cellular proliferation and survival (via 
activation of bcl2 and inactivation of caspase 9 and Bad), prostacyclin production 
(via activation of prostacyclin synthase via MAPK) and increased vascular 
permeability [50], [59].  Thus reduced VEGF via cigarette smoking may not only 
cause imbalance between vasoactive substances such as NO and ET-1, but may 
induce apoptosis and reduce angiogenesis and may therefore be of great 
importance in emphysema.  
 
1.12 Apoptosis 
Apoptosis was first described in by Kerr, Wyllie and Currie in 1972 as a programmed 
cell death, distinct from necrosis, which is a passive uncontrolled form of cell death 
usually precipitated by lack of cellular energy or membrane damage [60].  Apoptosis 
differs from necrosis in that this programmed cell death requires energy in the form 
of ATP and can be triggered by a number of different stimuli.  The distinct 
morphological and cellular changes of apoptosis were described from observing the 
development of the nematode caenohabditis elegans.  The deletion of cells during 
development of the nematode was shown to an active, energy dependant process, 
triggering a number of stereotyped responses that were highly conserved across the 
species.  Apoptosis has since been shown to be an important factor in both 
development and in normal tissue homeostasis however has also been 
demonstrated to be a response to injury[61]. 
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Apoptosis begins with cell shrinkage and pyknosis of the nuclei, as a result of 
chromatin condensation[61].  This can be visualised with haemotoxylin and eosin 
staining and light microscopy as single cells or small clusters of oval cells which 
appear dark due to eosinophilic cytoplasm and dense nuclear chromatin fragments.  
Thereafter, plasma membrane blebbing occurs with karyorrhexis and fragmentation 
into apoptotic bodies during a process termed budding.  Apoptotic bodies are then 
phagocytosed by macrophages and degraded within phagolysosomes.   
 
In response to injury, cells may undergo necrosis, apoptosis, senescence or a 
phenotype change.  However not all cells in a population will respond in the same 
way to a specified stimulus.  Some may undergo necrosis while others undergo 
apoptosis.  These responses may happen independently, successively or 
simultaneously.  Furthermore, the cellular pathways by which apoptosis may be 
triggered are numerous, being broadly split into the intrinsic and extrinsic pathway 
which merge to form a final common pathway leading to the pattern observed in 
programmed cell death.  To further add complexity, the same stimulus may cause 
differing responses at different doses i.e. apoptosis at low dose and necrosis at high 
dose.  
 
While clear differences exist between the active energy dependant apoptosis and 
passive cellular necrosis, these processes can co-exist with the balance of 
apoptosis/ necrosis determined by availability of apoptosis associated caspase 
enzymes and energy (ATP).  Thus not only is cell death dependant upon stimuli, cell 
signaling and tissue, but rather depends crucially upon the local environment in 
which the injury occurs.  Necrotic cells can also undergo blebbing, with membrane 
disruption and pyknosis and so is not a feature exclusive to apoptosis, therefore it is 
important to highlight other features which may differentiate these two processes[61].  
In contrast with necrosis, where large numbers of cells are deleted, apoptotic cells 
are more likely to be found as individual cells, as the host deletes only cells which 
are deemed to be defective.   Another important contrast with necrosis is that 
apoptosis does not lead to secondary inflammation, as cells do not release their toxic 
contents prior to being phagocytosed and digested[61].  Thus while individual 
14 
 
morphological changes between necrosis and apoptosis on occasions can appear 
similar, by studying the distribution of lesions andmicroenvironment in which these 
are found, one can differentiate between these two differing cell death pathways. 
 
There are two main apoptotic pathways: the extrinsic (death receptor pathway) and 
the intrinsic (mitochondrial pathway).  These pathways were traditionally thought to 
be distinct and mutually exclusive, however new evidence suggests that these 
pathways are linked and that molecular events in one may influence events in 
another[61].  In addition to the two classical pathways, there exists an additional 
mechanism involving T-cell mediated cytotoxicity and perforin-granzyme-dependant 
cell death[62].  The pathways merge to form a final common pathway with the 
cleavage and activation of caspase-3 with resulting DNA fragmentation, degradation 
of proteins and phagocytic uptake.  Phagocytosis involves translocation of 
phosphatidylserine onto the surface of apoptotic cells which then acts as phagocytic 
receptors, facilitating recognition, engulfment and disposal. 
 
The extrinsic pathway or death ligand pathway is triggered mostly by TNFα, Fas 
ligand and TRAIL (TNFα-related apoptosis inducing ligand).  Autophosphorylation of 
intracellular death domains, lead to recruitment of the FADD (fas associated death 
domain).  Upon activation of FADD, procaspase 8 and 10 are cleaved to form their 
active caspases, which transmit this apoptotic signal via further caspase activation to 
the mitochondria.  The intrinsic pathway is triggered via damage to DNA such as 
oxidative stress and UV light.  DNA damage causes activation of p53, which induces 
cell cycle associated genes.    
 
1.13 Endothelial Apoptosis in Emphysema 
Apoptosis was first suggested to be important in the pathogenesis of COPD in the 
landmark study by Kasahara et al [63].  Chronic treatment (3 weeks) of adult Sprague 
dawley rats with a VEGF receptor blocker (SU5416) led to air space enlargement 
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associated with alveolar septal apoptosis.  Lung proliferation was not inhibited.  
Barium gelatin angiograms from autopsy studies of these animals showed peripheral 
pruning of the arterial tree, with pronounced loss of the microvasculature.  Treatment 
of rats with SU5416 and a caspase inhibitor prevented the alveolar septal apoptosis 
and development of air space enlargement, thus proposing that this VEGF receptor 
blockade model of emphysema was apoptosis dependant.  A clinical study by the 
same group reported increased apoptotic endothelial and epithelial cells in the 
alveolar septa of emphysematous lung tissue when compared with tissue from non-
smokers and smokers without emphysema via TUNEL staining and DNA ligation 
assays [54].  VEGF and VEGF receptor 2 mRNA and protein were also reduced in 
tissue from patients with emphysema.  However SU5416 treated rats also had an 8 
fold increase in isoprostane levels and 100 fold induction of cytochrome p450, both 
of which could catalyse the production of reactive oxygen species (ROS) in 
endothelial cells and contribute to apoptosis. 
 
Apoptosis in emphysematous tissue has been investigated by other researchers with 
similar findings, with apoptosis rates between 1 and 2% of alveolar cells[64]–[67].  
Yokohori et al reported increased rates of apoptosis and proliferation in alveolar 
septal epithelial cells in patients with emphysema compared to asymptomatic 
smokers and non-smokers [67].  In addition, they highlighted the dynamic nature of 
emphysema, with ongoing alveolar cell death and proliferation. In this study the 
predominant cell type undergoing apoptosis was epithelial cells and not endothelial 
cells.  Imai et al demonstrated apoptosis of septal endothelial, epithelial and 
myofibroblasts in emphysematous tissue via cell morphology showing cytoplasmic 
condensation, shrinkage, condensation of nuclear chromatin of cells next to normal 
cells on electron microscopy [64].  These findings were confirmed via DNA 
fragmentation and apoptosis-related protein expression.  Proliferation rates of septal 
cells were also increased, similar to the findings of Yokohori et al [67].  Furthermore, 
they reported a negative correlation between surface area and apoptosis, while there 
was no such relationship between surface area and proliferation.  This finding may 
be crucial, as in order for tissue to be lost, apoptotic rates must exceed rate of 
ongoing proliferation to not support maintenance of normal tissue structure.  Imai et 
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al also investigated the pathways via which apoptosis may be initiated [64].  The 
anti-apoptotic bcl2 was not found in emphysematous or normal tissue.  However the 
pro-apoptotic Bax and Bad were.  Bax expression is increased when cells die by loss 
of adhesion to the extracellular matrix (ECM).  Thus apoptosis may be triggered by 
disruption of the ECM with increased caspase 3.  There is also some evidence that 
apoptosis may be triggered by activation of cell surface death receptors via the Fas 
ligand [68].  Importantly, these authors highlight that increased apoptotic rates 
persist on smoking cessation [64].   
 
It has also been reported that A1AT may have anti-apoptotic actions which may 
partly explain the accelerated emphysema witnessed in individuals homozygous for 
the PiZ allele.  Petrache et al showed in vitro and in vivo in a mouse model that 
A1AT prevented caspase-3 activation and thus apoptosis [69], [70].  Such evidence 
further supports the key role apoptosis may play in the development of emphysema.  
 
1.14Apoptosis and Oxidative Stress 
Tuder et al went on to link increased levels of oxidative stress and apoptosis in the 
rodent VEGF blockade model of emphysema [71].  Oxidative stress is a highly 
relevant stress in emphysema as cigarette smoke contains around 1017oxidants for 
each inhalation [72].  SU5416 treated rats had increased levels of oxidative stress 
compared with control animals [71].  Co-treatment of SU5416 treated rats with the 
manganese superoxide dismutase (MnSOD) mimetic M40419 prevented the 
development of air space enlargement and emphysema.  In addition, 
M40419/SU5416 treated rats had less activated caspase 3 and TUNEL positive 
cells, than SU5416 treated alone.  Caspase 3 was localised in the centrilobular 
region, the area in which most airspace enlargement occurred in SU5416 treated 
rats and which is the area most affected in smoking related emphysema.  Co-
treatment also significantly increased proliferation rates, as evidenced by the marker 
PCNA.  SU5416 treated rats demonstrated reduced phosphorylation of the pro-
survival akt, whereas higher levels were evident in co-treated animals.  Apoptosis 
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predominated in areas of oxidative stress, which supports the hypothesis of 
apoptosis and oxidative stress being linked by a positive feedback mechanism.  
 
A second animal model supports the role of oxidative stress in the development of 
emphysema [73].  Nrf-2 deficient mice have reduced anti-oxidant abilities due to their 
lack of Nrf-2 which binds to anti-oxidant response elements and leads to 
upregulation of anti-oxidant genes and gene products.  Nrf-2 deficient mice exposed 
to cigarette smoke for 6 months developed emphysema, associated with increased 
markers of oxidative stress and increased numbers of apoptotic septal cells, 
compared to wild types.  In keeping with the microvascular hypothesis of 
emphysema, endothelial cells were the predominant apoptotic cell type in this model 
of smoking induced emphysema.  
 
Clinical studies also support this hypothesis linking the importance of oxidative stress 
and reduced VEGF on microvascular function, as a possible mechanism of 
emphysema.  Kanazawa et al showed that nitrogen oxide levels were increased in 
sputum from patients with COPD and correlated with severity [74].  In addition, 
peroxynitrite stress increased with severity of COPD while VEGF levels decreased.  
Induced sputum also showed increased neutrophils and levels of the pro-
inflammatory cytokine IL8, which in addition has been shown to induce superoxide 
anion release from neutrophils in vitro.    
 
There are a number of possible interactions between loss of VEGF, witnessed in 
emphysema, and oxidative stress that results due to cigarette smoking.  VEGF 
upregulates the anti-oxidant MnSOD and the anti-apoptotic factor bcl-2 [71].   VEGF 
signalling inhibition may lead to further oxidant/antioxidant imbalance via decreased 
eNOS and prostacylin synthase.  In addition, cigarette smoke may have a direct 
effect on the endothelium, reducing eNOS and prostacylin synthase, with less Nitric 
Oxide to scavenge free radicals and block caspase activity, with reduced 
Prostacyclin derived glutathione [50].  Thus interruption of the feedback loop 
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between oxidative stress and apoptosis or free radical scavengers may represent 
novel targets to prevent further septal destruction.  
 
1.15Senescence 
Cellular senescence, first described in 1961, is the phenomenon by which normal 
diploid cells cease to divide and is classically attributed to the aging process as a 
result of telomere shortening [75].  In addition, senescence can also be induced by 
DNA damage caused by reactive oxygen species (ROS) and activation of 
oncogenes [75]. Senescent cells are unable to replicate but remain metabolically 
active and frequently express pro-inflammatory ligands and stain positively for 
senescence associated β-galactosidase activity [76].  Thus in addition to potentially 
limiting tissue repair and renewal, senescent cells may further contribute to organ 
damage.  Given that COPD is more commonly found with advancing age [3] and that 
emphysema (often called senile emphysema) can be found incidentally on HRCT 
scanning of elderly patients who have never smoked and who have normal lung 
function, it has been proposed that cellular senescence may play an important role in 
the pathogenesis of COPD.  Senile emphysema does differ in that alveolar spaces 
are enlarged with loss of elastic recoil, however unlike true emphysema there is no 
destruction of alveolar walls [77], [78].  One mechanism by which senescence may 
play a role in emphysema is by limiting the ability of damaged alveolar cells to 
continue to proliferate in response to injury, thus imposing a finite number of 
divisions that a single cell can make.  Once cellular senescence occurs, cell 
proliferation attempts to repopulate apoptotic alveolar cells ceases and the 
homeostasis between cell death and proliferation is lost, which may in part account 
for emphysema [79], [80].  Studies to date have furthermore shown accelerated 
senescence of alveolar epithelial and endothelial cells in patients with emphysema 
[79].  Detailed study of senescence is beyond the scope of this study but this 
response to cell injury should be considered when interpreting results.    
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1.16Repair and remodeling in emphysema 
Emphysema was originally defined as “destruction of alveolar walls without fibrosis” 
[15], however it is now accepted that complex tissue remodelling occurs, notably in 
centrilobular disease.  The ability to repair a tissue after injury is an inherent property 
of all tissues.  In addition to septal destruction, attempts at, albeit ineffective, tissue 
repair, are important in the pathology witnessed [24], [25], [81]–[84].  The interplay 
between inflammation and repair/ fibrosis may be of greater importance in 
centrilobular emphysema, the disease pattern witnessed in smokers, compared with 
the more uniform destructive pattern of panacinar emphysema seen more commonly 
in A1AT disease [24].  In centrilobular emphysema, while there is loss of overall 
tissue, thickening of the interstitium occurs, with collagen deposition in alveolar 
septal walls and increased interstitial fibroblasts [84].  Gosselink et al reported 
differential gene expression between bronchiolar and immediate surrounding lung 
tissue, with the balance reported to be in favour of degradation of lung tissue 
surrounding thickened small airways [85].  However, in both this study [85] and 
others [86] ECM-related genes have been shown to be upregulated in severe 
emphysema in support of connective tissue remodelling in severe ‘end-stage’ 
disease in humans.  Vlahovic et al demonstrated morphometrically that while 
alveolar and capillary surfaces reduce with increased mean linear intercept, there 
was deposition of collagen and elastin in the remaining septa, in keeping with 
remodelling of the connective tissue matrix in alveolar walls [84].  Kononov et al 
showed in the pancreatic elastase model of emphysema that the resulting thickened 
elastin and collagen fibres undergo larger distortions than normal tissue [87].  
Mechanical failure threshold for collagen is also reduced, such that the normal 
mechanics of breathing are sufficient to cause failure of the remodelled ECM that 
contributes to emphysema [88].  This immature collagen may be weaker and more 
distensible that allows distension of airspaces and breaks may cause emphysema.  
In keeping with the microvascular hypothesis of COPD, these changes may occur 
via endothelial to mesenchymal transition (EnMT) with the production of immature 
weak collagen and mesenchymal cells that secrete matrix metalloproteinases 
(MMPs) which further degrade alveolar septa and ECM.   
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1.17Endothelial to Mesenchymal Transition (EnMT) 
Endothelial to mesenchymal transition (EnMT) is a cellular response to chronic injury 
characterised by cytoskeletal rearrangement of cobblestone like endothelial cells into 
spindle shaped mesenchymal cells[89].  Cells lose endothelial markers and gain 
mesenchymal markers and may exhibit a proliferative and invasive phenotype, 
interacting with the ECM, causing deposition of collagen.  EnMT was first observed 
in aortic endothelial cells in response to Transforming Growth Factor β1 (TGFβ1) 
and was proposed as a novel mechanism in atherosclerosis [89].  While this 
phenomenon was initially reversible, after prolonged exposure, cells lost this 
plasticity.  Frid et al later demonstrated this phenomenon in mature endothelial cells 
from main pulmonary arteries [90].  This EnMT was inhibited by TGFβ1 neutralising 
anti-bodies, underlining the importance of TGFβ1 as a driver of EnMT.   
 
Ziesberg and Kalluri went on to propose evidence of in vivo EnMT occurring in 
response to TGFβ1 in cardiac fibrosis via lineage tracing [91]. They created double 
transgenic mice (Tie1Cre;R26RstoplacZ), which express the lacZ gene in all cells of 
endothelial origin in spite of phenotypic alterations.  Via this method they showed the 
appearance of mesenchymal cells within the areas of tissue fibrosis that were lacZ 
positive and thus of endothelial lineage.  They presented further evidence in support 
via immunofluorescence with double labelling for β-galactosidase (βgal) and 
fibroblast specific protein 1 (FSP1 or S100A4).  The use of β-galactosidase in this 
experiment to indicate cells of endothelial origin is confounded by the fact that β-
galactosidase is commonly used as a marker of senescence [92], as it is highly 
expressed and accumulated is lysosomes in senescent cells.  The authors do not 
raise this issue or discuss the potential that the endothelial cells that appear to 
undergo EnMT may have been senescent.  This further highlights the fact that 
cellular senescence may be important in the pathogenesis of conditions arising from 
chronic inflammation (cardiac fibrosis and emphysema) and may provide the correct 
milieu for apoptosis and cellular plasticity such as EnMT.   Importantly, in this study 
EnMT could be reversed by the addition of recombinant BMP7, which has a number 
of implications for clinical translation.  EnMT was also reduced in SMAD 3 null mice, 
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suggesting that this TGFβ1-driven EnMT is occurring via activation of SMAD 
signalling pathways.   
 
1.18EnMT and endothelial dysfunction 
Endothelial dysfunction occurs in response to cigarette smoke with reduction in NO 
and increased ET-1[34].  In addition to the important vasomotor actions of these 
substances, there is emerging evidence that they may play an important role in the 
maintenance of vascular structure and function.  Change in the balance of 
endothelial derived relaxing and constricting factors may also contribute to the tissue 
remodeling witnessed in emphysema.  O’Riordan et al have shown that NOS 
inhibition promotes EnMT [93].  Using human umbilical vein endothelial cells 
(HuVECS), they showed via phase contrast microscopy that cells treated with 
TGFβ1, endostatin and ADMA (an endothelial NOS inhibitor) underwent a 
phenotypic change becoming spindle shaped and elongated in keeping with 
transition to a mesenchymal phenotype.  In addition, loss of endothelial markers and 
gain of mesenchymal markers was evidenced via western blotting.  In further support 
of the role that NO may play in maintaining cell phenotype, Vyas-Read et al found 
that inhibition of NOS with L-NAME led to a phenotype change of alveolar epithelial 
cells into mesenchymal cells (epithelial to mesenchymal transition) (EMT) [94].     
Exogenous NO applied to these TGFβ1 treated alveolar epithelial cells led to 
reduced α smooth muscle actin (αSMA) expression and reduced collagen 
expression, suggesting that NO may attenuate this phenotypic change.  Reports in 
the cancer literature highlight further the role that vasoactive mediators might play in 
maintaining cell phenotype, with evidence of ET-1 as a driver of EMT in ovarian 
cancer cells [95].  Activation of ETa receptors by ET-1 leads to EMT via signaling 
down an integrin-linked kinase pathway with reversal of this phenotype change in the 
presence of ETa receptor antagonism.  In the pulmonary microvasculature, cigarette 
smoke injury may promote EnMT via increased ET-1 and loss of protective NO, and 
thus agents to stabilize/restore microvascular function may prevent the loss of 
endothelial cells and tissue remodeling typical to emphysema.  
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1.19TGFβ1 and Emphysema 
TGFβ1 is a complex mediator of tissue repair and plays a crucial role in lung 
homeostasis [81].  Many different cellular responses are elicited by TGFβ1 via 
activation of a number of signalling pathways, including activation of MAP Kinase, 
PI3 kinase, Rho like GTPases and SMAD signalling, which mediate changes in 
target gene transcription. The signalling pathway activated and subsequent cellular 
response is not only determined by cell type but is also affected by the 
microenvironment [81].  TGFβ1 is secreted as a latent complex with activities 
regulated by binding to latent TGFβ binding protein (LTBP).  There is evidence that 
reduced activation of latent TGFβ1 and defects in downstream TGFβ1 signalling 
leads to spontaneous lung inflammation and emphysema [25].  Homozygous mice 
with a mutant allele for LTBP4 (which binds only TGFβ1) develop severe 
emphysema with the reduced TGFβ1 and phosphorylated SMAD2 in epithelial cells 
[96].  Furthermore mice null for integrin αvβ6-which mediates TGFβ1 activation 
develop age-related emphysema [97].  These knockout mice have increased 
expression of MMP12, which is a matrix degrading zinc dependant protein implicated 
in the pathogenesis of emphysema [98].  αvβ6-integrin expression on epithelial cells 
may also be downregulated via toll like receptor (TLR) signalling of alveolar 
macrophages in response to bacterial and viral invasion [81].  Thus chronic low-
grade bacterial infection, as may occur in response to altered epithelial cell function 
in response to smoking, may allow unopposed macrophage activation.  Mice lacking 
this integrin develop age-related emphysema that can be prevented by transgenic 
expression of active TGFβ1 [97].  In further support of altered SMAD signalling, 
SMAD3 null mice develop age related increases in alveolar spaces associated with 
presence of MMP 9 and 12 in the lung, suggesting that TGFβ1 downstream 
signalling via SMADs may play a pivotal role in ECM metabolism [99].  However it is 
important to note that these increases in alveolar spaces do not fully equate with the 
complex tissue repair and remodelling that occurs in human emphysema and thus 
such animal models are an oversimplification.  
 
TGFβ1 activation in the lung is most well described in idiopathic pulmonary fibrosis 
(IPF); with the presence of TGFβ1 activation associated the rapid disease 
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progression [81].  However it is now accepted that this factor may play an important 
role in other models of lung injury and repair.  The pathology of septal destruction 
and airspace enlargement witnessed in emphysema on the surface appears far 
removed from the rampant fibrosis associated with IPF, however it is clear that 
complex tissue remodelling occurs in emphysema.  Emphysematous areas express 
fibrosis-associated genes and proteases and it could be suggested that emphysema 
arises via ineffective repair and associated secondary fibrosis.  [81].  In IPF the as 
yet unidentified injury may be relatively minor with an exaggerated fibrosis response, 
while in emphysema, repeated cigarette smoking may alter the microenvironment in 
susceptible individuals with a diminished, ineffective repair response to injury.   
 
The levels of expression of TGFβ1 in COPD are still debated and likely reflect the 
heterogeneous nature of this condition.  Some researchers believe there is reduced 
TGFβ1 and TGFβ receptor expression in COPD lung tissue, with decreased release 
from alveolar macrophages[100], [101], while others the report increased levels, 
attributing this to increased production by abundant alveolar macrophages [102].  
Furthermore, the effects of cigarette smoke on TGFβ1 are also debated.  There is 
however good evidence that alterations in redox state and increased oxidative 
stress, as occurs in cigarette smoking, contributes to TGFβ1 activation [81].  In 
addition TGFβ1 itself induces intracellular ROS, thus causing positive feedback to 
amplify the signal.  Thus TGFβ1 likely plays as yet undetermined role in the 
development of emphysema, either via reduced activity, defective signalling or 
ineffective septal repair/ fibrosis in response to oxidative stress.  
 
1.20Matrix metalloproteinases in emphysema 
Matrix metalloproteinases (MMPs) are a family of zinc and calcium dependant 
proteolytic enzymes that are involved in tissue remodelling and repair [98].  MMPs 
can degrade most components of the ECM and so are believed to play an important 
role in the pathogenesis of emphysema.  Studies in mice have provided insights into 
how MMPs may contribute to this pathology.  MMP1, MMP2, MMP8, MMP9 and 
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MMP12 have all been implicated in emphysema [98].  Mice deficient in MMP12 
(macrophage elastase) exposed chronically to cigarette smoking fail to recruit 
macrophages to the alveolar bed and do not develop emphysema [103].  Increased 
expression of MMP1 (collagenase) in mice leads to airspace enlargement [104].  
Cigarette smoking increases MMP9 (gelatinase B) and MMP12 expression [98].  In 
addition to their ECM degrading properties, MMP2, MMP7, MMP9, MMP12 are able 
to cleave A1AT, which inactivates this important inhibitor of neutrophil elastase, 
which may contribute to septal destruction via increased elastin destruction [105].  
Recent studies in humans have provided further support for the role of MMPs in 
emphysema.  MMP 8 and MMP9 are increased in bronchoalveolar lavage (BAL) fluid 
of subjects with COPD/emphysema compared with non-smokers [98].  There is also 
emerging evidence for MMP2 in emphysema.  Baraldo et al showed upregulation of 
MMP2 in the lung periphery of patients with emphysema compared with non-
smokers and smokers without emphysema [106].  In addition, they showed positive 
correlation of MMP2 with radiological severity of emphysema.    MMP2 is expressed 
in structural cells such as endothelial cells and smooth muscle cells and 
macrophages.  In this study, MMP2 was observed in alveolar macrophages, alveolar 
walls, peripheral airways and small arterioles.   Interestingly, while expression was 
significantly increased in the alveolar walls of smokers with severe COPD, 
expression in smokers with mild/moderate disease had levels similar to that of 
smoking and non-smoking controls suggesting that MMP2 activation may be 
important in the development of more severe emphysematous disease.  Importantly, 
this increase in MMP2 was unrelated to current smoking status, being related rather 
to the presence of COPD/emphysema.  In addition to these ECM degrading 
properties, MMP2 may also have important immunomodulatory functions.  
Unrestrained expression of MMP2 may contribute to the aberrant type1 immune 
response that has been suggested to occur in emphysema [107]. 
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1.21Apoptosis and EnMT 
A link between apoptosis and vascular smooth muscle cell growth was first reported 
in 2006 by Sakao et al [108].  Apoptosis was induced in normal human pulmonary 
microvascular endothelial cells via VEGF receptor blockade (SU5416).   The media 
from these apoptotic cells was then applied to rat pulmonary artery smooth muscle 
cells cultured with varying degrees of sheer stress.  After 24 hours incubation, cells 
cultured in conditioned media showed increased proliferation compared to cells 
cultured in non-conditioned media and serum free media.  The media from apoptotic 
endothelial cells had increased concentrations of TGFβ1 and VEGF as assessed by 
RT-PCR, with the combination of high shear stress and SU5416 treatment having 
the highest of all gene expression.  Because both TGFβ1 and VEGF were increased 
in the apoptotic media, they investigated the role that each might play in vascular 
smooth muscle proliferation via co-incubation with neutralising antibodies for each.  
Using this method they demonstrated that TGFβ-1 but not VEGF mediated this 
proliferation.  Extrapolating these findings, one could propose that apoptosis of 
endothelial cells leads to increased TGFβ1 which may drive both EnMT and 
mesenchymal proliferation. 
 
These researchers provided further evidence linking apoptosis and EnMT, as a 
mechanism behind the vascular remodelling witnessed in pulmonary hypertension 
[109].  They induced apoptosis of normal human pulmonary of microvascular 
endothelial cells via VEGF receptor blockade (via SU5416 treatment for 5 days) and 
then maintained these cultures for a further 3 to 5 passages.  This treatment 
suppressed PGI2 gene expression but induced COX2, VEGF and TGFβ1 expression 
and caused transdifferentiation of mature endothelial cells (as evidenced by dil-
acetylated LDL uptake, lectin and factor VIII expression) into smooth muscle like 
cells (expression of αsma) with some transitional cells expressing both markers.  To 
investigate the characteristics of the cells undergoing apoptosis and 
transdifferentiation, cell type was investigated via magnetic cell sorting of cells for 
CD34 prior to SU5416 treatment.  CD34 is expressed by haematopoietic progenitor 
cells, endothelial cells and some fibroblasts. They observed that only cells positive 
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for CD34 underwent this transition.  They suggest that VEGF blockade causes 
apoptosis of susceptible endothelial cells, creating a selection pressure for CD34+ 
progenitor cells which, via changes in the microenvironment due to apoptotic cells, 
undergo EnMT.  In contrast to the previous study, this transdifferentiation was not 
inhibited by the addition of VEGF and TGFβ-1 neutralising antibodies suggesting in 
this case, that these mediators do not drive this phenotype change.    
 
1.22 Possible reversal of apoptosis and EnMT 
In addition to caspase inhibition and anti-oxidants such as MnSOD preventing 
apoptosis, prostacyclin has been shown to prevent endothelial cell apoptosis 
induced by cigarette smoke [110].  Treatment of normal human pulmonary 
microvascular endothelial cells with 0.5 and 1% cigarette smoke extract (CSE), 
prepared according to a standard method [111] reduced prostacyclin gene 
expression in a dose dependant manner with a maximal effect at 24 hours.  This 
reduction in prostacyclin may be via acrolein, a highly toxic unsaturated aldehyde 
found in cigarette smoke extract, as treatment with acrolein alone also lead to a 
reduction in prostacyclin.  Treatment of cells with 1 and 2% CSE increased apoptosis 
rates (assessed by annexin V staining via FACS) from 3% in control cells to 9%.  
Pre-treatment of these normal pulmonary microvascular cells with the prostacyclin 
analogue iloprost significantly reduced this apoptosis in response to CSE.   
 
There is also evidence which suggests that simvastatin can inhibit cigarette smoking 
induced emphysema via reduction of inflammation and MMP-9 production [112].  In 
addition to anti-inflammatory actions, simvastatin may have anti-oxidant functions 
important to maintenance of microvascular function and prevention of emphysema.  
ROS in the serum of smokers can reduce eNOS expression leading to endothelial 
dysfunction, thus simvastatin may restore endothelial function via the removal of 
ROS.  Removal of ROS may prevent both apoptosis and EnMT, mechanisms which 
may be involved in the complex tissue remodelling witnessed in emphysema.   
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1.23 Summary 
Emphysema is a common lung condition with poor survival and very limited 
therapeutic options.  A major stumbling block to research has been the notion that 
emphysema simply equates with loss of lung tissue and destruction.  Understanding 
the role that endothelial cell loss may play may lead to advances in our 
understanding.  Furthermore the potential for realveolarisation is an attractive 
proposition.  Thus attempts to study the fate of LMVECs in response to cigarette 
smoke may allow improved understanding of the pathogenesis of emphysema, and 
allow identification of potential new therapeutic targets.    
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Chapter 2: Hypothesis and Aims 
2.1 Hypothesis 
Cigarette smoke injury to human lung microvascular endothelial cells causes 
apoptosis and endothelial-to-mesenchymal transition with resulting emphysema in 
susceptible individuals.     
 
2.2 Aims 
In this study I planned to use emphysematous lungs removed at the time of 
transplantation to create a new disease model to study emphysema with cells from 
individuals who had developed disease.  All cell culture models have limitations 
including the use of cancer resection specimens (the surrounding tissue removed 
may have altered expression of VEGF) or normal tissue obtained from lungs not 
suitable for transplantation (the brain death process with subsequent inflammation).  
I therefore aimed to use this new model to investigate emphysema in the hope that it 
would provide a new way to study ex vivo cellular responses, as close to in vivo 
conditions as possible.   
 
The use of severely emphysematous lungs to study the pathogenesis of emphysema 
with reference to endothelial cells can attract criticism with regards the relevance of 
studying end stage disease to the question of pathogenesis.  However, research 
shows that in severely damaged emphysematous lungs there is ongoing evidence of 
repair and active inflammation and that within severely damaged lung there are 
some areas of near normality [86].  One may postulate that cells isolated 
successfully from emphysema lung tissue are likely to be a reliable model as 
severely damaged cells would not survive the isolation process, thus the cells 
isolated are likely to be susceptible yet relatively normal endothelial cells.  
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Isolating, purifying, cryopreserving and re-culturing microvascular endothelial cells 
from patients with emphysema, although challenging, may provide a way in which to 
study emphysema that potentially demonstrates in vivo cell responses in a cell 
culture model.  In contrast to immortalised cell lines, animal models and the use of 
normal human primary cells, this model may allow study of the cellular response to 
injury (in this case, cigarette smoke) that led to the disease in cells from susceptible 
individuals, ex vivo, with the potential to improve our understanding of how cigarette 
smoking causes emphysema.  
 
 I therefore investigated my hypothesis using severely emphysematous lung 
tissue obtained at transplantation.   
 Firstly, I attempted to establish a reliable and reproducible method to isolate 
and fully characterise microvascular endothelial cells from the excess 
emphysematous tissue obtained at lung transplantation. 
 Secondly, I planned to use these cells from multiple patients to investigate:    
• Whether these susceptible endothelial cells undergo apoptosis in 
response to cigarette smoke, in comparison with untreated cells and 
rates of apoptosis in cells isolated from normal individuals. 
• The characteristics of cells which were resistant to apoptosis. 
• Endothelial plasticity in response to cigarette smoking, examining cell 
activation and phenotype via change in cellular expression and 
matrix production in response to cigarette smoke extract. 
 
I also studied the immunohistochemistry findings of severely emphysematous lungs 
with reference to apoptosis and endothelial to mesenchymal transition, using tissue 
blocks obtained from the lung tissue from which cells were obtained. 
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Chapter 3: Materials and Methods 
3.1 General Reagents 
3.1.1 Immunohistochemistry 
Phosphate buffered saline (PBS) and bovine serum albumin (BSA) were purchased 
from Sigma-Aldrich.  Envision flex and flex plus reagents were purchased from 
Invitrogen.  TSA kits were purchased from Perkin-Elmer.   
3.1.2 Cell isolation 
Dulbecco’s Modified Eagle medium (DMEM), Roswell Park Memorial Institute 
(RPMI) and PBS were purchased from Sigma-Aldrich.  Type II Collagenase was 
purchased from Worthington (47A9338).  The Dynal magnet, Dynabeads M-450 and 
CD31 Dynabeads were purchased from Invitrogen.  The lectin UEA-1 was 
purchased from Sigma. 
3.1.3 Cell Culture 
Cell culture plastics were purchased from Fisher Scientific.  Cryopreserved normal 
human pulmonary microvascular endothelial cells were purchased from Promocell 
(C12281) and Lonza (CC-2527).  All cells were cultured in MV2 media (C-22121, 
Promocell).  Cells were passaged using PBS (Sigma) and cell dissociation solution 
(Sigma C5789).  
3.1.4 Cigarette Exposure Experiments 
Kentucky research filterless cigarettes (Lot 4A1) were gifted from AstraZeneca R+D 
Charnwood and were used for all experiments.  A vacuum pump was purchased 
Laboport (Mini pump N86 KN.18) and used in all preparation of cigarette smoke 
extract (CSE). 
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3.1.5 Flow cytometry 
PE conjugated Annexin V kits were purchased from BD Biosciences (556422).    
3.1.6 Western blotting 
4-12% Bis Tris Nu-Page pre-cast Gels, MES running buffer and ‘See blue’ indicator 
were purchased from Invitrogen.  BCA protein assay kits (#23225) and Supersignal 
West Pico Chemiluminescent (#34080) kits were purchased from Pierce 
Laboratories.  PVDF membrane was purchased from Amersham biosciences 
(#NF1016).  
3.1.7 Confocal microscopy 
DAPI was purchased from vectashield (H-1200). 
3.1.8 RT-PCR 
RNA was isolated from cells using Absolutely RNA microprep kit (400805) Agilent.  
cDNA was then obtained using Affinity script qPCR cDNA synthesis kit (600559) 
Agilent. 
3.1.9 ELISA 
Endothelin-1 ELISA kits were purchased from assay designs (#900-020A).  
3.1.10 TUNEL 
Fluorescein In situ cell death detection kits were purchased from Roche 
(11684795910). 
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3.2 Antibodies: primary and secondary 
3.2.1 Confocal Microscopy 
For characterisation and EnMT work, CD31 (sc-53411, Santa Cruz), Ve-Cadherin 
(sc-6458, Santa Cruz), Vimentin (M7020, Dako), aSMA (F3777, Sigma) and 
fibronectin (F3648, Sigma) were used to detect cell surface expression via confocal 
microscopy and counterstained appropriately with either FITC (Mouse) (F2012) 
(Sigma) or TRITC (Rabbit) (T6778) (Sigma) with DAPI nuclear staining (H-1200, 
Vectashield). 
3.2.2 Live Cell imaging 
DEVD-NucView 488 Caspase 3 substrate (Biotium Inc) was used to detect apoptosis 
via live cell imaging.  DEVD-Nucview is a fluorogenic enzyme which can freely pass 
into the nucleus.  Upon activation of the substrate (caspase 3) enzymatic cleavage of 
Nucview leads to fluorescence.   
3.2.3 Flow Cytometry 
For cell characterisation, FITC conjugated CD31 (#555445, BD Bioscience) was 
used to identify endothelial cells.  PE cy5 conjugated CD90 (# 555597, BD 
Bioscience) was used to identify fibroblast/ mesenchymal cells.  APC conjugated 
CD62E (E-selectin) (#551144, BD Bioscience) was used to detect response to 
stimulation with TNFα. 
 
Apoptosis was investigated using Annexin V (# 556422 BD Bioscience), as an early 
marker of apoptosis via detection of phosphatidylserine residues.  Necrotic cells 
were detected using 7AAD (BD Bioscience), which is fluorescent and has strong 
affinity for DNA but requires cell membrane disruption in order for it to bind, thus 
labeling only dead cells and not viable cells. 
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3.2.4 Western Blotting 
Recombinant human TGFβ1 (100-21) was purchased from Peprotech. CD31 (sc-
53411, Santa Cruz) and VE-Cadherin (sc-6458, Santa Cruz) were used to detect 
endothelial cell protein expression.  Alpha smooth muscle actin (ab32575, Abcam), 
Vimentin (M7020, Dako), and Fibronectin (F3648, Sigma) were used to investigate 
cellular plasticity and endothelial to mesenchymal transition.  β actin (A2228, Sigma) 
was used as a loading control. 
3.2.5 PCR 
Taqman probes were purchased to detect 18s (4331182) and VEGF KDR (4465807) 
(Applied Biosystems). 
3.2.6 ELISA 
Endothelin-1 ELISA kits were purchased from Assay Designs (900-020A). 
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3.3 Patients 
Ethical approval for the isolation and study of diseased cells was given by the 
Northumberland Local Ethics and Research Committee in January 2007 (REC 
reference 06/Q0902/57).  All patients awaiting lung transplantation at Freeman 
Hospital were invited to take part in the study.  Patients gave informed consent to 
donate their explanted lung for research purposes outlined in the study.  The study 
was performed in accordance with ICH-GCP.  Study patient information leaflet and 
consent form appear in Appendix 1. 
 
Ethical approval to obtain excess normal tissue from patients undergoing lobectomy/ 
pneumonectomy was given by County Durham and Tees Valley 2 Research Ethics 
Committee in July 2009 (REC reference 09/H0908/35).  Patients were identified 
according to the study protocol (Appendix 2) and excluded should they have 
evidence of emphysema/ fibrosis on radiology or pulmonary function testing.  The 
study was performed in accordance with ICH-GCP.  Study protocol, patient 
information leaflet and consent form appear in Appendix 2.  
 
Clinical data such as primary diagnosis, age, body mass index, arterial oxygenation 
(PaO2) and pulmonary function tests were obtained from each individual who 
donated tissue.  Smoking status and smoking history from each patient was also 
obtained.  Those with emphysema were also categorised according to the updated 
GOLD criteria (2003) [113], [114].  Clinical data is summarised in Table 1.  Further 
detail is provided in individual patient data sheets in Appendix 3. 
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Table 1: Patient demographics, histopathological diagnosis and clinical data 
Patient 
No: 
Gender Diagnosis Age BMI Smoking 
History 
(Pack yrs.) 
FEV1 
(%) 
TLC 
(%) 
KCO 
(%) 
GOLD 
stage 
1 M A1AT 
emphysema 
(Panacinar) 
46 28.7 15 18 133 15 IV 
2 F Emphysema 54 21.5 30 10 178 - IV 
3 F Emphysema 
(Centrilobular) 
53 20.9 30 22 131 32 IV 
4 F Emphysema 51 20.8 30 28 150 33 IV 
5 F Emphysema 
(Centrilobular) 
46 20.2 20 21 150 43 IV 
6 M Emphysema 
(Centrilobular) 
58 22.7 35 15 130 46 IV 
7 F Emphysema 
(Centrilobular) 
59 21.8 25 34 155 38 III 
8 M Emphysema 
(Centrilobular) 
44 23 15 14 138 69 IV 
9 F Emphysema 60 28.3 20 26 95 25 IV 
10 M Emphysema 45 21.3 27 26 156 42 IV 
11 M Emphysema 
(Centrilobular) 
55 20.8 55 17 130 24 IV 
12 F A1AT 
emphysema 
(Panacinar) 
40 26.1 25 16 136 33 IV 
13 M Emphysema 
(Centrilobular) 
47 22.3 30 17 150 42 IV 
14 M A1AT 
emphysema 
(Panacinar) 
52 21.2 15 22 127 71 IV 
15 F Normal 68 - 15 104 - - N/A 
16 F Normal 65 - 40 80 - - N/A 
17 F IPAH 60 26.4 0 83 107 109 N/A 
36 
 
3.4 General Methods 
3.4.1 Obtaining diseased lung tissue 
At the time of transplantation, the lung was inspected to confirm the macroscopic 
pathology was in keeping with pre-operative diagnosis and to exclude any 
unexpected pathology.  A lobe/part of lobe was then dissected and stored at 4°C 
until clinical pathology assessment (which was performed within 24 hours).  
Following routine clinical pathology, blocks of tissue were placed in neutral buffered 
formalin for fixation for histology experiments.  The remaining tissue (typically around 
50g) was used immediately for cell isolation.   
3.4.2 Obtaining normal tissue 
The operating surgeon performing lobectomy for suspected lung cancer identified a 
wedge of normal tissue within the tissue removed at surgery but discrete from the 
tumour resection margins.  This was stapled off from the remaining tissue and 
tumour and placed in media.  Both samples were transported to clinical pathology 
where the wedge sample was inspected and once confirmed to be free from disease, 
was used immediately for cell isolation.  Tissue samples ranged from 5-30g.   
3.4.3 Tissue preparation 
Tissue samples were fixed for 48 hours at room temperature (RT) in 10% neutral 
buffered formalin (Pioneer Chemicals, Surrey).  The tissue was then dissected into 
3mm thick blocks and processed overnight on a Leica Tissue Processor (LEICA TP 
1050 fully enclosed vacuum tissue processor), an automated way in which to take 
tissue through graded alcohols and into paraffin. The tissue was then positioned and 
set into a paraffin wax block on a Leica Histoembedder.  Blocks were stored at RT 
ready for use. 
3.4.4Sectioning 
4μm sections were cut with a Leica Jung RM2155.  Cut sections were floated on 
water (37°c) and transferred to Thermo Shandon Colourfrost Plus positively charged 
microscope slides. Positively charged slides are used to ensure that the tissue 
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remained adhered to the slide throughout the subsequent staining. The slides were 
dried overnight at 45°c and then stored at RT. 
3.4.5Immunohistochemistry 
4µm sections were dewaxed in xylene and taken through graded alcohols to water.  
Antigen retrieval was determined according to each antibody and included no pre-
treatment, vector unmasking fluid, microwave in low pH solution, microwave in high 
pH solution, boric acid at 65°C for 16 hours.  Endogenous tissue peroxidase activity 
was quenched with pre-treatment of sections with v/v hydrogen peroxide (0.5-6%) in 
methanol for 10 minutes.  Sections were then washed in PBS +0.05% tween 
(pH7.4).  Non-specific binding was blocked with 20% normal goat serum in PBS with 
1% BSA (pH7.4) or flex block for 20 minutes at room temperature.  Sections were 
then incubated in primary antibody diluted in PBS 1% w/v BSA pH7.4 for 30 minutes 
at room temperature.  Corresponding isotype controls (no primary antibody) were 
used in all experiments.   After incubation with primary antibody, sections were 
washed in PBS +0.05% tween (pH7.4) before applying corresponding HRP linked 
secondary antibodies.  HRP activity was detected using the chromagen DAB (Dako).   
Sections were counterstained with Gills haematoxylin, dehydrated through graded 
alcohols to xylene then mounted.   
3.4.6Cell Culture 
3.4.6.1 Isolation of microvascular endothelial cells from explanted lungs 
Tissue excess to pathology requirements was stored in DMEM prior to cell isolation.  
Alveolar macrophages were firstly removed by inflation of the tissue with PBS.  The 
alveolar macrophage rich fluid which seeps out of the tissue was then discarded.  
The pleura and macroscopic vessels and airways were also dissected and 
discarded.  The remaining tissue was finely chopped, washed in media and filtered 
through a 40µm filer to remove red blood cells.  Tissue pieces were incubated in 
0.2% type II collagenase (RPMI + 0.1% BSA) with gentle agitation at room 
temperature for 2 hours and then filtered, firstly through a large filter and secondly 
through a 100µm filter.  The filtrate was centrifuged (250G for 5 minutes), 
supernatant removed and cell pellet resuspended.  An automated cell count was 
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performed and cells plated onto 0.2% gelatin-coated flasks (10,000 cells/cm2)in MV2 
media (Promocell).  Following 24 hours incubation, the flasks were washed in PBS to 
remove non-adherent cells and red blood cells.  MV2 media was replaced and 
changed every 2-3 days. 
3.4.6.2 Passage of isolated microvascular endothelial cells 
At 70-80% confluence, cells were passaged using cell dissociation solution (Sigma).  
Cells were washed in PBS before incubation in cell dissociation solution for 
approximately 15 minutes at 37°.  Detached cells were removed and remaining 
adherent cell attachment disrupted with gentle scraping.  The detached cell 
suspension was centrifuged with the resulting pellet ready for cell separation.  
3.4.6.3 Preparation of UEA Dyna beads  
Dynabeads M-450 Tosylactivated (Invitrogen) were washed in 0.2M Sodium 
Tetraborate (pH 9.5) before being placed in the Dynal magnet (MPC-1, Invitrogen) 
for one minute.  The wash was then discarded.  After a further wash, the beads were 
resuspended in 1ml 0.2M Sodium Tetraborate (pH 9.5) containing 0.2mg/ml Ulex 
europaeus-1 lectin (UEA-1) (Sigma L5505) and incubated with gentle agitation at RT 
for 48 hours to allow coupling of the ligand to Dynabeads.  After incubation, the 
bead-ligand mixture was washed, by adding 1ml of PBS containing 0.1% BSA, 2nM 
EDTA (pH 7.4) and was placed in the magnet for 1 minute.  The wash was removed, 
and 2 further washes performed by resuspending beads in 1ml of PBS containing 
0.1% BSA, 2nM EDTA (pH 7.4) and incubated on the roller for 5 minutes before 
removal of the wash by magnetic separation.  After the final wash, beads were 
resuspended in 1ml of PBS containing 0.1% BSA, 2nM EDTA (pH 7.4) (bead 
concentration 4x108 beads/ ml) and stored until use in separation experiments. 
3.4.6.4 Separation of cells 
UEA and commercially available CD31 Dynabeads (25 µl each) were washed in PBS 
containing 0.1% BSA, 2nM EDTA (pH 7.4).  The cell pellet was then resuspended in 
2ml of PBS containing 0.1% BSA, 2nM EDTA (pH 7.4) containing the beads.  The 
cells/ beads suspension was incubated on a roller at 4°C (to reduce non-specific 
binding)for 20 minutes.  Following incubation, a further 5ml of PBS containing 0.1% 
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BSA, 2nM EDTA (pH 7.4) was added and the beads/cells mixture placed in a 
magnet.  The buffer containing cells unattached to beads was removed.  The 
beads/cells mixture was washed as above a further four times with the bead-
negative fraction removed each time.  The bead positive cells were re-suspended in 
media and counted using a haemocytometer.  Cells were plated onto 0.2% gelatin-
coated flasks at 2000-3000 cells/cm2.  The bead negative fraction, containing mostly 
fibroblasts, was at plated out similarly. 
3.4.6.5 Cryopreservation 
Once cells are a pure population, with no contaminating fibroblasts, cells were 
cryopreserved (1x106cells/ml) in MV2 media (Promocell) containing 1% DMSO 
(Sigma). 
3.4.6.6 Reanimation and Passage of cells 
Cryopreserved pulmonary microvascular cells isolated from patients in our centre or 
commercially available (Promocell and Lonza), were grown on sterile tissue culture 
flasks in complete MV2 media (Promocell) with supplemental antibiotic/ antimycotic 
(Invitrogen).  When the cells reached 70-80% confluence, cells were washed with 
PBS and cell dissociation solution (Sigma) added to detach the cells.  After 2-3 
minutes incubation, the detached cells were removed and centrifuged.   The number 
of cells in the resulting pellet was calculated using a haemocytometer and cells 
seeded at 2-5000 cells/cm2.  
3.4.6.7 Harvesting Cells 
Media was removed and stored at -80°C to allow later analysis.  Cells were washed 
in PBS to remove debris and then detached via gentle scraping.  Flasks were 
washed in PBS, and the resulting cell suspension centrifuged (250G for 4 minutes).  
The supernatant was removed.  The cell pellet was re-suspended in phosphosafe 
extraction buffer.  Cells were sonicated to lyse the cells.  
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3.4.7Preparation of Cigarette smoke extract 
Cigarette smoke extract (CSE) was prepared according to the method published by 
Carp and Janoff [111].  This method has been widely used for over 30 years, with 
some researchers making their own modifications, and is highly cited in the 
literature.  Briefly, the smoke of 1 Kentucky filterless research cigarette (Lot 4A1) 
was bubbled through 25ml endothelial MV2 media containing 5% FCS (Promocell), 
using a vacuum pump (Laboport), over approximately 6 minutes (to mimic the time to 
smoke a cigarette) to give a concentration of 100% CSE (Figure 3.1).  Due to the 
precious nature of the cells, the resulting CSE was sterile filtered through a 0.2u 
filter.  CSE was used to treat cells within 30 minutes of preparation.  To standardise 
CSE as much as feasibly possible it was made on each occasion by the same 
operator (LSM) and when analysed on a spectrophotometer had the same 
absorbance.  pH of CSE was also unaltered among CSE preparations and when 
compared with whole media.   
 
Figure 3.1 Apparatus used to prepare cigarette smoke extract (CSE). 
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3.4.8 Flow cytometry 
Cells were harvested using cell dissociation solution (Sigma), centrifuged and 
washed in PBS prior to staining.  100,000 cells/100ul were typically used for each 
analysis.  For characterisation experiments, cells were resuspended in PBS (100ul) 
and volumes of cell surface markers added according to optimisation experiments.  
Cells and antibodies were incubated for 30 minutes at 4°C to reduce non-specific 
binding.  Following incubation, cells were washed in 4ml PBS, centrifuged at 10,000 
rpm for 5 minutes, resuspended in 200ul PBS and analysed on facs scan LSR II.   
For apoptosis experiments, cells were resuspended in 100ul 1x binding buffer (BD 
bioscience).  5ul of Annexin V and 5ul 7-AADwere added to each and incubated at 
RT for 15 minutes, before analysis on FACS scan.  Data was analysed using Venturi 
software.  
3.4.9 BCA protein assay 
A BCA protein assay was performed on all samples to ensure equal loading 
concentrations for western blotting.  Standard dilutions of BCA (2000, 1500, 1000, 
750, 500, 250 and 125ng/ml) were prepared on a 96 well plate and read on an 
Opsys MR microplate reader (Dynex technologies) at 570nm.  A standard curve was 
constructed and used to determine protein concentration of unknown samples.  
Briefly, 80 µl of phosphosafe extraction buffer was added to 5µl of each sample.  
25µl of this mixture was added in triplicate onto a 96 well plate.  200µl of BCA 
working reagent was added to each sample and incubated at 37°C for 30 minutes 
before reading at 570nm.  Protein concentration was calculated according to the 
standard curve.      
3.4.10 Western blotting 
Samples were prepared on ice with equal loading according to BCA protein assay.  
To each sample equal volume of sample buffer (laemmli buffer/ β-ME, 10%(v/v) was 
added to denature the protein.  Samples were vortexed and heated for 5 minutes at 
95°C.  Samples were then loaded onto Nu-PAGE pre-cast gels (Invitrogen) together 
with See blue pre-stained indicator and ran in MES running buffer at 100V.  Gels 
were transferred overnight at 20V onto PVDF membranes in 1x transfer buffer 
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(0.02M tris, 0.192M glycine, 10% methanol).  The following day, PVDF membranes 
were blocked in TBS-T with 5% dried milk (marvel) for 60 minutes at room 
temperature.  Primary antibodies were then applied in 5% marvel TBS-T overnight at 
4°C.  The next day, membranes were washed twice for 10 minutes in TBS-T.  
Corresponding secondary antibodies were applied in 5% marvel TBS-T.  Following 
90 minute incubation, membranes were washed three times for 10 minutes in TBS-T.  
Membranes were then exposed to ECL Chemiluminescence solution (50:50 
concentration) (Amersham) with protein bands detected via Gel-Doc. 
3.4.11 Confocal microscopy 
Cells were seeded onto an 18mm coverslip and treated as per each experiment.  On 
completion of each treatment course, cells were washed in PBS and fixed with 
freshly prepared 4% paraformaldehyde for 30 minutes.  The paraformaldehyde was 
removed and cells stored in PBS.  For staining, the cells were quenched with 100mM 
glycine for 30 minutes.  Cells were then permeabilised with PBS plus 1% Triton X-
100 (PBST) for 30 minutes.  PBST was then removed and cells washed three times 
in PBS.   Cells were blocked with 5% BSA for 60 minutes.  Primary antibodies in 5% 
BSA were then applied for 60 minutes at room temperature and then washed with 
PBS with 0.2% tween and PBS.  Secondary antibodies were then applied in 5% BSA 
for a further 60 minutes before 3 washes in PBST and one final wash in PBS.  The 
cells on coverslips were thereafter mounted with 4’,6-diamidino-2-pheylindole (DAPI) 
stain and viewed on a Leica Sp2UV laser scanning confocal microscope and 
analysed with software from Leica (LCS 2.61).  
3.4.12 RT-PCR 
3.4.12.1 RNA isolation 
RNA was isolated using a commercially available micropreparation kit.  Briefly cells 
were lysed a mixture of βmercaptoethanol and lysis buffer (βME0.7ul and 100ul lysis 
buffer per <500,000 cells).  An equal volume of 70% ethanol was then added to the 
mixture and vortexed.  DNase were then deactivated by incubating with RNase-free 
DNase I and DNase digestion buffer followed by a series of high and low salt buffer 
washes and microcentrifuge.    RNA was isolated by incubation with an elution buffer 
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for 2 minutes at room temperature and then centrifuged.  RNA concentration was 
determined using a nanodrop.  A 2% agarose gel containing 4ul ethidium bromide 
was then cast and RNA samples run with loading buffer of 30% glycerol, 70% TAE 
(Tris-acetate-EDTA) and bromophenol blue in 1% TAE to assess quality of RNA.  A 
trackIt (Invitrogen) DNA ladder was used to identify molecular weight.  RNA was 
stored at -80°C until used for cDNA preparation. 
3.4.12.2 cDNA preparation 
cDNA was prepared from RNA using a commercially available kit.  Briefly each 
sample was made to RNA concentration according to nanodrop, with 3ul random 
primers and DEPC water to a total volume of 15.7ul.  This mixture was then 
incubated at 65°C for 5 minutes and then cooled to room temperature over 
approximately 10 minutes.  To each sample 2ul 10X affinity script, 0.8ul dNTP mix, 
0.5ul RNase block and 1ul affinity script were added.  This was then incubated at 
25°C for ten minutes to allow the primers to extend and then to 55°C for 60 minutes 
to allow the polymerase chain reaction to take place.  The reaction was then 
terminated by increasing the temperature to 70°C for 15 minutes.  cDNA was stored 
at -80°C until used for Q-PCR. 
3.4.12.3 Q-PCR 
Samples were prepared and plated onto 96 well optical plates (Applied Biosystems).  
Briefly, 10ul mastermix, 6.5ul RNAse free H2O and 1ul primers were added to each 
well.  2.5ul of cDNA (diluted according to optimisation experiments) was then added 
to each well.  Samples were then centrifuged and ran on the PCR machine and 
analysed on ABI Prism 7000 SDS software.  Real-time reaction products for each 
primer were confirmed on 2% agarose gel electrophoresis. 
3.4.13 ELISA 
Media from control and treated cells removed at the time of harvesting was used 
together with commercially available ELISA kits to detect levels of Endothelin-1 (ET-
1) released from treated cells.  Samples and standards were added to wells pre-
treated with ET-1.  After incubation, samples were washed.  HRP labelled 
monoclonal antibody to ET-1 was then added and incubated prior to further washing 
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to remove unbound antibody.  TMB substrate solution was then added which 
generates a blue colour when catalysed by HRP.  Stop solution (1N solution 
hydrochloric acid in water) was thereafter added with the resulting yellow read at 
450nm.  The amount of signal detected was directly proportional to the level of ET-1 
and so a standard curve was constructed from which the concentration of ET-1 
within the samples (unknowns) could be determined. 
 
3.4.14 Statistical Analysis 
Much of the work presented in this thesis is exploratory.  Statistical analysis was 
performed where appropriate and is reported in figures and text.  Excel and Graph 
Pad Prism were used for all statistical analyses.  Where the data was found to be 
parametric t-tests or ANOVA (for multiple comparisons) were performed.  For non-
parametric data, Mann Whitney U-tests were performed.  Statistical significance was 
taken as p<0.05. 
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Chapter 4: Endothelial Cell isolation and Characterisation 
4.1 Abstract 
The Pulmonary microvasculature plays an important role in the maintenance of lung 
homeostasis via its response to injury and role in repair.  Animal models, 
immortalised cell lines, primary cells isolated from large pulmonary arteries and 
human umbilical vein endothelial cells (HUVECs) have all been used to model the 
human microvasculature but each have limitations as to how truly they reflect in vivo 
conditions.  Commercially available human pulmonary microvascular cells have 
overcome many of these limitations, however the ability to study disease 
mechanisms in cells isolated from individuals with the disease in question, whose 
cells have been exposed to the milieu associated with disease, may mimic in vivo 
conditions more accurately.   Observing how these cells respond to injury may 
provide valuable insights into disease pathogenesis.  I therefore attempted to isolate 
pulmonary microvascular endothelial cells from individuals undergoing lung 
transplantation for severe end stage emphysema.  Cells were also isolated from 
excess normal tissue from patients undergoing lobectomy for cancer to act as 
controls. 
Methods:  Following informed consent, a lobe or part of lobe was dissected at the 
time of surgery.  The pleura, large airways and large blood vessels were removed 
and contaminating macrophages and neutrophils flushed from the peripheral lung 
tissue before digestion with collagenase.  This cell mixture was then cultured until 
colonies of cells were present.  Endothelial cells were purified from the cell mixture 
via selection with CD31 and UEA-1 magnetic beads and characterised by confocal 
microscopy and flow cytometry. 
Results:  Successful isolation was achieved from 10 (71%) of 14 emphysematous 
lungs.  Endothelial cells exhibited a classical cobblestone morphology with high 
expression of endothelial cell markers (CD31) and low expression of mesenchymal 
markers (CD90, αSMA and fibronectin). E-selectin (CD62E), which is reported to be 
absent on quiescent microvascular endothelial cells but inducible on intraacinar 
arterioles and venules upon stimulation, was observed in a proportion of the isolated 
46 
 
CD31 positive cells following stimulation with TNFα, confirming that these cells were 
of microvascular origin. 
Conclusions:  Susceptible human pulmonary microvascular cells from severely 
emphysematous lungs can be isolated with high yields.  Characterisation confirms 
these to be of high purity.  These cells provide a valuable research tool to investigate 
cellular mechanisms in the pulmonary microvasculature relevant to the pathogenesis 
of emphysema. 
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4.2 Introduction 
The pulmonary microvasculature, which comprises the luminal barrier of intra-acinar 
arterioles and venules and the alveolar capillary network, plays an important role in 
lung tissue homeostasis in health and disease [50][115].  Lung endothelial cell injury 
is hypothesised to be a key event in the pathogenesis of emphysema [116] and 
forms the increasingly credible “microvascular hypothesis” as an alternative to the 
classical hypothesis in which inflammatory cells are seen as the orchestrators of 
tissue destruction [117].  
 
Early cellular studies exploring the pulmonary circulation tended to use large vessel 
endothelial cells, typically from the main pulmonary trunk, and HUVECs (human 
umbilical vein endothelial cells) as a surrogate for the lung microvasculature [118].  
However, wide heterogeneity exists between endothelial cells isolated from different 
organs and between endothelial cells isolated from different vascular beds within 
organs [119]–[121].  The vascular bed of the lung is perhaps the best example of this 
heterogeneity, due to its numerous branching arteries, arterioles, capillaries and 
venules, which unlike the systemic circulation are exposed to low pressure and high 
flow.  The resulting large surface area has important metabolic functions that may 
contribute to disease when disordered [119].  Such complexity may explain differing 
results found between ex vivo models and the difficulties when trying to translate 
research into clinical practice.  The ability to study the disease in cells isolated from 
tissue from individuals in whom the disease has developed has been largely 
overlooked, instead relying on more readily available models and simply 
acknowledging the limitations of each.    
 
Immortalised cell lines are a widely used model in cell biology.  Originally derived 
from embryos and cancer tissue, cell lines can be used to high passage due to 
clonality of the cells, which escape the normal controls within the cell cycle [122].  
Such a model has the advantage that they provide a stable cell population that does 
not have a finite lifespan, however they do not always express markers characteristic 
of the tissue in which they originated[123][124] and their responses in vivo are 
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unlikely to reflect the true response of cells to injury[125][126], thus limiting their use.  
Microvascular endothelial cells (MVECs) isolated from animals are an alternative 
model.  MVECs have been isolated from bovine [127], ovine [128], and rodent lungs 
[121].  These animal cell models have the advantage that are provide an important 
way in which cellular response to injury and disease mechanisms can be studied, 
however these may not reflect the true in vivo response in humans.  Such studies 
have however provided valuable insights into the responses of rat lung 
microvascular endothelial cells to injury and also have afforded the development of 
methods to effectively isolate lung microvascular cells [129][130][131][121].  The 
development of successful isolation techniques has then allowed these to then be 
applied to isolation of human LMVECs.  
 
The emergence of commercially available primary cells in recent years has provided 
an alternative way in which to study cellular responses ex vivo [120].  While these 
cells are fully compliant with regulatory legislation, with information given regarding 
the patient age and in some cases smoking status, there exists no way in which to 
clarify whether the individuals from which these cells were isolated had normal 
pulmonary function or indeed whether they had evidence of respiratory disease.  
Therefore, the ability to isolate and compare cells from individuals characterised to 
be free from respiratory disease and from those who have developed severe disease 
is attractive.  Furthermore, the observation that only 20% of individuals who smoke 
develop emphysema [1] supports the view in this disease that it is an individual’s 
disordered cellular response to injury rather than the injury per se that leads to 
pathology.  The study of disease in cells isolated from individuals in whom the 
disease has developed therefore has clear relevance.  The demonstration that 
emphysema is not simply a disease of “loss of lung tissue” and rather a disease in 
which there is active response to injury and attempts at repair [25], adds further 
weight to the goal of isolating cells from individuals in whom the disease has 
developed and may provide valuable insights into the pathogenesis of emphysema.  
By comparing how these susceptible cells behave in contrast to cells isolated from 
individuals free from COPD may provide unique insights into the cellular responses 
to cigarette smoke which lead to COPD. 
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I therefore attempted to isolate human pulmonary microvascular endothelial cells 
(HPMVECs) from patients with severe end stage lung disease undergoing lung 
transplantation, obtaining clinical details such as lung function and smoking history to 
contextualise samples.  This approach allowed both the isolation of cells from well 
characterised patients with advanced diseases such as emphysema and pulmonary 
arterial hypertension (using tissue obtained at lung transplantation).  In addition, cells 
were isolated using the same method from healthy individuals with normal lung 
function without COPD (using excess tissue removed at lobectomy for lung cancer).  
All isolated cells were characterised and compared with normal LMVECs, using 
immunocytochemistry to confirm the cells were endothelial, uncontaminated by 
mesenchymal cells and of microvascular pedigree.   
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4.3 Subjects 
Ethical approval for the isolation and study of diseased cells was submitted and 
approved by the Northumberland Local Ethics and Research Committee in January 
2007 (REC reference 06/Q0902/57).  All patients awaiting lung transplantation at 
Freeman Hospital were invited to take part in the study.  Patients gave informed 
consent to donate their explanted lung for research purposes outlined in the study.  
The study was performed in accordance with ICH-GCP.  Study patient information 
leaflet and consent form appear in Appendix 1.   
 
Ethical approval to obtain normal tissue from patients undergoing lobectomy/ 
pneumonectomy was given by County Durham and Tees Valley 2 Research Ethics 
Committee in July 2009 (REC reference 09/H0908/35).  Patients were identified 
according to the protocol (Appendix 2) with subjects excluded should they have 
evidence of emphysema/ fibrosis on radiology or pulmonary function testing.  The 
study was performed in accordance with ICH-GCP.  Study protocol, patient 
information leaflet and consent form appear in Appendix 2.  
 
Clinical data such as primary diagnosis, age, body mass index, arterial oxygenation 
(PaO2) and pulmonary function tests were obtained from each individual who 
donated tissue.  Smoking status and smoking history from each patient was also 
obtained.  Those with emphysema were also categorised according to the updated 
GOLD criteria (2003) [113], [114].     
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4.4 Methods 
4.4.1 Obtaining diseased lung tissue 
At the time of transplantation, the lung was inspected to confirm the macroscopic 
pathology was in keeping with pre-operative diagnosis and to exclude any 
unexpected pathology.  A lobe/part of lobe was then dissected and stored at 4°C 
until clinical pathology assessment (which was performed within 24 hours).  
Following routine clinical pathology, blocks of tissue were placed in neutral buffered 
formalin for fixation for histology experiments.  The remaining tissue (typically around 
50g) was used immediately for cell isolation.   
4.4.2 Obtaining normal tissue 
The operating surgeon performing lobectomy for suspected lung cancer identified a 
wedge of normal tissue within the tissue removed at surgery but discrete from the 
tumour resection margins.  This was stapled off from the remaining tissue and 
tumour and placed in media.  Both samples were transported to clinical pathology 
where the wedge sample was inspected and once confirmed to be free from disease, 
was used immediately for cell isolation.  Tissue samples ranged from 5-30g.   
4.4.3 Cell isolation 
Contaminating alveolar macrophages were firstly removed via repeated inflation of 
the tissue with sterile PBS.  The pleura, visible arterioles, bronchioles and venules 
were then dissected to prevent overgrowth with mesothelial and epithelial cells and 
prevent contamination with macrovascular endothelial cells.  The remaining tissue 
was washed in RMPI containing 10% FCS and 1% PSA and finely chopped (1-2mm2 
pieces).  The tissue pieces were then washed through a 40µm filter to remove red 
blood cells before incubation with 0.2% type II collagenase (Worthington) in RPMI 
containing 0.1% BSA for 2 hours at room temperature.  Following incubation, the 
suspension was filtered through a 400-500µm mesh and then a 100µm sterile filter.  
The filtrate was centrifuged (250g for 5 minutes).  The supernatant was discarded 
and resulting cell pellet re-suspended in endothelial growth MV2 media (Promocell) 
containing 1% PSA.  An automated cell count was performed and cells plated onto 
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flasks pre-coated with 0.2% gelatin (w/v in MilliQ water, coated for 30min at room 
temperature, excess gelatin solution was removed before cell addition) at 
approximately 10,000 cells/cm2.  Cells were cultured at 37˚C in the presence of 5% 
CO2.    Non-adherent cells were removed after 24 hours in culture by gentle flushing 
with PBS over the flasks.  MV2 media was replaced every 3-4 days until the cells 
reach confluence. 
4.4.4 Endothelial cell purification 
When the cells reached approximately 80% confluence, they were passaged using 
cell dissociation solution (Sigma) and separated from any contaminating fibroblast 
and epithelial cells using CD31 Dynal beads (Invitrogen) and pre-prepared Ulex 
europaeus agglutinin-1 (UEA-1) coated Dynal beads.  UEA-1 binds to the α-L-
Fucosyl residues of glycoprotein present on the surface of human microvascular 
endothelial cells, thus in conjugation with magnetic beads allows the selection of 
endothelial cells from a mixed cell suspension [132].  The cells were re-suspended in 
PBS containing 0.1% BSA and 2mM EDTA (Dynal Buffer) and 25ul each of CD31 
Dynal beads and UEA-1 coated beads were added.  The cells/beads mixture was 
incubated on a rocker at 4˚C for 20 minutes, to minimise non-specific binding.  The 
beads were then washed in Dynal buffer and placed in a Dynal magnet.  The bead 
negative fluid was discarded.  After repeated washing and magnetic separation, the 
bead positive cells were counted and plated on 0.2% gelatin coated tissue culture 
flasks at approximately 3,000 cells/cm2 and incubated at 37˚C in the presence of 5% 
CO2.  Bead separation was performed over 3-5 passages of the cells until pure 
cobblestone cultures were obtained. 
4.4.5 Cryopreservation of cells 
When cultures appeared free from contaminating cells, cells were cryopreserved in 
MV2 media (Promocell) containing 1% DMSO (Sigma).  All emphysema cultures 
were cryopreserved and then later reanimated for characterisation and explorative 
experiments. 
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4.4.6 Commercial Human Pulmonary Microvascular Endothelial cells 
Commercial HLMVECs were purchased from Promocell (C12281) and cultured after 
reanimation at 37 ˚C with 5% CO2 using endothelial growth MV2 media (Promocell) 
supplemented with 1% PSA (as used with cells isolated from patients). 
4.4.7 Mycoplasma testing 
All isolated cells and commercial cells were routinely tested for mycoplasma infection 
using Myco Alert kits (LT07-218, Lonza).  Testing was carried out on all isolated cells 
prior to experimentation and on commercial cells on a monthly basis.  The cells 
showed no evidence of mycoplasma infection.  
4.4.8 Phase contrast Microscopy 
Cells were grown to confluence and images taken on canon image shot. 
4.4.9 Confocal microscopy 
Cells were cultured on 18mm glass coverslips in 12 well plates.  At confluence, cells 
were washed in PBS and fixed in freshly prepared paraformaldehyde (4%).  
Following fixation, cells were quenched in 100mM glycine for 30 minutes, before 
permeabilisation in PBS Triton X-100 (1%v/v) for 20 minutes.  Following 
permeabilisation, cells were washed with PBS containing 0.2% tween (0.2% PBST) 
and PBS.  After blocking with 5% BSA for 60 minutes, coverslips were incubatedwith 
primary antibodies (CD31 (Sc53411, Santa Cruz) Fibronectin (F3648, Sigma), 
αSMA, (F3777, Sigma) in 0.5% BSA overnight at 4˚C.  Cells were then washed as 
before with 0.2% PBST and PBS.  Fluorochrome pre-conjugated secondary 
antibodies (FITC: Mouse (F2012) and TRITC: Rabbit (T6778), Sigma) were then 
applied (0.5% BSA) for 60 minutes and then washed in 0.2% PBST and PBS.  The 
cells were then mounted with DAPI mounting medium (H-1200, Vector Labs) and 
viewed on a Leica Sp2UV laser scanning confocal microscope and analysed with 
software from Leica (LCS 2.61).  
54 
 
4.4.10 Flow cytometry 
Initial experiments to determine optimal concentrations of antibodies were conducted 
using microvascular endothelial cells purchased from Promocell.  Each cell 
population was stained using the same conditions. 
CD31/CD90 characterisation 
Cells at 70-80% confluence were used in all characterisation experiments.  Cells 
were harvested using cell dissociation solution (Sigma) with approximately 100,000 
cells per 100ul used for each stain.  Cells were washed and re-suspended in 100ul 
PBS and incubated with FITC conjugated CD31 (#555445 BD Bioscience) and PE 
cy5 conjugated CD90 (# 555597 BD Bioscience) for 30 minutes at 4°C, to reduce 
non-specific binding.  Cells were then washed in PBS, centrifuged at 250g for 4 
minutes, re-suspended in 200ul PBS and analysed on FACS Scan (Becton 
Dickinson).   
CD62E characterisation  
Cells were grown in 6 well plates and at 70-80% confluence were treated with TNFα 
(1ng/ml).  Following treatment cells were harvested using cell dissociation solution 
with approximately 100,000 cells per 100ul used for each stain.  Cells were washed 
and re-suspended in 100ul PBS and incubated with APC conjugated CD62E (E-
selectin) (#551144 BD Bioscience) for 30 minutes at 4°C, to reduce non-specific 
binding.  Cells were then washed in PBS, centrifuged at 250g for 4 minutes, re-
suspended in 200ul PBS and analysed on FACS Scan.     
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4.5 Results 
Cell isolation was attempted from 17 patients (11 emphysema, 3 alpha-one anti-
trypsin related emphysema, 2 normal, 1 pulmonary arterial hypertension) and was 
successful from10 (71%) of 14 emphysematous lungs.  Table 3 shows the baseline 
characteristics and clinical data from the 17 individuals in whom cell isolation was 
attempted.  In addition to diagnosis, smoking history, PaO2 and spirometry 
measures were included where available.  Those patients with emphysema was 
categorised according to disease severity based upon the GOLD classification[3].  
Cell yield from successful cultures is documented. 
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Table 2: Patient demographics and cell yield 
Patient 
No: 
Gender Diagnosis Age BMI Smoking 
History 
(Pack 
yrs.) 
FEV1 
(%) 
TLC 
(%) 
KCO 
(%) 
GOLD 
stage 
Cell Yield  
(passage number at 
cryopreservation) 
1 M A1AT 
emphysema 
46 28.7 15 18 133 15 IV 1.9 x10
6
 cells (passage 4) 
2 F Emphysema 54 21.5 30 10 178 - IV 2.5 x10
6
 cells (passage 4) 
3 F Emphysema 53 20.9 30 22 131 32 IV 9.4 x10
6 
cells (passage 5) 
5.4 x10
6
 cells (passage 4) 
4 F Emphysema 51 20.8 30 28 150 33 IV 5.6 x10
6
 cells (passage 4)  
28.8x10
6
 cells (passage 5) 
5 F Emphysema 46 20.2 20 21 150 43 IV Unsuccessful 
6 M Emphysema 58 22.7 35 15 130 46 IV Unsuccessful 
7 F Emphysema 59 21.8 25 34 155 38 III 12x10
6
 cells (passage 4) 
8 M Emphysema 44 23 15 14 138 69 IV 3.2 x10
6
 cells (passage 4) 
21.5x10
6
 cells (passage 6) 
9 F Emphysema 60 28.3 20 26 95 25 IV 5.2x10
6
 cells (passage 6) 
10 M Emphysema 45 21.3 27 26 156 42 IV 5.4x10
6
 cells (passage 4) 
11 M Emphysema 55 20.8 55 17 130 24 IV Unsuccessful 
12 F A1AT 
emphysema 
40 26.1 25 16 136 33 IV 18.2x10
6
 cells (passage 6) 
13 M Emphysema 47 22.3 30 17 150 42 IV 13.9x10
6
 cells (passage 4) 
14 M A1AT 
emphysema 
52 21.2 15 22 127 71 IV Unsuccessful 
15 F Normal 68 - 15 104 - - N/A 1x10
6
 cells (passage 3) 
16 F Normal 65 - 40 80 - - N/A Unsuccessful 
17 F IPAH 60 26.4 0 83 107 109 N/A 10x106 cells (passage 3) 
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4.5.1 Phase contrast microscopy 
Prior to the first passage, cells in culture were a mixed population of elongated cells 
and cobblestone cells together with red blood cells.  Following the initial bead 
separation, at the first passage, the bead positive fraction of cells displayed 
cobblestone morphology and grew in a monolayer in colonies (Figure 4.1A).  Small 
beads could also be seen attached to many of the cobblestone cells.  In contrast, the 
bead negative fraction (Figure 4.1B) consisted of elongated spindle cells which grew 
in sheets, becoming confluent more quickly.  At the first passage there were areas in 
which a mixed population of cells was still present (Figure 4.1C) with some 
elongated cells growing together with cobblestone cells.  For this reason, repeated 
bead separation was performed until cultures contained only cobblestone cells.  
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Figure 4.1:  Phase contrast microscopy 
(magnification x20) of cells following the initial bead 
separation (Patient 4).  A) Cobblestone cells 
growing in colonies. B) Bead negative fraction 
showing elongated spindle cells.  C) Areas showing 
a mixture of cobblestone cells and more elongated 
cells.   
1B 1A 
1C 
59 
 
4.5.2 Characterisation of cells via confocal microscopy 
Around passages 4-6, when cultures appeared free from contaminating spindle cells 
on phase contrast microscopy, cells were plated onto glass coverslips and 
immunocytochemistry performed with images taken via confocal microscopy.  Figure 
4.2 shows representative images for (a) commercially available LMVECs 
(Promocell), the standard to which we controlled our isolated cells, b) LMVECs 
isolated from a patient with emphysema (patient 8), (c) LMVECs isolated from 
excess normal tissue (patient 15) and contrasted with (d) the bead negative fraction 
from excess normal tissue (patient 15).  Cells stained positively for the endothelial 
cell surface marker CD31 (FITC green) (Figure 4.2 a-c).  Cells displayed contact 
inhibition with the formation of a lattice of tight junctions.  The bead negative cells 
showed no CD31 staining (Figure 4.2d).  The mesenchymal marker alpha smooth 
muscle actin (αSMA) (TRITC red) was absent on CD31 positive cells (Figure 4.2 a-c) 
but was present on the CD31 negative fraction (Figure 4.2d) in an elongated spindle 
shaped pattern (red).  CD31 positive cells (Figure 4.2 a-c) also had very low levels of 
the intracellular matrix protein fibronectin, in contrast to CD31 negative cells (Figure 
4.2d) which demonstrated high staining (red) in sheet like form.    
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Figure 4.2: Confocal Microscopy characterisation of cells 
 
 
 
 
 
 
 
 
 
Figure 4.2: Detection of immunocytochemical markers via confocal microscopy (CD31: FITC 
green, aSMA: TRITC red, DAPI: blue). (a) LMVECs (Promocell) were compared to (b) LMVECs 
isolated from patient 8 with emphysema and (c) _LMVECs isolated from excess normal tissue 
(patient 15).  Cellular expression on these cells was compared with that of the (d) bead negative 
fraction from excess normal tissue.  All images were taken at X 63 magnification.  
 
 
a) Promocell 
     LMVECs 
b) Patient 8 
     LMVECs 
c) Patient 15 
     LMVECs 
d) Bead  
Negative cells 
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4.5.3 Flow cytometry 
LMVECs (Promocell) and dermal fibroblasts (gifted by ICM, Newcastle) were used to 
determine the optimal concentrations of each antibody (CD90 and CD31) required 
for flow cytometry characterisation experiments (Figure 4.3a-e).  Once 
concentrations for each antibody alone were determined, a second set of 
experiments were conducted to determine the optimal concentration of CD31 (1ul) 
and CD90 (0.5ul) to separate a mixed population of HLMVECs and fibroblasts 
(Figure 4.3f).  Following these preliminary experiments, cells from 5 patients with 
emphysema and a normal donor were characterised using the established protocol.  
The cell populations isolated from all donors were characterised by high expression 
of CD31 and low expression of CD90 (Figure 4.4).  Cells from the normal donor 
(patient 15) were characterised at passage 2, as evidenced by the slightly lower 
number of CD31 positive cells (78%). 
 
CD62E (E-Selectin) expression on isolated CD31 positive cells at baseline and after 
stimulation with TNFα was also investigated.  CD62E is a cell surface adhesion 
molecule involved in leukocyte trafficking that is absent on microvascular endothelial 
cells but is inducible upon cytokine stimulation [133].   Capillaries do not express 
CD62E at baseline or upon activation.  I therefore hypothesised that the isolated 
CD31 positive cells would be CD62E negative at baseline and that a proportion 
representing microvascular cells excluding capillaries would become CD62E positive 
upon stimulation while a second subpopulation representing the capillaries would 
remain CD62E negative.  LMVECs (Promocell) were first investigated to determine 
the concentration of TNFα, CD62 antibody and appropriate time course required.  
Approximately 40-50% cells stained positively for CD62E at a low concentration of 
TNFα (1ng/ml) after 1 hour and 24 hours, across a range of antibody concentration 
(2.5ul-10ul) (Figure 4.5).   A similar percentage of cells were positive for CD62E with 
higher concentrations of TNFα(2-8ng/ml) (figure 4.6).  CD31 positive cells from 3 
patients with emphysema were selected at random and thereafter stimulated with 
1ng/ml TNFα for 1 hour and stained for CD62E to investigate whether these cells 
were microvascular in origin.  The emphysema cells demonstrated minimal baseline 
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CD62E expression (<5%) with a rightward shift in response to TNFα stimulation at 1 
hour with approximately 30% cells staining positively for CD62E (Figure 4.7).  Cells 
from one emphysema donor (patient 8) were used to further investigate CD62E 
expression on these isolated cells at further time points (2, 4 and 8 hours) (Figure 
4.8).  There was similar induction of CD62E expression that became maximal at 8 
hours and then fell at 24 hours to levels similar to previous experiments.  Due to the 
precious nature of these cells, this time course was not repeated in multiple donors, 
as having demonstrated that the CD31 positive cells isolated were negative at 
baseline for CD62E but inducible in a proportion of cells, I had confirmed these to be 
of microvascular origin. 
.   
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Figure 4.3:  Representative flow cytometry scatter plots showing CD31 (FITC) and CD90 (PE 
cy5).  Figure 4.3(a) shows scatter plot of unstained mixed cell population, LMVECs (Promocell) 
and fibroblasts. Figure 4.3(b) Endothelial cells stain positively for CD31 and 4.3(c) negatively for 
CD90.  Figure 4.3(d) Fibroblasts stain negatively for CD31 but (e) strongly positive for CD90.  
Figure 4.3(f) Mixed Endothelial cells and fibroblasts show separation of the cell populations. 
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Figure 4.4: (a) Representative scatter plots depicting CD31 (FITC):CD90 (PEcy5) 
characterisation of cells isolated from patients 2,3,4,7 and 8 with emphysema and patient 15 
(normal) via flow cytometry.  Scatter plots show a single cell population positive for CD31 and 
negative for CD90 confirming these to be of endothelial origin.     (b) Summary chart showing high 
percentage of CD31+/CD90- cells, with small number of cells negative for both markers (CD31-
/CD90-).  There was also a small percentage positive for both markers (CD31+/CD90+)using the 
gating of forward scatter and side scatter, however there were no cells which were significantly 
CD90+ when compared with staining on fibroblasts (Figure 4.3(e)). 
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CD62 CD62 
1 HOUR 
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TNFα 1ng/ml UNSTIMULATED UNSTAINED 
Figure 4.5: Representative flow cytometry scatter plots showing the response of LMVECs 
(Promocell) to TNFα (1ng/ml) stimulation at 1 and 24 hours as detected by differing 
concentration of CD62E antibody (2.5-10ul).  Approximately 40-50% cells stained positively for 
CD62E at a low concentration of TNFα (1ng/ml) for 1 hour and 24 hours, across a range of 
antibody concentration (2.5ul-10ul).  Due to the precious nature of these cells the data 
represented reflects n=1. 
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CD62 CD62 CD62 
Unstimulated TNFα 2ng/ml TNFα 4ng/ml TNFα 8ng/ml 
Figure 4.6: Representative scatter plots and histograms for LMVECs (Promocell) in response to 
stimulation with increasing concentration of TNFα (0-8ng/ml).  A similar percentage of cells 
(~50%) were positive for CD62E following stimulation with higher concentrations of TNFα (2-
8ng/ml). 
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Figure 4.7: Representative scatter plots showing the response of microvascular endothelial 
cells from patients 4, 8, 10 with emphysema to TNFα (1ng/ml) stimulation for 1 hour as 
measured via CD62E immunostaining via flow cytometry.  The emphysema cells demonstrated 
minimal baseline CD62E expression (<5%) with a rightward shift in response to TNFα 
stimulation at 1 hour with approximately 30% cells staining positively for CD62E 
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Figure 4.8: Percentage CD62E positive cells (patient 8) determined via flow cytometry (Mean 
+/- SD; n=3) following treatment with TNFα (1ng/ml). Untreated cells did not express CD62E. 
The percentage of treated cells that expressed CD62E was maximal at 8 hours before falling at 
24 hours. The profile observed is most likely the result of TNFα induced transcriptional induction 
at early time points and cleavage of CD62E from the cell surface at 24 hours. 
 
69 
 
4.6 Discussion 
Microvascular endothelial cells have been isolated previously from a variety of 
tissues including human lung, however this is the first report of the ability to isolate 
these cells from emphysema lung tissue.  This method allows ex vivo study of a cell 
population which may be key in the pathogenesis of emphysema.    Importantly, this 
method allows the isolation and culture of large numbers of human LMVECs (Table 
1) with a high success rate (71%).  The isolated cells were successfully expanded 
following purification prior to cryopreservation and later re-animated for use in 
studies. All cells used in these experiments had been cryopreserved and later 
reanimated apart from cells from patient 15 (normal) which were used at passage 2 
and had not been cryopreserved.  The data presented include cells between 
passage 2 and 7, thus confirming that cells showed stability of phenotype. 
 
Certain steps were critical to the success of this method. The tissue could be stored 
for up to 24 hours from the time of transplant until histopathological processing, 
however once processing began, cell isolation had to follow immediately otherwise it 
was unsuccessful.  Careful dissection of the large vessels and removal of pleura to 
prevent overgrowth by contaminating mesothelial cells was also vital.  Daily 
observation of cell numbers and doubling time was also required in order to 
determine the optimal time for bead separation as time between each passage 
differed between donors and did not appear related to passage number or disease 
severity.  
 
Endothelial cell extraction employed bead separation with magnetic dynal beads for 
CD31 (endothelial cell surface marker) and UEA-1 (an endothelial based lectin).  
Other researchers have previously reported difficulties when using CD31 dynal 
beads, hypothesising that disruption of cell surface CD31 by beads inhibited the cell 
to cell interactions required for successful growth in culture [133].  I did not encounter 
such problems, although doubling time immediately post bead separation was more 
prolonged.   
 
70 
 
By passage 3-5, cells appeared free from contaminating spindle shaped cells 
(mesenchymal cells and fibroblasts) and were characterised according to a standard 
protocol developed using commercially available cells.  The commercially available 
cells were used both to set a standard against which the cells isolated could be 
characterised and to ensure the precious isolated cells were not used for preliminary 
optimisation of dose and time characterisation experiments.  Comparing the cells 
isolated from patients with emphysema to those isolated from lung resection 
operations and commercially available cells provided a further control.  
 
The immunocytochemical detection of cell surface markers via confocal microscopy 
confirmed the isolated cells were endothelial, staining positively for the endothelial 
marker CD31 with weak/absent staining for mesenchymal markers.   This was 
further confirmed by flow cytometry, with cells staining positively for the endothelial 
cell marker CD31 and negatively for the fibroblast marker CD90.  These approaches 
proved very cell efficient, requiring only small numbers of cells for full 
characterisation (~1x106), thus preserving large numbers of cells for use in future 
studies.   
 
Plant derived lectins have previously been employed to differentiate between 
microvascular and macrovascular endothelial cells [119].  I encountered difficulties 
with non-specific binding of the lectins Griffonia (Bandeiraea) simplicifolia and Helix 
pomatia previously used to differentiate between microvascular and macrovascular 
endothelial cells respectively both on single cells and on paraffin embedded tissue.  
As a result, I investigated E-selectin (CD62E) expression as an alternative method to 
differentiate between microvascular and macrovascular endothelial cells.  E-Selectin 
(CD62E) and P-Selectin (CD62P) are receptor molecules for monocytes and 
neutrophils that are expressed on activated endothelial cells [134].  CD62E, in 
contrast to CD62P which is stored in Weibel-Palade bodies in endothelial cells, is 
transcriptionally induced on microvascular endothelial cells in response to cytokine 
stimulation [133].  Capillaries are not thought to express CD62E [135], [136].  Thus 
quiescent microvascular cells do not express CD62E but following activation 
intraacinar arterioles and venules express CD62E, while capillaries remain negative 
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for CD62E.  In this study, the isolated CD31 positive cells showed very low (<5%) 
staining for CD62E at baseline.  In response to stimulation with TNFα, there was 
inducible staining in around 30-50% of the isolated cells at 1 hour.  Inducible CD62E 
in response to TNFα suggests these endothelial cells are microvascular.  
Furthermore, the presence of a subpopulation that was endothelial (i.e. positive for 
CD31) but did not up-regulate CD62E in response to TNFα suggests that the cells in 
this subpopulation are pulmonary capillary endothelial cells.  Importantly this 
subpopulation was greater in the cells isolated from patients with emphysema 
compared with commercially available cells from Promocell used in the optimisation 
experiments.  These pulmonary microvascular endothelial cells may therefore 
provide a more appropriate model than the current commercially available cells. 
 
Infection is undoubtedly the major challenge to successful isolation and investigation 
of human pulmonary microvascular endothelial cells.  Due to the inherent risks of 
introducing infection whilst culturing the cells, the lobe of lung was placed in DMEM 
containing 0.1% penicillin streptomycin and amphotericin (PSA) prior to processing.  
0.1% PSA was included in all MV2 media used in cell culture, the risk of infection 
being deemed greater than any adverse effect on growth kinetics the antimicrobials 
may have.  In spite of this, a number of cell cultures were lost to infection, mostly 
around P5-P6.  With cell aging, growth kinetics reduced, with greater time to 
confluence.  Thus cells spent longer time in culture at each passage, increasing the 
likelihood of infection.  Amphotericin was included as we encountered more fungal 
infections than bacterial infections.     
 
As with all ex vivo cell culture systems, inherent limitations are associated.  Cells 
were passaged 3-5 times prior to obtaining pure cobblestone cultures which were 
characterized as endothelial.  Cells therefore have a protracted culture period, with 
possible associated increased senescence and change in cell characteristic.  Cells 
were grown in MV2 media (Promocell) which included 5% fetal calf serum 
supplementation and other survival factors such as hydrocortisone (0.2ug/ml), 
recombinant human epidermal growth factor (5ng/ml) fibroblast growth factor 
(10ng/ml) vascular endothelial growth factor (0.5ng/ml) and insulin like growth factor 
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(Long R3) (20ng/ml).  The addition of hydrocortisone to cell culture media has been 
a contentious matter due to concerns over increased cell stress and how this may 
change cellular physiology.  The concentration of hydrocortisone in MV2 media 
(Promocell) is considerably lower than in other types of microvascular endothelial 
cell media and its omission led to cell death.   
 
Isolation of cells from patients with the disease in question, namely emphysema, was 
initially time consuming, requiring ethical approval and significant commitment in 
order to obtain fresh tissue at the time of transplantation.  Furthermore, full 
characterisation of these cells to confirm their pedigree once again was more 
laborious than the use of an immortalised cell line or indeed the use of commercially 
available cells.  However, following the initial outlay of work, one obtains a valuable 
resource that has been isolated and characterised via a standard methodology, with 
corresponding clinical data to further characterise the cells. This cell isolation method 
can also be applied to other respiratory diseases in which the pulmonary 
microvasculature may be pivotal such as pulmonary arterial hypertension and 
idiopathic pulmonary fibrosis.  Indeed large numbers of cells from IPAH were 
obtained at lower passage and with higher yield than the emphysema model.    
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Chapter 5: Endothelial cell apoptosis in emphysema 
5.1 Abstract 
Apoptosis has been suggested to be important in the pathogenesis of emphysema 
and is linked to loss of the microvasculature.  A number of researchers have shown 
in animal models that loss of VEGF leads to apoptosis and may lead to emphysema 
like changes.  Studies of human pathology have further confirmed apoptosis of 
alveolar cells however the predominant cell type is still debated.  It is also unclear, 
although a relatively simple scientific question that is sometimes alluded to as being 
a known fact, whether microvascular endothelial cells undergo apoptosis in response 
to CSE.  I therefore investigated apoptosis in response to CSE using the susceptible 
HLMVECs isolated from patients with severe emphysema.  In addition VEGFR2 
gene expression was also investigated. 
Methods: LMVECs (Promocell) were used for viability studies via flow cytometry.  
These studies were then repeated with cells isolated from individuals with 
emphysema and apoptosis detected via flow cytometry using Annexin V as a marker 
of apoptosis.  Cells were also TUNEL stained as a second method to detect 
apoptosis.  Due to inherent difficulties of ascertaining the most appropriate time point 
and concentration of CSE at which to look for apoptosis, fluorescent live cell imaging 
was employed to detect fluorescence generated upon activation of caspase 3 using 
DEVD Nucview-488.  q-PCR for VEGFR2 was thereafter investigated to examine 
gene expression in response to CSE. 
Results:  Cell viability studies confirmed cells were resistant up to 10% CSE and 
that the isolated emphysema cells were less viable at baseline and more susceptible 
to injury.  Fluorescence live cell imaging showed both short and prolonged low dose 
CSE treatment caused an increase in fluorescence counts in both LMVECs 
(Promocell) and in cells isolated from a patient with emphysema.  CSE treatment 
alone however caused autofluorescence of the cells and although control 
experiments were performed in attempt to quantify this, it was therefore not possible 
to determine whether these cells undergo apoptosis. q-PCR for VEGFR2 was 
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unchanged in normal HLVECs (Promocell) in response to CSE while HLMVECs 
isolated from emphysema tissue show a reduction in VEGFR2 in response to CSE at 
48 hours compared with untreated isolated cells.  The influence of the cell isolation 
procedure on apoptosis and VEFR2 was not determinable. 
Conclusions:  Apoptosis in response to CSE was studied in both commercial 
LMVECs (Promocell) and LMVECs isolated from patients with emphysema using a 
number of techniques including Annexin V, TUNEL and detection of caspase 3 
activation.  Unfortunately all of these techniques employed the use of fluorescence 
and as CSE itself causes autofluorescence, despite attempts to control for this, it 
was not possible to state whether cells undergo apoptosis in response to this injury. 
qPCR suggests that LMVECs down regulate VEGFR2 in response to CSE, in 
contrast to normal LMVECs (commercial primary cells) which may suggest a 
maladaptive response to CSE injury in cells from susceptible individuals.  
Unfortunately due to the number of cells isolated in the same manner from normal 
patients free from disease it was not possible to repeat this experiment in these cells 
thus limiting the conclusions that can be drawn from comparing commercial primary 
LMVECs with the emphysema LMVECs. 
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5.2 Introduction 
Apoptosis is an energy dependant programmed cell death for the deletion of 
unwanted individual cells that is important in morphogenesis and is also thought to 
be crucial for ongoing tissue homeostasis [61].  Apoptosis has long been recognised 
to play an important role in tumour biology[137] and more recently has been 
implicated in emphysema[138].  Rats treated with a VEGF receptor blocker 
(SU5416) develop airspace enlargement and loss of the microvasculature similar to 
emphysema that can be prevented by the addition of a caspase-3 inhibitor [63].  
Clinical studies support this animal model with increased apoptotic endothelial and 
epithelial cells in the alveolar septa of emphysematous lung tissue when compared 
with tissue from non-smokers and smokers without emphysema [54].  VEGF and 
VEGF receptor 2 mRNA and protein are also reduced in emphysema tissue [54].  
A1AT has also been reported to have anti-apoptotic actions [6],[7], accounting for the 
accelerated emphysema witnessed in individuals homozygous for the PiZ allele and 
further supports the key role apoptosis may play in the development of emphysema.  
These studies led other researchers to investigate apoptosis rates in 
emphysematous tissue with similar findings, with Yokohori and Imai also highlighting 
the dynamic nature of emphysema; the balance between co-existent alveolar cell 
death and proliferation determining the complex pathology witnessed[17,20]. 
 
The response of endothelial cells to cigarette smoking ex vivo is however less well 
studied.  Tuder et al presented an abstract entitled “Cigarette smoke extract 
decreases the expression of vascular endothelial growth factor by cultured cells and 
triggers apoptosis of pulmonary endothelial cells” [139]  at a meeting in 2000 
however while this data is noteworthy it has since not been published.  U937 
(monocyte cell line), HepG2 (hepatocellular carcinoma) and A549 (alveolar epithelial 
cell line) cells were treated with 10% CSE for 24 hours and reduced VEGF protein 
and mRNA was observed on western blotting and ribonuclease protection assays 
[139].  CSE treatment was also reported to induce a two fold increase in NO 
production in all cell lines studied [139].  They then investigated apoptosis in these 
cells lines and bovine pulmonary artery endothelial cells in response to treatment 
76 
 
with 10% CSE for 24 hours.  They reported “apoptosis and complete detachment 
from the culture dish of bovine pulmonary artery endothelial cell, while minimal 
detachment and apoptosis were seen with the U937, HepG2 and A549 cells”.  
Importantly they did not specify how apoptosis was measured and did not quantify 
relative rates of apoptosis.  Other researchers have published studies examining 
apoptosis in response to cigarette smoke extract but have not focused on endothelial 
cells, in contrast reporting apoptosis in alveolar macrophages[140], human lung 
fibroblasts[141] and in A549 cells, the alveolar type II cell derived line[142].  Michaud 
et al reported impairment of HIF-1alpha/VEGF in response to cigarette smoke 
extract on HUVECs but reported no toxicity up to 10%CSE and detected no 
apoptosis via TUNEL [143].   Later studies reported the ability of alpha-one 
antitrypsin [144] and prostacyclin [110] to attenuate apoptosis in cell culture models.  
Interestingly, these authors allude to apoptosis in response to cigarette smoke being 
a published and accepted finding and report simply the ability to reverse this.  One of 
these reports used pulmonary artery endothelial cells isolated from the main 
pulmonary arteries of 6 month old pigs, thus has the major limitations of species 
specific differences and that fact that these cells are PAECs and not LMVECs.  The 
cigarette smoke used in these experiments was also different to the standard 
method developed by Carp and Janoff [111].   Rates of apoptosis were surprisingly 
high also, with approximately 50% of cells undergoing apoptosis [144].  For these 
reasons, further investigative work was conducted to investigate the response of 
human pulmonary microvascular cells to cigarette smoke extract.  
 
Smoking a single cigarette exposes an individual to around 6000 compounds, a 
large number of which are toxic [72].  Developing a model to study the effects of 
cigarette smoking is therefore complicated by the sheer number of compounds which 
can be studied and also the variability in how an individual smokes (number of 
inhalations, volume of inhalation etc.).  Not withstanding these factors, a number of 
models of cigarette smoking have been developed to study the effects of smoking ex 
vivo [111][145], [146].  One of the most widely accepted methods is that developed 
by Carp and Janoff more than 30 years ago [111].  It involves entraining smoke and 
bubbling this through an aqueous solution, to produce a cigarette smoke extract.  
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This method has the major disadvantage that CSE is in the liquid as opposed to 
gaseous phase and some volatile and rapidly reactive compounds are lost.  It may 
also be less physiological, as endothelial cells are not directly exposed to cigarette 
smoke in vivo.  Other models have been developed which involve cells being 
exposed to cigarettes via a smoking chamber [146], which may be more 
physiological, however adding such complexity without large scale machinery such 
as a smoking robot can make the stress more variable and less reproducible.  Some 
researchers have also developed models using individual toxins such as acrolein 
[147], however this model does not reflect the likelihood that smoke related injury 
arises via compound effects rather than the sum of multiple independent toxicities.  
Rejecting a model because it does not perfectly reproduce some aspect of human 
smoking has been correctly stated as unscientific and likely to hamper advances in 
our understanding [72].  Instead, it is widely accepted that a model must act as a 
reasonable surrogate in which investigation of a hypothesis may be conducted.  In 
this thesis I have used the method developed by Carp and Janoff [111] due to its 
simplicity, highly published rate and relative reproducibility. 
 
There are a number of methods via which apoptosis may be studied.  Two of the 
commonest methods are the detection of phospholipid phosphatidylserine (PS) and 
activated caspase 3.  A key step in apoptosis is the changes in plasma membrane 
structure, with translocation of PS from the inner to the outer leaflet of the plasma 
membrane[148].  On the outer leaflet of the plasma membrane PS acts as a signal 
for phagocytic cells in the apoptosis cascade.  Annexin V is a 36kDa calcium 
dependant phospholipid binding protein with high affinity for PS[149].  This affinity 
has been exploited as a method for detecting apoptosis, with conjugation of Annexin 
V to a number of fluorochromes that can be detected via fluorescence, commonly via 
flow cytometry and confocal microscopy.  In these studies I have used flow 
cytometry to identify apoptosis via FITC Annexin V, together with 7-Amino-
Actinomycin.  7-AAD labels cells without an intact membrane, thus does not 
differentiate between cells which have died via necrosis and cells which have 
undergone apoptosis per se, as in the late stages of apoptosis cell membrane 
integrity is lost and cells appear indistinguishable from necrotic cells. 
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Detection of activated caspase 3 is another method which is frequently employed to 
investigate apoptosis[150].  Caspases (cysteine aspartase) are cysteine proteases 
which exist in their inactive pro-form in living cells.  The apoptosis pathways lead to 
cleavage of a number of pro-caspases to caspases, with the acquisition of their 
protease activity, which allows transmission of apoptotic signals to the 
nucleus/mitochondria.  Activated caspase 3 is therefore a useful marker of 
apoptosis.  Activated caspase 3 can be detected on cell lysates via western blotting 
or ELISA and on tissue via immunohistochemistry.  In these studies I have examined 
activated caspase-3 expression on emphysema tissue from which the cells were 
isolated in order to determine apoptosis in severe end stage emphysema. 
 
DNA fragmentation and degradation occurs late in apoptosis and can be detected 
via TUNEL (TdT-mediated X-dUTP nick end labelling)[151].  TUNEL uses the nicks 
that appear in DNA in apoptosis as a marker that can be detected.  Terminal 
deoxynucleotidyl transferase (tdt) identifies these nicks in DNA and catalyses the 
addition of dUTPs to these.  dUTPs are labelled with a marker, that can be detected, 
most commonly via fluorescence, thereby allowing apoptosis to be quantified.  In this 
study I have examined TUNEL staining both on cells exposed to CSE and on the 
tissue from which these cells were isolated.   
 
When studying apoptosis it is important to take into account cell type, time course, 
dose in addition to the dynamic nature of apoptosis.  Thus one could postulate that 
between commercially available lung microvascular cells and primary cells isolated 
from differing patients with emphysema, cells may undergo apoptosis at differing 
rates at differing time points.  In addition the dose of cigarette smoke extract that 
may trigger apoptosis may differ.  The ability therefore to image cells in real time via 
live cell imaging, over a wide variety of concentrations is attractive.  The emergence 
of fluorogenic enzyme substrates that are highly cell permeable have been exploited 
in order to capture apoptosis via live cell imaging.  DEVD-Nucview488 is a 
fluorogenic caspase 3 substrate that can be used for this purpose [152].  Ac-DEVD is 
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a highly negatively charged caspase-3 recognition site that is linked to Nucview488, 
a positively charged DNA binding dye.  In its stable state, DEVD-Nucview488 is 
highly bound and does not stain the nucleus, however due to its cell permeability can 
pass freely into the cell where it remains.  Apoptosis, with activation of caspase-3 
cleaves Ac-DEVD from Nucview488, which allows the positively charged 
Nucview488 to migrate to the nucleus and bind to DNA, causing excitation at 488nm 
that can be detected via fluorescence microscopy.  This method was therefore used 
in these studies, as it allows cell efficient investigation of apoptosis in precious 
primary cells in real time.   
 
I hypothesised that pulmonary microvascular endothelial cells undergo apoptosis in 
response to cigarette smoke extract and will investigate this using the above 
techniques.  Apoptosis was firstly investigated in the tissue from which microvascular 
endothelial cells were isolated via immunohistochemistry for activated caspase-3 
and TUNEL.  The receptor (KDR/FLK1) for the pro-endothelial survival factor, VEGF, 
was also assessed via immunohistochemistry.  The ex vivo work began with viability 
studies using LMVECs (Promocell) in response to CSE to identify a concentration 
which would stress cells but not cause mass cell death.  Apoptosis was then 
investigated via flow cytometry for Annexin V and 7-AAD.  Following these 
preliminary studies, viability studies were repeated on the primary cells isolated from 
emphysema tissue followed by investigation of apoptosis via Annexin V.  TUNEL 
staining on cells post CSE exposure was also investigated.  DEVD-Nucview488 was 
used to detect apoptosis in real time via live cell imaging in both commercially 
available normal cells and in emphysema cells isolated from patients.  Finally, 
VEGF-KDR mRNA expression in response to CSE was also investigated via qPCR 
and is reported in this chapter. 
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5.3 Materials and Methods 
5.3.1 Immunohistochemistry 
Immunohistochemistry for Activated caspase-3 (AF835 R+D 2.5ug/ml) and FLK1 
(Santa Cruz) were performed on 4um paraffin embedded tissue sections from 
emphysema and control tissue.  The Envision Flex system was used with reaction of 
the primary antibody, after blocking agent, with Flex HRP.  Immunoreactants were 
visualised using diaminobenzidine (DAB) substrate solution.  Isotype controls were 
included in each experiment to assess quality of staining.   
5.3.2 TUNEL 
TUNEL was performed on paraffin embedded tissue and cells isolated from 
emphysema tissue using commercially available kits from Roche (11684795910).  
Tissue was dewaxed through xylene to graded alcohol prior to antigen retrieval via 
low pH microwave treatment.  Endogenous tissue peroxidase was quenched with 
6% H2O2.   Cells were fixed in freshly prepared 4% paraformaldehyde and 
permeabilised on ice with 0.1% TritonX-100 in 0.1% sodium citrate.  A positive 
control was included for experiments on tissue and cells, by pre-treatment with 
DNase. After washes, TUNEL reaction mixture containing TdT and fluorescein-dUTP 
was added and incubated at 37˚C in the dark. Incubation with TdT catalyses the 
addition of fluorescein-dUTP to free 3'-OH groups (DNA breaks/nicks), thus allowing 
detection of apoptosis.  After washing, incorporated d-UTP was visualised by 
fluorescence microscopy.  Tissue sections had high background autofluorescence, 
and so converted via POD to HRP/DAB for visualisation by light microscopy. 
5.3.3 Cell culture 
Commercially available human pulmonary microvascular endothelial cells 
(Promocell) and cells isolated from emphysematous human lung were grown in 
complete MV2 media (Promocell) containing supplements and 5% FCS. Cells were 
grown in 25cm2 flasks (qPCR), on 6 well plastic plates coated with gelatin (cell 
viability and apoptosis via flow cytometry), on 18mm coverslips (TUNEL) and on 96 
well gelatin coated plates for live cell imaging.  
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5.3.4 CSE preparation 
Cigarette smoke extract was prepared according to the method by Carp and Janoff 
[111].  As outlined in figure 3.1, one Kentucky filterless research cigarette was 
attached via tubing to a vacuum pump and the smoke from this cigarette gently 
bubbled through 25ml endothelial cell culture media (containing 5% FCS), over 
approximately 6 minutes.  The resulting media was tar stained and final 
concentration stated as 100% CSE.  CSE was made on each occasion by the same 
operator (LSM) and when analysed on a spectrophotometer had the same 
absorbance.   pH of CSE was also unaltered compared with whole media.  Due to 
the precious nature of the cells, CSE was filtered through a 0.2um filter and then 
used within 30 minutes of preparation. 
5.3.5 Flow cytometry 
Initial cell viability studies were conducted using propidium iodide.  Apoptosis was 
investigated using Annexin V/7AAD kits purchased from BD Bioscience. (#559763 
BD Bioscience).  After stimulation, cells were harvested using cell dissociation 
solution (Sigma).  Cells were resuspended in 100ul 1x binding buffer (BD 
Bioscience).  5ul of Annexin V and 7-AAD were added to each tube and incubated at 
RT for 15 minutes, before analysis on FACS scan.  Flow cytometer settings were 
controlled using unstained cells, cells stained with Annexin V alone and 7AAD alone 
prior to each experiment.  Data was analysed using Venturi software.  
5.3.6 Live cell imaging via DEVD-Nucview488 
DEVD-Nucview 488 (stock concentration 1mM) was purchased from Biotium 
(10400).  Cells were grown on 96 well gelatin coated costar plates.  CSE treatments 
were applied in whole media, together with Nucview added (1ul stock per ml of 
media) and 100ul of media with DEVD-Nucview488 (final concentration 1uM) added 
to each well.  Cells were then placed in an incubator at 37˚C with 5% CO2 and 
observed with a fluorescence microscope in real time and analysed via Incucyte 
software. 
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5.3.7 VEGF-KDR qPCR 
RNA was isolated from cells using the Absolutely RNA microprep kit (400805) 
Agilent.  RNA yield and purity was determined via UV absorbance using a 
NanodropSpectrophotometer (ND-1000).  All RNA used had a ratio of absorbance at 
260 nm and 280 nm (A260/280) of 2.0 or above. Quality of RNA was further assessed 
via running samples on a 2% agarose gel containing 4ul ethidium bromide with 
loading buffer of 30% glycerol, 70% TAE (Tris-acetate-EDTA) and bromophenol blue 
in 1% TAE.  A trackIt (Invitrogen) DNA ladder was used to identify molecular weight.  
cDNA was thereafter prepared from RNA using an Affinity Script Multiple 
temperature cDNA synthesis kit according to RNA concentration.  cDNA was stored 
at -80°C until used for q-PCR. 
 
Samples for qPCR were prepared on 96 optical well plates (Applied Biosystems) by 
adding 10ul mastermix, 6.5ul RNAse free H2O and 1ul primers (18s and KDR) to 
each well.  2.5ul of cDNA was then added to each well.  Samples were ran on ABI 
PRISM 7000 Taqman real-time PCR machine (Applied Biosystems) and analysed on 
ABI Prism 7000 SDS software.  Real-time reaction products for each primer were 
confirmed on 2% agarose gel electrophoresis. 
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5.4 Results 
TUNEL staining was firstly employed to investigate apoptosis as this has been 
widely reported in the emphysema literature[64][54].  The commercial kit (Roche 
11684795910) recommended optimisation for each tissue with differing pre-
treatment protocols.  Pre-treatments including proteinase K, triton x100, low pH 
microwave and no pre-treatment were all assessed.  High autofluorescence in 
peripheral lung caused by elastin made the signal uninterpretable and so the signal 
was converted to peroxidise/DAB using the POD converter contained within the kit.  
The staining with TUNEL HRP-DAB was very variable with large areas of tissue 
showing high staining while some areas showed no staining.  A review of the 
literature supports this and highlights that TUNEL in archived paraffin-embedded 
tissue has at best 50% sensitivity[153].  The TUNEL technique relies on being able 
to detect breaks in DNA.  Fixation of tissue in paraffin-embedded archived blocks 
tends to be variable across the block being greater in the centre of the block and less 
in the periphery, thus explaining some of the variability observed in the stain.  
Secondly pre-treatments (antigen retrieval) such as proteinase K and microwave low 
pH can in themselves lead to breaks thus leading to false positives.  The use of 
frozen tissue sections may prove more reliable with TUNEL staining, but as with 
most tissues banked for research, all samples in this study were paraffin embedded.  
Some researchers have tried to optimise TUNEL staining in paraffin-embedded 
tissue, reporting sensitivity up to ~80%, however I rejected this method as such false 
positive and false negative staining could make the apoptosis work in vivo 
uninterpretable, as emphysema is a disease in which there are areas of relative 
normality next to areas of severe disease.  Activated caspase-3 
immunohistochemistry was therefore employed to investigate apoptosis in vivo. 
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5.4.1 Apoptosis of endothelial cells in emphysema in vivo 
Both (a) control and (b) emphysema tissue show DAB positive cells indicating the 
presence of apoptotic cells (activated caspase-3 positive cells) in health and disease 
and thus validate the immunostain.  Isotype controls also confirmed this staining to 
be specific (Appendix).  Activated caspase-3 positive cells were more frequent in 
alveolar septa of (d) emphysema tissue than (c) control tissue indicating increased 
apoptosis in keeping with other researcher’s findings. 
 
 
 
 
 
 
  
Figure 5.1: Immunocytochemistry images for a) control lung tissue and b) emphysema lung tissue 
(Image taken at x20 magnification).  Activated caspase 3 (DAB positive cells) indicate the 
presence of apoptotic cells in both (a) control and (b) emphysema tissue.  Further magnification 
(boxes) of the (c) control and (d) emphysema tissue shows that the positive (activated caspase 3) 
cells were a more frequent finding in alveolar septa of (d) emphysema tissue than (c) control 
tissue in agreement with the findings of other researchers of increased apoptosis in emphysema 
tissue. 
(a) (b) 
(c) (d) 
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5.4.2 Cell viability studies in response to cigarette smoke extract 
Human Lung Microvascular endothelial cells (LMVECs) (Promocell) at passage 3 
were grown to 70% confluence and then treated (n=3) with varying concentrations 
(0-100%) of cigarette smoke extract (CSE).  Cell viability was measured via flow 
cytometry using propidium iodide (PI) as a marker of cell death.  The results are 
shown in figure 5.2.  After one hour, cells showed no significant cell death up to 10% 
CSE, (Viable cells (mean ± sem): Control 76.18±3.12 vs 10% CSE 76.12 ±4.62, 
p=0.99) (Figure 6.3a).  Exposure to 100% CSE for 1 hour led to significant cell death 
with only 55.36% ± 1.47 remaining viable (p=0.004).  At 24 hours, there was no 
significant cell death up to 10% CSE (Control 79.26% ±3.47 vs 10% CSE 78.46 
±1.52, p=0.843) (Figure 5.3b).   However, exposure for 24hours to 100% CSE led to 
mass cell death with only 15.61% ±2.69 cells remaining viable (p=0.000).   
 
In order to verify this result and investigate cell viability at higher passage, LMVECs 
(Promocell) (n=3) at passage 5 were treated with the same varying concentrations of 
CSE as before (0-100%) (Figure 5.4).  Similar results were found with no change in 
cell viability up 10% after 1 hour (Control 75.26±3.12 vs 10% CSE 67.30±4.62, 
p=0.075) and 24 hours treatment (Control 73.10±3.47 vs 10% CSE 70.54±1.54, 
p=0.308).  Reduced cell viability was again observed with 100% CSE for 1 hour 
(57.83±1.47, p=0.001) and mass cell death at 24 hours (23.5±2.70, p=0.000).   
 
From these preliminary studies I chose 3% CSE as a stress stimulus for cells in 
initial apoptosis studies in Promocell LMVECs.   
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Figure 5.2: Flow cytometry data for LMVECs at passage 3 (Promocell) treated with 0-100% CSE 
and stained for propidium iodide.  After one hour CSE exposure, cells showed no significant cell 
death up to 10% (Viable cells (mean±sem): Control 76.18±3.12 vs 10% CSE 76.12 ±4.62, p=0.99) 
(Figure 5.3a).  Exposure to 100% CSE for 1 hour led to significant cell death with only 55.36% ± 
1.47 remaining viable (p=0.004).  At 24 hours, there was no significant cell death up to 10% 
(Control 79.26% ±3.47 vs 10% CSE 78.46 ±1.52, p=0.843) (Figure 5.3b).   However, exposure for 
24hours to 100% CSE led to mass cell death with only 15.61% ±2.69 cells remaining viable 
(p=0.000).  All data points represents n=3.    
a) 
b) 
87 
 
 
 
 
 
 
CSE 1 hour
0
20
40
60
80
100
0 0.1 1 3 10 100
CSE (%)
P
e
rc
e
n
ta
g
e
 C
e
ll
s
 (
%
)
ALIVE
DEAD
CSE 24 hour
0
20
40
60
80
100
0 0.1 1 3 10 100
CSE (%)
P
e
rc
e
n
ta
g
e
 C
e
ll
s
 (
%
)
ALIVE
DEAD
Figure 5.3: Flow cytometry data for LMVECs passage 5 (Promocell) treated with 0-100% CSE 
and stained with propidium iodide.  After 1 hour treatment with CSE, there was no change in cell 
viability up 10% (Control 75.26%±3.12 vs 10% CSE 67.30% ±4.62, p=0.075) (Figure 5.4a).  There 
was also no effect on cell viability with up to 10% CSE treatment at 24 hours (Control 73.10% 
±3.47 vs 10% CSE 70.54% ±1.54, p=0.308) (Figure 5.4b).  Following 100% CSE for 1 hour there 
was significant cell death with only 57.83 ±1.47 remaining viable (p=0.001) and mass cell death at 
24 hours with only 23.5%±2.70 remaining viable (p=0.000). All data points represents n=3.    
 
 
a) 
b) 
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5.4.3 Apoptosis in commercially available normal cells in response to 
cigarette smoke extract 
 
LMVECs (Promocell) at were grown to 70% confluence and then treated with 3% 
cigarette smoke extract (CSE).  Apoptosis was then investigated via flow cytometry 
via FITC conjugated annexin V with non-viable cells detected via 7-AAD (Figure 
5.4).There was no significant change in cell viability (P=0.23) among cells, untreated 
vs treated with 3% CSE for up to 72H.  There was no significant apoptosis detected 
in response to 3% CSE (P=0.39) across all time points.  Of the non-viable cells 
(necrotic/late apoptotic) there was a trend towards increased cell death after 
exposure to 3% CSE for 1 hour as compared with untreated/control cells and cells 
treated for 24,48 and 72 hours (P=0.087) although this did not reach significance.    
  
89 
 
 
 
 
 
ANOVA 
• Alive P= 0.233 
• Apoptotic P= 0.39 
• Dead P= 0.087 
Figure 5.4: Flow cytometry data for LMVECs (Promocell) treated with 3% CSE and stained for 
annexin V to detect apoptosis and 7-AAD to detect non-viable cells.  There was no significant 
change in viability (P=0.23) among cells treated with 3% CSE for up to 72H.  There was no 
significant apoptosis detected in response to 3% CSE (P=0.39).  Of the non-viable cells 
(necrotic/late apoptotic) there was a trend towards increased cell death after exposure to 3% CSE 
for 1 hour as compared with untreated/control cells and cells treated for 24,48 and 72 hours 
(P=0.087) but this did not reach significance.    
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5.4.4 Isolated Cells: Viability studies in response to cigarette smoke 
extract 
Cell viability and apoptosis was then investigated in LMVECs isolated from 
emphysema lung tissue (patient 10) at passage 5 (figure 5.5).  Cells were grown to 
70% confluence and then treated with varying concentrations (guided by previous 
viability studies conducted earlier in commercial LMVECs) of CSE.  Cells were 
treated (n=2) with 0-30% CSE for 24 hours and viability assessed via 7-AAD.  
Annexin V was also added to gain insights into apoptosis.  In this experiment, cell 
viability was generally lower with only 55.6% control cells viable.  In response to CSE 
there was no significant change in cell viability up to 10% CSE (p=0.065) however 
treatment with 30% CSE led to a large reduction in cell viability, with only 14.89% 
±4.32 viable at 24 hours (p=0.011).  Due to low baseline cell viability and relatively 
wide standard errors, it is not possible to comment on any trends that may be 
apparent in cells undergoing apoptosis, however these emphysema cells with lower 
baseline viability may be more susceptible to cell death, including apoptosis.     
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Figure 5.5: Flow cytometry data for emphysema cells (patient 10) (n=2) with varying 
concentrations of CSE (0-30%) for 24 hours and stained for 7-AAD to detect non-viable cells (and 
annexin V to detect apoptosis).  Cell viability was generally low with only 55.6% control/untreated 
cells viable at the time of analysis.  In response to CSE there was no significant change in cell 
viability up to 10% CSE (p=0.065).  30% CSE led to a large drop in cell viability, with only 14.89% 
±4.32 viable at 24 hours (p=0.011).   
 
 
P =0.065 
P =0.011 
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To examine viability of cells at later passage and at 48 hours, cells at passage 7 
(patient 10) were treated (n=2) with 0-12% CSE for 48 hours and viability assessed 
via 7-AAD (annexin V was added to gain insights into apoptosis) (figure 5.6).  The 
concentrations of CSE investigated in this 48 hour exposure were reduced in 
anticipation that a more prolonged exposure to CSE was likely to further reduce cell 
viability.  This assumption was made in order to try to investigate cells as efficiently 
as possible, gaining as much information from each experiment in a cell efficient 
manner, maximising the precious nature of these cells and time taken to grow cells 
sufficient for each experiment. 
 
Cell viability was again lower than in the commercially available normal LMVECs, 
with 68.6% control cells viable.  In response to CSE there was a stepwise decrease 
in cell viability in response to CSE compared with controls (Control 68.6%, 1% 
64.9%, 3% 57.38%, 6% 57.6%) (p=0.005).  12% CSE led to a large drop in cell 
viability, with only 27.9% ±2.9 remaining viable after 48 hours treatment (p=0.003).  
In this experiment, there appeared to be a stepwise increase in apoptosis however 
as this experiment was not designed to investigate apoptosis, further analysis was 
not performed.      
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Figure 5.6: Flow cytometry data for emphysema cells (patient 10) at passage 7 treated (n=2) with 
varying concentrations of CSE (0-12%) for 48 hours and stained for 7-AAD to detect non-viable 
cells.   Annexin V was added to detect apoptosis.  Cell viability was 68.6% in control/untreated 
cells.  In response to CSE, there was a stepwise decrease in cell viability in response to CSE 
(Control 68.6%, 1% 64.9%, 3% 57.38%, 6% 57.6%) (p=0.005).  12% CSE led to a large drop in 
cell viability, with only 27.9% ±2.9 remaining viable after 48 hours treatment (p=0.003).  
 
 
P =0.005 P =0.003 
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In order to study apoptosis over a time course, I investigated cell viability in control 
(untreated) cells (Patient 10) with media having been changed 24, 48, and 72 hours 
before FACS analysis, to investigate whether separate controls were required for 
each experiment or whether controls (n=3) for cells treated for 72 hours without 
media change could be used as controls for cells treated for only 24 hours.  This 
experiment was important as it would further help cell efficiency if there was no 
difference.  Figure 5.7 shows no change in cell viability in control cells (24 hours 
87.22%, 48 hours 82.5%, 72 hours 87.68%).  This experiment suggests that there 
was no difference in control cells for a 72 hour experiment with control cells for a 24 
hour exposure.         
 
Figure 5.7: Patient 10 cells (n=2) untreated with simple media change at 24, 48, and 72 hours 
prior to experiment.  7-AAD was used to detect non-viable cells (annexin V to detect apoptosis).  
Cell viability was unaffected by media changes and not significantly different across time points, 
(24 hours, 87.22%; 48 hours, 82.5%; 72 hours, 87.68%, p=0.236). 
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5.4.5 Apoptosis in cells isolated from patients with emphysema in 
response to cigarette smoke extract 
From cell viability studies, 3% CSE was used in these experiments an injury 
sufficient to stress cells without causing non-physiological mass cell necrosis.  Cells 
from patients 4, 8 and 10 were treated with freshly prepared 3% CSE in triplicate for 
72, 48, 24 and 1 hour prior to harvesting and labelling with annexin V and 7-AAD.   
 
Figure 5.8 confirms difference in baseline cell viability between donors with 
unstimulated cells from patient 10 and patient 8 approximately 70% viable, whereas 
only 55% of unstimulated cells were viable in cells from patient 4.  In patient 10 there 
was a significant change detected in apoptosis (ANOVA p=0.003) but this was of 
less apoptosis compared with controls after 3% CSE for 1 hour.  In patient 8 there 
was no significant apoptosis detected in response to 3% CSE (ANOVA, p=0.61) 
(Figure 5.8b).  In patient 4 there was also significant apoptosis detected (p=0.017) 
with an increase in apoptosis in cells treated for 48 hours compared with untreated 
cells (Figure 5.8c).  Figure 5.9d shows a representative scatter plot from flow 
cytometry with annexin V on the y axis and 7-AAD on the x axis, with four distinct 
populations of alive, apoptotic and dead cells (in G1 and G0).  In view of the 
difference in low baseline cell viability and conflicting results, I attempted to repeat 
this experiment in patient 4 in order to investigate whether low cell viability impacted 
upon susceptibility to apoptosis.  This was however not possible due to poor cell 
growth leading to insufficient number of cells and infection and so apoptosis was 
investigated further by more cell efficient methods.   
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Figure 5.8: Apoptosis in cells isolated from three emphysema donors (Patient 10 (5.8a) Patient 8 
(5.8b) Patient 4 (5.8c) treated (n=3) with 3% CSE for 1, 24, 48 and 72 hours).  A difference in baseline 
cell viability was observed between donors with control cells from patient 10 and patient 8 
approximately 70% viable, whereas only 55% of control cells were viable in cells from patient 4.  In 
patient 10 there was a significant change detected in apoptosis (ANOVA p=0.003) but this was of less 
apoptosis after 3% CSE for 1 hour compared with controls (5.8a).  In patient 8 there was no significant 
apoptosis detected in response to 3% CSE (ANOVA, p=0.61) (5.8b).  In patient 4 there was also 
significant apoptosis detected (p=0.017) with an increase in apoptosis in cells treated for 48 hours 
compared with control cells (5.8c).  Figure 5.9d shows a representative scatter plot from flow 
cytometry with annexin V on the y axis and 7-AAD on the x axis, with four distinct populations of alive, 
apoptotic and dead cells (in G1 and G0).   
a) b) 
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5.4.6TUNEL to detect apoptosis in cells isolated from patients with 
emphysema in response to CSE 
From flow cytometry experiments, 48 hours was chosen as a time point for which to 
stress cells and examine for apoptosis via TUNEL.  Cells were grown on 11mm 
coverslips in 12 well plates and at around 70% confluence were treated with freshly 
prepared CSE (0-9%) for 48 hours, before fixation in 4% paraformaldehyde and 
TUNEL staining.  DNAse was used as a positive control in order to induce DNA 
breaks that could be detected and a negative control (without enzyme) was also 
included to ensure quality of staining.  Figure 5.9 summarises the data.  There was 
no apoptosis detected in response to CSE (0-9%) compared with controls.  Positive 
and negative controls validated the staining.      
 
 
 
 Control Negative 
3% 5% 9% 
DNAse I 
Figure 5.9: TUNEL staining to detect apoptosis in cells isolated from a patient with emphysema 
(patient 3) following treatment with 3% CSE for 48 hours.  There was no apoptosis detected in 
response to CSE (0-9%) compared with controls.  Positive (treatment with DNAse to induce DNA 
breaks) and negative (no enzyme) controls prove staining.       
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5.4.7Live cell imaging and DEVD-Nucview488 to detect apoptosis 
Such inconsistent results and difficulty in defining the concentration with which to 
stress cells and at which time point to examine for apoptosis, led to the use of live 
cell imaging with a caspase 3 substrate (DEVD-Nucview 488) [152] to allow 
investigation of apoptosis over time in emphysema patients with multiple 
concentrations of CSE in a cell efficient manner.   
 
Emphysema cells were grown in 96 well plates at 10,000 cells per well (100ul) and 
investigated (n=3) over multiple concentrations (0-12%) of CSE across a time course 
(0-72 hours) via live cell fluorescence imaging.  Preliminary experiments using 
prolonged CSE exposure to LMVECs (Promocell, and patient 7 and 8) showed a 
dose dependant increase in fluorescence object counts over time, suggesting 
increased apoptosis (Figures 5.10-5.12).  However concerns over the level of 
fluorescence raised the issue as to whether this was simply a dose dependant 
increase in autofluorescence caused by increasing concentration of CSE.  The 
experiments were therefore repeated, examining fluorescence object counts when 
cells were treated with increasing concentration of CSE (0-12%) in the absence of 
DEVD-Nucview 488 i.e. measuring cellular autofluorescence induced by CSE.  Cells 
were treated for either the entire 72 hours (prolonged exposure), as the previous 
experiment, or with a short one hour exposure.  In the prolonged exposure 
experiment, cells demonstrated autofluorescence that increased proportionally with 
increasing concentration of CSE (Figure 5.13).  This became more marked at 
concentrations of 4% CSE and above.  In the short exposure experiment, cells 
treated with CSE for one hour only prior to detection of fluorescence counts, there 
was initially dose dependant increase in autofluorescence but was low level (less 
than 20 fluorescent object counts) across all concentrations of CSE studied (Figure 
5.14). 
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Figure 5.10:  Apoptosis as detected via live cell imaging Nuc-view Fluorescence counts over 72 hour time course in Promocell LMVECs.  
High counts were observed at the higher concentrations of CSE (5-12%).  At lower concentrations of CSE (1-4%) the same dose 
dependant rise was not observed, with control cells and cells treated with 0.5% CSE showing higher fluorescence than low dose CSE 1-
4% treated cells.   
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Figure 5.11:  Apoptosis as detected via live cell imaging Nuc-view fluorescence counts over 72 hour time course in cells from patient 7 
with emphysema (Patient 7).  Similar to the previous experiment using LMVECs (Promocell), high counts were observed at the highest 
concentrations of CSE (9-12%).  On these isolated emphysema cells, 5 and 6& CSE caused a slightly higher fluorescence count initially 
suggesting higher apoptosis.  At lower concentrations of CSE (1-4%) similar to the Promocell experiment fluorescence was generally 
stable throughout while untreated and 05% treated cells showed increasing fluorescence over time.     
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Figure 5.12:  Apoptosis as detected via live cell imaging Nuc-view fluorescence counts over 72 hour time course in cells from patient 8 
with emphysema.  High fluorescence counts were observed at the highest concentrations of CSE (9-12%) with 5 and 6% also showing 
higher fluorescence counts in this experiment.  Lower concentrations of CSE (1-4%) similar to the Promocell experiment fluorescence 
was generally stable throughout while untreated and 05% treated cells showed increasing fluorescence over time.     
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Figure 5.13: Mean autofluorescence of normal cells (Promocell) treated with varying concentrations of CSE (0-12%) as detected by 
fluorescence counts captured via live cell imaging over 72 hours.  In this experiment, there was a stepwise increase in autofluorescence 
with increasing concentration of CSE.  The highest fluorescence counts were observed at the highest concentrations of CSE (9-12%).  
At concentrations of 3% CSE or less, although greater than in control cells, autofluorescence was generally low. 
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Figure 5.14: Mean autofluorescence of normal cells (Promocell) treated with varying concentrations of CSE (0-12%) for one hour and 
then followed for 72 hours.  In this experiment, there was very low background autofluorescence with no difference between cells treated 
with 0.05% or 12% CSE. 
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In an attempt to model cigarette smoking closely, very short (fifteen minutes) CSE 
treatments to promocell cells and cells from 4 donors were conducted with the 
results shown below.  Patients 2, 4 and 8 showed no response/ change in 
fluoresence counts and therefore no apoptosis over 90 hours (Figure 5.15).  
Promocell LMVECs showed no change in fluoresence counts initially with a late rise 
(after 48 hours) in fluoresence counts that was not dose dependant and actually was 
greatest for the control (untreated cells) (Figure 5.16a).   Similarly patient 7 treated 
for fifteen minutes showed initially no change in fluoresence counts but a late rise 
(after 48 hours) with again the control cells and low concentration treated cells 
showing higher fluoresence counts than the cells treated with higher concentrations 
(Figure 5.16b).  These experiments suggest that such a short CSE treatment was 
not sufficient to stress cells, with some donors showing no treatment response and in 
others the control cells had more cell death than the treated cells.  This supports 
data which shows the effect of smoking a single cigarette persists for much longer 
than the time taken to smoke the cigarette. Therefore the short exposure (1 hour) 
and prolonged exposure experiments were therefore repeated and cellular 
responses further investigated.     
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Figure 5.15: Cells from patients 2,4, and 8 treated with varying concentration of CSE (0-12%) for 
fifteen minutes and then apoptosis detected via DEVD Nucview-488 fluorescence counts via live 
cell imaging over 96 hours.  There was no treatment effect observed in these cells in response to 
the very short fifteen minute treatment. 
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Figure 5.16: Promocell cells and cells from patient 7 treated with varying concentration of CSE (0-
12%) for fifteen minutes with apoptosis thereafter detected via DEVD Nucview-488 fluorescence 
counts via live cell imaging over 96 hours.  Promocell cells showed no change in fluoresence 
counts initially until a late increase (after 48 hours) in fluoresence counts that was not dose 
dependant and notably was greatest for the control (untreated cells) (Figure 5.17a).   Similarly 
patient 7 treated for fifteen minutes showed initially no change in fluoresence counts.  After 48 
hours, once again there was an increase in fluoresence counts that was most evident among the 
untreated (control) cells and cells treated at low concentration (Figure 5.17b).    
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LMVECs (Promocell) and from patient 7 were grown to confluence on 96 well plates 
and treated (n=3) for either 1 hour (short exposure) or a prolonged expsoure with 
CSE and imaged for 64 hours.  Although intitial experiments suggested that 
autofluorescence of cells was only encountered with the prolonged CSE exposure 
experiments (figure 5.13), all experiments included cells treated without DEVD 
Nucview-488 (n=3) to act as an internal control to assess autofluorescence in each 
individual experiment.  
 
Promocell LMVECs treated with 0-12% CSE for one hour prior to cell imaging 
demonstrated high fluoresence counts (1 hour post treatment) above 6% CSE with 
lower fluorescence counts in cells treated with 5% CSE and lower (Figure 5.17a).  
This is likely to represent CSE induced autofluorescence of cells and is confirmed by 
Figure 5.17b which shows stepwise autofluorescence of cells treated with CSE in the 
absence of DEVD Nucview-488.  Cells treated with concentrations of 4%CSE and 
above produced notable autofluorescence.  In cells treated with 6-12% this was 
maximal at the start of imaging and fell over time.  In 4% and 5% CSE treated cells 
this became maximal at 2 hours and then fell over time.  Thus higher concentrations 
(>4% CSE) were therefore excluded from the analysis.   The data for this experiment 
for concentrations up to 3% is presented in Figure 5.17c.  When examining cells 
treated with up to 3% CSE compared with untreated (control) cells, there is no 
significant difference in fluoresence object counts at the start of imaging, however at 
24 hours, the lines have become divergent, with statistically significant more 
fluoresencent object counts at 24 hours in the 3% CSE treated cells compared with 
control cells (P=0.05).  To further investigate thisthe autofluorescence data obtained 
during this experiment (figure 5.17b) was subtracted from the data in figure 5.17c to 
examine whether this divergence at 24 hours between control and CSE treated cells 
persisted (Figure 5.17d).  Figure 5.17d which shows divergence of lines at 24 hours 
with similar fluorescence counts for 1-3% treated CSE cells, however this failed to 
reach statistical significance and so did not confirm apoptsis.   
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Figure 5.17a:  Fluorescence counts of cells (Promocell) treated with varying concentrations of CSE (0-12%) for one hour and then 
imaged for 64 hours. 
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Figure 5.17b:  Autofluorescence of CSE treated cells (Promocell) (0-12%) for one hour and then imaged for 64 hours.  Increasing 
autofluorescence was seen with increasing concentration of CSE.  This was apparent from concentrations greater than 3%.   
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Figure 5.17c:  Promocell HLMVECs treated with low dose (0-3%) CSE and followed for 64 hours.   
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Figure 5.17d: Promocell HLMVECs treated with low dose (0-3%) CSE and followed for 64 hours.  Data shown here includes 
subtraction of autofluorescence from all data points. 
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LMVECs (Promocell) were treated with a prolonged exposure to CSE (concentration 
0-3%) and followed for 64 hours via live cell imaging to detect apoptosis via DEVD 
Nucview-488 Fluorescence counts.  At the start of imaging higher fluorescence 
counts were observed in the CSE treated than control cells (Figure 5.18a).  However 
this quickly became similar in all groups, including control (untreated cells).  At 24 
hours, there was divergence of the lines between the treated and untreated cells with 
greater fluorescence counts in the CSE treated cells.   By 36 hours fluorescence 
counts started to increase in the control (untreated) cells to such an extent that by 64 
hours there was an inverse relationship between CSE treatment and fluorescence 
counts.  Autofluorescence was investigated as before in tandem with this experiment 
with all concentrations examined in triplicate for fluorescent counts with increasing 
concentration of CSE in the absence of DEVD Nucview-488.  Control and 0.5% CSE 
treated cells had very low autofluorescence at baseline (Figure 5.18b).  Over time 
this increased.  Cells treated with 1 and 2% CSE had initial high autofluorescence 
that fell, remained stable and then demonstrated a late rise.  In this experiment, cells 
treated with 3% CSE had surprisingly low autofluorescence at baseline that then 
increased and remained high.  This result in not keeping with the previous however 
was similar across all values (n=3).  The autofluorescence observed in the 
experiment with 3% CSE treated cells cannot be easily explained.  To examine the 
effect of autofluorescence in this experiment, fluorescence counts observed in sham 
treated cells were subtracted from the fluorescence counts observed with the DEVD 
Nucview-488 cells as before (Figure 5.17c).  Control cells had no fluorescent counts 
at baseline but began to rise at 24 hours and became highest at 64 hours.  0.5, 1 
and 2% CSE treated cells had initially higher fluorescence counts that fell and then 
gradually rose with divergence from control cells at 24 hours, which may support 
CSE induced apoptosis.  As previous, the results observed for the 3% CSE treated 
cells in this experiment are difficult to interpret but are presented for completeness. 
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Figure 5.18a: Promocell LMVECs treated with low dose (0-3%) CSE and followed for 64 hours via live cell imaging to detect 
apoptosis via DEVD Nucview-488 Fluorescence counts.  Immediately after treatment at the start of imaging there was higher 
counts in the CSE treated than control cells.  However this quickly became similar in all groups.  At 24 hours there was divergence 
of the lines between the treated and untreated cells with greater fluorescence counts in the CSE treated cells.   At 36 hours 
fluorescence counts started to increase in the control (untreated) cells to such an extent that by 64 hours there was an inverse 
relationship between CSE treatment and fluorescence counts.    
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Figure 5.18b: Promocell HLMVECs treated with low dose (0-3%) CSE and followed for 64 hours via live cell imaging with no DEVD 
Nucview-488 added to detect background autofluorescence due to CSE.  Control cells at baseline had very low autofluorescence.  
Similarly cells treated with 0.5% CSE had similar low autofluorescence at baseline and then increased with time.  Cells treated with 
1 and 2% CSE had initial high autofluorescence that fell, remained stable and then demonstrated a late rise.  In this experiment, 
cells treated with 3% CSE had surprisingly low autofluorescence at baseline that then increased and remained high.  This result in 
not keeping with the previous however was similar across all values (n=3).     
 
 
 
Time (Hours) 
115 
 
 
 
 
-50
0
50
100
150
200
250
300
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64
F
lu
o
re
sc
e
n
ce
 O
b
je
ct
 C
o
u
n
ts
Promocell HLMVEC prolonged CSE exposure with subtraction of 
autofluorescence
Control
0.5% CSE
1% CSE
2% CSE
3% CSE
Time (Hours) 
Figure 5.18c: Promocell HLMVECs treated with low dose (0-3%) CSE and followed for 64 hours via live cell imaging to detect 
apoptosis via DEVD Nucview-488 fluorescence counts with autofluorescence subtracted.  Control cells had no fluorescent counts 
at baseline but began to rise at 24 hours and became highest at 64 hours.  0.5, 1 and 2% CSE treated cells had initially higher 
fluorescence counts that fell and then gradually rose with divergence from control cells at 24 hours.  As previous, the results 
observed for the 3% CSE treated cells in this experiment are difficult to interpret but are presented for completeness. 
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LMVECs from patient 7were also treated with CSE for short 1 hour exposure and a 
prolonged exposure and analysed as previously.  LMVECs isolated from patient 7 
and thentreated with 0-12% CSE for one hour prior to cell imaging demonstrated 
high fluoresence counts (1 hour post treatment) above 5% CSE (Figure 5.19a)  
similar to the promocell cells (Figure 5.18a).  This CSE induced autofluorescence of 
cells is confirmed by Figure 5.19b which shows stepwise autofluorescence of cells 
treated with CSE in the absence of DEVD Nucview-488, most notably for the cells 
treated with 9 and 12% CSE.  Cells treated with concentrations of 5%CSE and 
above produced most autofluorescence and were therefore excluded from the 
analysis.   The data for this experiment for concentrations up to 4% is presented in 
Figure 5.19c.  Cells treated with up to 4% CSE compared with untreated (control) 
cells show no difference in fluoresence object counts at the start of imaging, however 
at 24 hours, the lines have become divergent, with statistically significant more 
fluoresencent object counts at 24 hours in the 1% CSE treated cells compared with 
control cells (P=0.048).This result was similar to that observed in Promocell 
LMVECs, but occurred at lower concentration of CSE in the emphysema cells 
(patient 7).  Tofurther investigate this,the autofluorescence data obtained during this 
experiment (figure 5.19b) was subtracted from the data in figure 5.19c to examine 
whether this divergence at 24 hours between control and CSE treated cells persisted 
(Figure 5.19d).  Figure 5.19d which shows divergence of lines between 24 and 48 
hours most notably for the lowest dose of CSE treatment (0.5% and 1% CSE) but 
this failed to reach statistical significance and so did not comfirm apoptosis.  
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Figure 5.19a:  Fluorescence counts of emphysema primary LMVECs (patient 7, EC295A) treated with varying concentrations of 
CSE (0-12%) for one hour and then imaged for 64 hours. 
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Figure 5.19b:  Autofluorescence of patient 7 cells (EC295A) (0-12%) for one hour and then imaged for 64 hours.  Increasing 
autofluorescence was seen with increasing concentration of CSE.   
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Figure 5.19c: HLMVECs isolated from patient 7 (EC295A) treated with low dose (0-3%) CSE and followed for 64 hours via DEVD 
Nucview-488 live cell fluorescence imaging. 
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Figure 5.19d: HLMVECs isolated from patient 7 (EC295A) treated with low dose (0-3%) CSE and followed for 64 hours via DEVD 
Nucview-488 live cell fluorescence imaging with autofluorescence subtracted. 
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Emphysema LMVECs (patient 7) were treated with a prolonged exposure to low 
dose CSE (concentration 0-3%) and followed for 64 hours via live cell imaging to 
detect apoptosis via DEVD Nucview-488 Fluorescence counts.  All cells treated had 
similar fluorescence object counts for the first 12 hours (Figure 5.20a).  Thereafter 
there was divergence of fluorescence counts with CSE treated cells (notably the 
lowest doses 0.5-1% CSE) showing greater counts than the control cells.  By 48 
hours fluorescence counts had begun to converge again, although the low dose CSE 
treated cells continued to be divergent.  Autofluorescence was investigated as before 
in tandem with this experiment with all concentrations examined in triplicate with 
increasing concentration of CSE in the absence of DEVD Nucview-488.  Control and 
0.5% CSE treated cells had very low autofluorescence (Figure 5.20b) and unlike the 
Promocell experiment this remained largely unchanged over time.  Cells treated with 
1-3% CSE demonstrated a stepwise increase in autofluorescence.  All cells including 
control cells showed a transient increase in fluorescence counts at 48 hours.  This is 
likely to represent a technical signaling error of the equipment and should not be 
interpreted as a real effect as was seen in all cells.  Autofluorescence (Figure 5.20b) 
was subtracted as before from original data (Figure 5.20a) to give fluorescence 
count data taking into account autofluorescence (Figure 5.20c).  There was no 
difference in fluorescence in the first 12 hours.  After 12 hours, cells treated with very 
low dose (0.5-1% CSE) had more fluorescence counts observed than control cells, 
suggesting apoptosis in response to CSE.  As in previous experiments, the results 
observed for 2-3% CSE treated cells in are difficult to interpret due to the high 
autofluorescence but are presented for completeness. 
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Figure 5.20a: HLMVECs isolated from patient 7 (EC295A) treated with low dose (0-3%) CSE and followed for 64 hours via DEVD 
Nucview-488 live cell imaging. 
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Figure 5.20b: HLMVECs isolated from patient 7 with emphysema (EC295A) treated with low dose (0-3%) CSE and followed for 64 
hours via fluorescence live cell imaging.  No DEVD Nucview-488 was added to allow detection of autofluorescence.  There was a 
stepwise increase in autofluorescence with increasing concentration of CSE, although in this experiment autofluorescence for the 
2% CSE treated cells was greater than the 3% CSE treated cells.  
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Figure 5.20c: HLMVECs isolated from patient 7 with emphysema (EC295A) treated with low dose (0-3%) CSE and followed for 64 
hours via fluorescence live cell imaging.  Autofluorescence was subtracted from each time point from the corresponding repeat 
experiment without DEVD Nucview-488 added.  Cells treated with 2 and 3% CSE appeared to be influenced by autofluorescence, 
with lower fluorescent object counts than control cells, after subtracting autofluorescence.  Both 0.5% and 1% CSE treatments in 
this experiment seemed to lead to more apoptosis as detected by fluorescence counts than control treated cells.  This was most 
apparent at 24 hours but persisted for the 0.5% CSE treated cells.  
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In summary, I attempted to systematically assess apoptosis in real time in a number 
of patients with emphysema employing DEVD Nucview-488 to detect caspase 
activation and thus apoptosis.  Unfortunately this technique employs fluorescence 
and unfortunately throughout this experiment it became apparent that CSE treatment 
of cells causes cells to autofluoresce thus limiting the use of this technique and 
limiting any conclusions that can be drawn from this data. The data suggests, while 
taking into account the effect of CSE induced autofluorescence of cells treated with 
both short (1 hour) and prolonged treatments, with careful controls, that low dose 
CSE may cause an increase in apoptosis.  This was witnessed in both normal 
HLMVECs (Promocell) (Figure 5.17, Figure 5.18) and in cells isolated from a patient 
with emphysema (patient 7) (Figure 5.19, Figure 5.20) over both a short exposure (1 
hour) and prolonged exposure.  The effect was generally maximal at 24 hours and 
was witnessed with low dose CSE.  Interestingly, the dose of CSE required to 
achieve this was lower in the emphysema cells than the Promocell, in keeping with 
my hypothesis that these cells are more susceptible. However due to the 
autofluorescence of cells no firm conclusions can however be drawn. 
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5.4.8qPCR for VEGF KDR 
The VEGF KDR/FLK1 receptor may play a key role in the pathogenesis of 
emphysema in relation to apoptosis of the microvasculature[26].  VEGF KDR cellular 
expression on normal and emphysema cells in response to CSE was therefore 
investigated via qPCR. 
 
Initial qPCR validation experiments were performed using untreated commercial 
HLMVECs (Promocell).  RNA was isolated as described and UV absorbance via 
spectrophotometry plotted with the ratio of absorbance at 260 nm and 280 nm 
(A260/280) found to be 2.12 confirming purity (Figure 5.21).   RNA quality was further 
assessed on 2% agarose gel electrophoresis with DNA ladder to investigate 
contamination with DNA (Figure 5.22).  Two discrete ribosomal bands corresponding 
to 28S and 18S were visualised in an approximate 2:1 ratio with little degradation.  
cDNA was thereafter prepared from RNA as described.   
 
Before using the comparative CT (ΔΔCT) method for relative gene quantification, 
validation experiments were performed to investigate the efficiencies of the gene of 
interest (VEGF KDR) and housekeeping gene (18S). Initially, the probe for gene of 
interest (VEGF KDR) and housekeeping gene (18S) were used with undiluted cDNA 
to determine at which cycle a signal appeared (Figure 5.24).   A 96 well optical plate 
was loaded with probes alone (no template control), template plus probe and RNA 
plus probe for both VEGF and 18S to confirm detection of PCR product (Figure 
5.23).  Negative controls (probe alone) and RNA plus probe were included to ensure 
there was no genomic DNA contamination with which probes reacted.  In this initial 
experiment 2 amplification plots were identified with 18S being relatively more 
abundant than VEGFR2 as evidenced by the earlier CT.  No other products amplified 
confirming no reaction with the negative control and RNA plus probe.      
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qPCR can be used to determine gene quantity via an absolute or relative method.  
Calculation of the number of gene copies can be determined from a standard curve if 
absolute quantification is required.  Change in gene expression in response to a 
treatment with reference to a standard housekeeping gene which does not change in 
response to this treatment i.e. relative quantification, is also a sensitive validated 
method[154] and was used in this study to determine the response of VEGFR2 
(KDR/FLK1) in response to CSE using 18S as a housekeeping gene, which has 
been reported to be unaffected by apoptosis [155].  Relative quantification requires 
construction of a dilution series from which ΔCT (difference between CT between 
GOI and housekeeping gene) can be determined.  This then allows the use of the 
ΔΔCT method which is a sensitive method to detect change that has been validated.   
A dilution series was performed, with cycle threshold (CT) plotted against log10 
dilution of primers with gradient and line of best fit (r2) calculated (Figure 5.24).  The 
ideal PCR increases one CT with each dilution, thus giving slope y=-log10= -3.3.  
The results obtained in the dilution series for 18S and VEGFR2 are in good 
agreement (r2=0.99) with gradient of slope validating the dilution series and thus the 
use of the comparative CT method.  
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Figure 5.24: Results from the dilution series to validate the comparative CT method.  A) 
Amplification plot showing CT for 18S and KDR multiple dilutions.  B) CT determined from 
amplification plot plotted against dilution (Log
-10
).  The ‘perfect PCR’ amplification increases one 
CT upon dilution (y=log
-10
= -3.3) thus the gradient of slope of both 18S and KDR is within 
acceptable limits with good correlation (r
2
=0.99) and so validates the use of the comparative CT 
method.    
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The comparative ΔΔCT method was then used to investigate relative change in 
VEGFR2 gene expression in response to 3% CSE at 0 (control), 24, 48 and 72 
hours.  Promocell cells were first investigated.  There was no significant change in 
CT across treatments in VEGFR2 expression (n=3) when controlled for 18S and 
expressed as a fold change (Figure 5.25a).  Cells isolated from four emphysema 
patients (Patient 2 (EC208A), Patient 7 (EC295A), Patient 8 (EC300C), Patient 10 
(EC326C)) were similarly investigated following a validation dilution series 
experiment as before.  Emphysema cells (n=3 for each donor) showed biological 
variation in their response that is common to experimentation with primary cells.  
There was however a trend towards a reduction in VEGFR2 in response to 3% CSE 
treatment that was significant at 48 hours (P<0.05).  Thus VEGFR2 gene expression 
is unchanged in normal cells (Promocell) in response to CSE (with a possible trend 
towards upregulation), while emphysema cells show a reduction in VEGFR2 in 
response to CSE at 48 hours.  This supports my hypothesis of a maladaptive 
response to injury in cells from a susceptible individual.     
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Figure 5.25: HLMVECs (Promocell (a) and isolated from patients with emphysema (b)) treated 
with 3% CSE for 0 (control), 24, 48 and 72 hours.  Cells were harvested and RNA and cDNA 
isolated as before.  Q-PCR was performed using 18S as a calibrator/ housekeeping gene.  Fold 
change CT fold change relative to housekeeping gene is presented for each of the treatments for 
(a) Promocell and (b) cells isolated from patients with emphysema.  In Promocell cells there was 
no significant change in VEGFR2 gene expression in response to CSE across the treatments 
(P=NS).  In the Emphysema cells, 4 patients were examined.  Patient 2 (EC208A), Patient 7 
(EC295A), Patient 8 (EC300C), Patient 10 (EC326C).  While there was variation between the 
donors, there was a trend towards reduction in VEGFR2 in response to CSE that was significant 
at 48 hours (P<0.05).  
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5.5 Discussion 
In this chapter I attempted to investigate apoptosis in vivo and ex vivo.  
Immunocytochemical detection of the apoptosis marker caspase 3 in emphysema 
lung tissue was more frequent in the alveolar bed compared with normal lung tissue 
in keeping with the findings of other studies which report increased apoptosis in 
emphysema.  I then went on to study apoptosis in vivo using the cells isolated from 
emphysema lung tissue.  Initially I hoped to study responses in diseased 
emphysematous tissue and normal control tissue, isolating the cells using the same 
method.  Unfortunately due to the time constraints of the study and the time taken to 
isolate emphysema cells, similar time could not be devoted to isolating enough 
normal cells from excess lung tissue for the same experiments to be conducted.  
Commercially available primary LMVECs (Promocell) which were also relatively slow 
growing, precious cells that were prone to infection and a greater challenge than a 
conventional cell line, were therefore used in initial viability and pilot studies and 
unfortunately were also used as to represent normal cells in more detailed later 
experiments.  This is a major limitation of this study.  There was however an internal 
control (untreated cells) in all experiments to allow assessment of response to 
treatment.   
 
Initial viability studies confirmed that normal LMVECs (Promocell) were viable up to 
and including 10% CSE at 24 hours.  However in view of the possibility that cells 
isolated from patients with emphysema would be more susceptible to cell injury, 
viability studies were also performed on these diseased cells.  These additional 
experiments confirmed that indeed the cells were more susceptible with lower 
baseline viability of these cells including the untreated controls.  The lower cell 
viability of isolated cells and death response to CSE at lower concentration and 
earlier time course suggests these cells are indeed more susceptible to injury and 
may explain the differences observed between these and normal LMVECs 
(Promocell). 
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Investigation of apoptosis in multiple emphysema donors with the chosen (3% CSE) 
stimulus/injury via flow cytometry yielded rather inconsistent results.  There was no 
clear apoptosis of cells that was measurable by flow cytometry or via TUNEL.  This 
was perhaps not unsurprising given the limitations of the model.  In essence, trying 
to stress primary cells with CSE, while not overtly killing them via necrosis with high 
concentrations of CSE, and assess this at a limited number (24,48,72 hours) of time 
points may explain the lack of results.  The dynamic nature of apoptosis and also the 
variation from one donor make this difficult to study.  Live cell imaging was therefore 
employed to overcome these difficulties.   
 
Investigating in triplicate the response in real time of cells to multiple concentrations 
of CSE via live cell imaging yielded more encouraging results.  There was a step 
wise increase in fluorescence counts with increasing concentration of CSE.  This led 
me to question whether CSE caused autofluorescence of cells.  Further experiments 
were therefore conducted as negative controls with no active Nucview-488 added i.e. 
any fluorescence counts above baseline were therefore autofluorescence of cells 
and not caused by cleavage of caspase3 and thus not indicative of apoptosis.  This 
experiment confirmed significant autofluorescence of cells in response to CSE and 
has highlighted a major challenge for researchers when studying the effect of 
cigarette smoking that has to my knowledge not been reported before.  
Autofluorescence of LMVECs in response to CSE suggests changes in cell structure 
which is fascinating from an endothelial biology perspective but from a practical point 
of view makes analysis of results obtained via fluorescence very difficult to interpret.  
The results presented in this chapter from the live cell imaging are presented in such 
a way to attempt to tease out whether there is an important signal i.e. apoptosis of 
cells in response to CSE.  Multiple experiments via live cell imaging show with 
careful controls and allowance for autofluorescence may suggest low dose CSE (0-
3%) may cause an increase in apoptosis.  This was witnessed in both normal 
LMVECs (Promocell) and in cells isolated from a patient with emphysema over both 
a short exposure (1 hour) and prolonged exposure.  The effect was generally 
maximal at 24 hours and was witnessed with low dose CSE.  Interestingly, the dose 
of CSE required to achieve this was lower in the emphysema cells than the 
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Promocell, in keeping with my hypothesis that these cells are more susceptible 
injury.  Unfortunately due to autofluorescence it is not possible to state conclusively 
that this increase in fluorescence count (after controlling for autofluorescence) is 
directly attributable to apoptosis and further experiments to detect apoptosis via live 
cell imaging that do not rely upon the use of fluorescence imaging is now required.  
 
Trying to link the apoptosis witnessed in response to low dose CSE with the seminal 
in vivo and ex vivo studies which showed emphysema arising due to loss of 
VEGFR2[63][54] led me to investigate VEGFR2 gene expression via Q-PCR in 
response to CSE.  After initial validation experiments, RNA and cDNA were prepared 
from emphysema cells treated with 3% CSE for 24, 48 and 72 hours and compared 
with untreated control cells.  This was repeated in emphysema cells isolated from 4 
donors and in Promocell (normal) cells.  In response to CSE there was no significant 
change in VEGFR2 in Promocell (normal) cells.  In 4 emphysema donors there was 
however a fold reduction in VEGFR2 that was significant at 48 hours.  Further work 
is required to investigate this preliminary signal. 
  
137 
 
Chapter 6: Alveolar septal remodelling in emphysema: the 
role of endothelial cell plasticity and mesenchymal 
transition. 
6.1 Abstract 
Classically, thin sparsely cellular septa are seen in emphysematous lungs, but in 
addition remodelling of the alveolar bed also occurs, with matrix deposition and 
increased collagen content and turnover.  Expansion of alveolar matrix may arise via 
proliferation of resident fibroblasts or recruitment of circulating bone marrow derived 
fibrocytes to the lung.  A further novel mechanism which may link matrix deposition 
with endothelial loss is endothelial to mesenchymal transition (EnMT).  EnMT has a 
well-documented role in embryogenesis, however the potential of mature cells to 
undergo this process has now also been demonstrated in epithelial cells and larger 
endothelial cells.  I therefore investigated plasticity of human lung microvascular 
endothelial cells in response to cigarette smoke extract and other inflammatory 
mediators, to investigate EnMT in emphysema.      
Methods:  LMVECs (commercially available cells and cells isolated from patients 
with emphysema undergoing lung transplantation) were stimulated with TGFβ, and 
CSE.  Endothelial plasticity was investigated on phase contrast microscopy, confocal 
microscopy and western blotting.  Change in cell function was also investigated via 
examination of matrix deposition from the cells and production of matrix 
metalloproteinases.  Paraffin embedded lung tissue was dual stained for an 
endothelial marker (CD34) and mesenchymal marker (aSMA) and co-localisation of 
markers investigated. 
Results:  Morphological changes in cell structure were detected following treatment 
with TGFβ1 and CSE when compared with untreated control cells.  In addition, cells 
appeared to downregulate the endothelial cell surface marker CD31 on confocal 
immunofluorescence.  Co-localisation of markers was also investigated but did not 
show evidence of dual staining of endothelial and mesenchymal markers.  Flow 
cytometry evaluation of CD31/CD90 suggested there was down regulation of CD31, 
no upregulation of CD90.  Furthermore there was no change in protein concentration 
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detected via western blotting across all treatments.  EnMT was also investigated in 
vivo via immunohistochemistry however there was no clear evidence of dual stained 
transitional cells in emphysema.  
Conclusions:  Endothelial cells change morphology in response to TGFβ1 and CSE 
and appear to down regulate endothelial cell surface markers.   This may however 
reflect endothelial activation with internalisation of cell surface markers as opposed 
to a true mesenchymal transition.  Immunohistochemistry for CD34/aSMA in 
emphysema show evidence of endothelial loss with associated sclerotic casts and 
increased mesenchymal markers.  Further work is required to determine whether 
these are transitional cells or whether this is simply a response of an endothelial cell 
to injury.    
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6.2 Introduction 
Complex changes occur in the alveolar wall of patients with emphysema.  In addition 
to well documented thin alveolar walls with sparse capillaries [25], thickening of the 
alveolar interstitium occurs in some regions, with collagen deposition and increased 
interstitial fibroblasts [87].  Although somewhat at odds with the classical description 
of emphysema as “destruction of alveolar walls without fibrosis” [15], 
emphysematous areas express several fibrosis associated matrix genes and 
proteases [82], with the balance of these factors dictating the direction in which 
damage proceeds, either towards fibrosis or septal destruction.  The relationship 
between endothelial loss and fibrosis has been studied in chronic heart and kidney 
disease with some researchers hypothesising that that immature fibrosis may 
originate from injured endothelial cells acquiring mesenchymal cell characteristics 
and potential [91][93].  This endothelial to mesenchymal transition (EnMT) has been 
reported by other researchers to be one of many cellular responses to chronic injury.  
Cytoskeletal rearrangements of cobblestone endothelial cells into spindle shaped 
mesenchymal cells have been described and put forward as evidence of EnMT [89].  
In addition to morphological changes, cells have been shown to down regulate 
endothelial markers and acquire mesenchymal markers.  Functionally, transitional 
cells may also demonstrate proliferative, invasive and secretory characteristics, not 
displayed by native endothelial cells [156].  This chapter aims to investigate the fate 
of lost endothelial cells in emphysema, in particular whether regional endothelial 
plasticity/ EnMT may contribute to endothelial loss and septal fibrosis witnessed in 
emphysema.   
 
EnMT is less well studied than epithelial to mesenchymal transition (EMT), of which 
there are over 3000 citations in the literature.  EMT is implicated as an important 
mechanism in cancer biology, kidney fibrosis, post lung transplant obliterative 
bronchiolitis and idiopathic pulmonary fibrosis [157].  The plasticity witnessed in 
EMT/EnMT is also a key event in utero during embryogenesis [39].  In recent years 
there has been controversy surrounding the origin of myofibroblasts in chronic 
inflammatory diseases [158].  A number of researchers report expansion of resident 
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tissue myofibroblasts, while others report phenotype transition (EMT/EnMT) or 
recruitment of circulating bone marrow derived progenitor cells.  Any one or 
combination of these mechanisms may give rise to myofibroblasts and may be 
dictated by the tissue in which the injury occurs [159].  In emphysema, there is 
disruption of the vasculature with endothelial loss, thus making it theoretically difficult 
for circulating bone marrow derived progenitor cells to reach the site of injury.  
Furthermore, resident myofibroblasts may be in low numbers in the delicate alveolar 
structures of the adult lung.  Therefore cellular plasticity may be an important source 
of myofibroblasts in emphysema linking microvascular injury and repair.  
 
EnMT was first described in aortic endothelial cells in response to Transforming 
Growth Factor β1 (TGFβ1) as a novel mechanism in atherosclerosis [89].  This 
plasticity was initially reversible but became irreversible with time.  The importance of 
TGFβ1 as a driver of this response to injury has been highlighted by many more 
studies [90], [157], [160], [161].  TGFβ1 driven EnMT has been reported in vivo in a 
mouse model of cardiac fibrosis via lineage tracing [91].   This could be reversed by 
the addition of recombinant BMP7 and was attenuated in SMAD 3 null mice, 
providing insights into the cell signalling pathways which support this plasticity.   
 
TGFβ1 is expressed in most tissues and is secreted by many cell types including 
epithelial, endothelial, smooth muscle cells, fibroblasts and also most immune 
system cells [162].  Levels of TGFβ1 in emphysema are still debated, with some 
researchers reporting reduced TGFβ1 and TGFβ receptor expression in COPD lung 
tissue [100], [101] while others report increased levels [102].  The effect cigarette 
smoking may have on TGFβ1 is also debated.  Alterations in redox state with 
increased oxidative stress that occurs in cigarette smoking is reported to contribute 
to TGFβ1 activation [81].  In addition, TGFβ1 itself induces intracellular ROS[163], 
thus causing positive feedback to amplify the signal.  Thus TGFβ1 may play a role in 
the pathogenesis of emphysema, via reduced activity, defective signalling or 
inappropriate septal fibrosis as an example of dysregulated repair in response to 
oxidative stress in the areas that remain.  Both TGFβ1 and CSE were used to stress 
cells in these experiments and investigated systematically. 
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EnMT/EMT has been defined in many ways with some researchers reporting 
morphological change and down regulation of endothelial cell surface markers with 
acquisition of mesenchymal markers as sufficient evidence of a phenotypic change 
[161].  Others have sought greater evidence such as change in protein expression of 
cell surface markers and functional change such as deposition of collagen and 
release of matrix metalloproteinases [156].  Due to the exploratory nature of this 
work, using diseased human primary cells,  cell morphology and cell surface marker 
expression in response to treatment with TGFβ1 was initially assessed, progressing 
later to look for evidence of change in protein expression and function.  More 
detailed examination of the signalling pathways behind such EnMT was also 
planned.  
 
The time between injury and observation of phenotype change varies between cell 
type and between the various methods reported by investigators.  Arciniegas et 
al[89] isolated and characterised adult bovine endothelial cells and used these in 
experiments between passage 11 and 30.  Cells were treated at ~20% confluence 
with control media or media containing 1ng/ml of TGFβ1.  The cultures were 
incubated for up to 20 days changing the media every 2-3 days.  After 3 days 
incubation, the TGFβ1 treated cells were enlarged compared with controls and 
displayed a ragged morphology, with only 50-60% cells staining positively for 
endothelial markers.  By 5 days, only 30-40% cells stained positively for endothelial 
markers while 40-60% stained positively for αsma.  Plasticity was further suggested 
by dual immunofluorescence with the endothelial marker factor VIII and αsma after 5 
days incubation.  Withdrawal of TGFβ1 after 10 days incubation caused cells to 
revert to their original polygonal morphology with positive endothelial markers with 
absent αsma, however this reversibility was not apparent following withdrawal of 
TGFβ1 at 20 days.  Frid et al reported the appearance of mesenchymal cells 
spontaneously over time (44% by passage 2) in endothelial cells isolated from adult 
bovine aortas and main pulmonary arteries [90].  This was only apparent in arterial 
cells purified on day one post isolation via FACs for Dil-Acetylated-LDL.  Cells which 
were left for more than 5 days prior to sorting did not give rise to mesenchymal cells.  
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These methods to investigate EnMT differ significantly in that Arciniegas reports 
plasticity in cells between passage 11 and 30, at a much higher passage than 
primary cells are normally used.  Frid in contrast reports this phenomenon was only 
seen in cells sorted on day one post isolation i.e. prior to the first passage.  From the 
morphological description of Arciniegas, the cells they observed may have become 
senescent (enlarged raggy morphology) with age related reduction in cell surface 
markers rather than showing a true phenotypic switch.  The description by Frid et al 
suggests they may have been witnessing appearance and rapid growth of small 
numbers of contaminating mesenchymal cells.   
 
Zhu et al isolated cells from porcine small arteries and examined evidence for EnMT 
following 1 day and 7 days hypoxia [161].  They reported morphological and cell 
surface expression change as evidence of EnMT at 7 days.  Zeisberg et al, in 
addition to lineage tracing in their mouse model, cultured coronary endothelial cells 
and between passages 3 and 5 treated cells with TGFβ1 (10ng/ml) or control media 
for 6 days [91].  They demonstrated change in morphology and immunofluorescence 
via confocal microscopy in the TGFβ1 treated cells compared with control cells.  
Zeisberg also demonstrated that the cell culture media from TGFβ1 treated cells 
contained more collagen I and fibronectin on ELISA.  Cell viability, investigated via 
MTT assay, was reduced not increased.  O’Riordan et al used HUVECs as a model 
of chronic kidney disease to examine endothelial plasticity in response to inhibition of 
nitric oxide for up to 72 hours [93].  Collagen XVIII expression was increased via 
western blotting and qPCR following treatment of HUVECs with the eNOS inhibitors 
ADMA and L-NAME when compared with untreated cells.  In addition the endothelial 
marker Tie-2 reduced and αsma increased when detected via immunofluorescence 
after treatment with ADMA.  Borthwick et al using primary bronchial epithelial cells 
obtained from patients with bronchiolitis obliterans observed change in cell surface 
markers, protein expression and function in cells treated with TGFβ1 and TNFα for 
72 hours [156].  Although this work was conducted in bronchial epithelial cells and 
not lung microvascular endothelial cells, this is the most similar model to date as it 
uses primary cells isolated from individuals who have developed the disease of 
study.  From these published experiments, cells were treated with TGFβ1 5ng/ml 
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and 10ng/ml and CSE 3% (based upon viability studies) for 1 hour and 24 hours 
initially with EnMT examined at 5 days and 7 days.  Later I examined plasticity in 
response to 3% CSE stimulation for 24, 48, and 72 hours.         
 
In addition to investigating EnMT in cell culture models using primary cells from 
patients with emphysema, I also investigated the relationship between endothelial 
loss and mesenchymal deposition/repair in vivo using immunohistochemical staining 
on paraffin embedded lung sections from the tissue from which cells were isolated.  
In addition I utilised dual staining to investigate the presence of cells staining positive 
for both endothelial and mesenchymal markers.  Such dual stained cells would 
investigate in vivo evidence of this phenomenon, with examination of the 
environment in which dual stained cells were found highlighting the biological 
relevance of this mechanism and giving important clues as to the pathogenesis.     
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6.3 Materials and Methods 
 
6.3.1 Immunohistochemistry 
Immunohistochemistry for CD31, CD34 and aSMA was performed on 4um paraffin 
embedded tissue sections from emphysema and control tissue.  Immunoreactants 
were visualised using diaminobenzidine (DAB) substrate solution and vector red 
substrate.  Isotype controls were included in each experiment to assess quality of 
staining.   
6.3.2 Cell culture 
Commercially available human pulmonary microvascular endothelial cells 
(Promocell) and cells isolated from emphysematous human lung and excess normal 
tissue were grown in complete MV2 media (Promocell) containing supplements and 
5% FCS. Cells were grown on 6 well plastic plates coated with gelatin (cell viability), 
in 75cm2 flasks (western blotting) and on 18mm coverslips (Confocal microscopy).  
6.3.3 CSE preparation 
Cigarette smoke extract was prepared according to the method by Carp and Janoff 
[111] as outlined previously and used within 30 minutes of preparation. 
6.3.4 Phase Contrast Microscopy 
Images were taken on a cannon image shot. 
6.3.5 Cell Viability 
Cell viability studies were performed via flow cytometry using 7-AAD to detect non-
viable cells, with FITC annexin V to detect early apoptotic cells.  All experiments 
were conducted in triplicate.    
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6.3.6 Confocal Microscopy 
Cells were fixed in 4% (w/v) paraformaldehyde as before, permeabilised, blocked in 
BSA and incubated with primary antibodies and detected using an appropriate 
fluorochrome-linked secondary antibody. DAPI was used as a nuclear counter stain. 
Images acquired using a LSM 510 laser scanning confocal microscope. 
6.3.7 Western blotting 
Cell lysates (5–20 μg determined via BCA protein assay) were separated via gel 
electrophoresis (4–12% bis-Tris gels, Invitrogen, Paisley, UK) and then transferred 
overnight onto PVDF membranes.  Membranes were then blocked prior to incubation 
with primary antibodies and detected with horseradish peroxidase (HRP)-labelled 
IgG conjugates (Abcam, Cambridge, UK). Antibody complexes were visualised using 
the SuperSignal West Pico chemiluminescent kit (Perbio Science).  β-actin and β-
tubulin loading controls were detected for each experiment. 
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6.4 Results 
6.4.1 Cell Viability in response to TGFβ1 and CSE at 24 hours 
Initial cell viability results were conducted using LMVECs (Promocell) prior to 
replication of work in the emphysema LMVECs.  Cells were treated with complete 
MV2 media containing TGFβ1 10ng/ml, CSE 3% or control.  Cells treated with CSE 
were exposed for 1 hour and 24 hours before replacement with complete media.  
Cells were harvested at 24 hours and viability examined via annexin V and 7AAD 
staining via flow cytometry.  Results (mean± sem, n=3) are shown in figure 6.1.  
There was no significant cell death in cells exposed to TGFβ1, or 3% CSE for 1 hour 
or 24 hours compared with controls (p=0.338).     
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Figure 6.1: Human pulmonary microvascular endothelial cells (HLMVECs) were treated in triplicate 
with complete MV2 media containing TGFβ1 10ng/ml, CSE 3% for 1 hour or 24 hours or control.  Cells 
were harvested at 24 hours and viability investigated via annexin V and 7AAD staining via flow 
cytometry.  There was no significant cell death in cells exposed to TGFβ1, or 3% CSE for 1 hour or 24 
hours compared with controls (p=0.338).   
ANOVA  Alive p=0.369 
  Apoptotic p=0.635 
  Dead p=0.338 
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Cell Viability in response to TGFβ1 and CSE at 7 days 
From the 24 hour viability experiment, I concluded that cell viability remained 
unchanged across the treatments.  I therefore examined cell viability after 7 days 
exposure to TGFβ1 and 7 days from treatment with 3% CSE for 1 hour and 24 
hours.  Cells were treated at time zero with complete MV2 media containing TGFβ1 
1ng/ml, TGFβ1 10ng/ml, CSE 3% or control.  Cells treated with CSE were exposed 
for 1 hour and 24 hours before replacement with complete media.  Cells were 
harvested at 7 days and viability examined investigated via annexin V and 7AAD 
staining via flow cytometry.  Results (mean± sem, n=3) are shown in figure 7.2.  Cell 
viability was much lower (approximately 40-45% viable) than at 24 hours with an 
apparent increase in apoptosis (p=0.001).  There was however no significant cell 
death in cells exposed to TGFβ1, or 3% CSE for 1 hour or 24 hours compared with 
controls (p=0.321).   
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Figure 6.2: Human pulmonary microvascular endothelial cells (HLMVECs) were treated in triplicate with 
complete MV2 media containing TGFβ1 1ng/ml, TGFβ1 10ng/ml and CSE 3% for 1 hour or 24 hours or 
control.  Cells were harvested at 7 days post treatment and viability investigated via annexin V and 7AAD 
staining via flow cytometry.  There was no significant difference in cell death in cells exposed to TGFβ1 or 
3% CSE for 1 hour or 24 hours compared with controls (p=0.321).  Cell viability was however much lower 
with only approximately 40-45% viable compared with approximately 70% at 24 hours (figure 6.1) and may 
account for apparent increase in apoptosis observed (p=0.001).    
 
ANOVA  Alive p=0.349 
  Apoptotic p=0.001 
  Dead p=0.321 
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Cell viability studies (Promocell LMVECs and cells isolated from emphysema 
patients) in response to CSE treatment for 1, 24, 48 and 72 hours was shown in 
chapter 5.  There was no significant cell death among cells treated with up to 3% 
CSE for 1, 24, 48 and 72 hours.  Control cells (untreated) with media change at 24, 
48 and 72 hours also showed no significant difference in viability.  Due the the 
precious nature of these cells, these experiments were not repeated and the data 
used to guide CSE treatment dose for investigation of EnMT.   
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6.4.2 Cell Morphology 
Examination of cell morphology 7 days post TGFβ1 10ng/ml (Figure 6.3b), 3% CSE 
for 1 hour on day one (Figure 6.3c) and 3% CSE for 24 hours on day one (Figure 
6.3d), revealed elongated spindle cells compared with untreated control cells (Figure 
6.3a).  TGFβ1 and CSE treated cells appeared less dense than control cells, but as 
evidenced in Figure 6.2, cell viability was unchanged despite these treatments.  In 
view of these morphological changes on phase contrast microscopy, cell surface 
marker expression was investigated similarly at 7 days via confocal microscopy.     
 
 
 
Figure 6.3: Cell morphology 7 days post TGFβ1 10ng/ml, 3% CSE for 1 hour on day 1 and 3% CSE 
for 24 hours on day 1 was examined and compared with untreated cells (controls).  Phase contrast 
microscopy images demonstrated untreated control endothelial cells maintained their cobblestone 
morphology at 7 days.  TGFβ1 treated cells were a mixture of elongated spindle cells and some 
cobblestone cells.  Similarly the 3% CSE treated cells that were elongated compared with untreated 
cells.   
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6.4.3 Cell surface marker expression of human pulmonary microvascular 
endothelial cells (HLMVECs) in response to TGFβ1 and control 
HLMVECs and fibroblasts 
 
Cells treated with TGFβ1 10ng/ml for 7 days and untreated cells (controls) were fixed 
and stained for the endothelial markers VE-Cadherin and PECAM-1 and the 
mesenchymal markers vimentin and fibronectin with FITC (green, mouse secondary) 
and TRITC (red, rabbit secondary) secondary antibodies.  DAPI was used to counter 
stain nuclei.  Isotype controls with secondary antibody alone were included for all 
experiments to exclude nonspecific staining (figure 6.4).   
 
 
 
 
 
 
 
 
Figure 6.4: Example of secondary antibody only for FITC mouse secondary antibody and TRITC 
rabbit secondary antibody, counterstained with DAPI to stain nuclei blue.  As demonstrated in both 
images there is no non-specific secondary antibody signal. 
FITC-secondary TRITC-secondary 
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Control HLMVECs were cobblestone shaped and stained positively for the 
endothelial cell surface markers VE-Cadherin (Figure 6.5a (i)) and PECAM-1 (Figure 
6.5a (ii)).  Control cells also stained positively for vimentin (Figure 6.5a (iii)).  
Vimentin is a cytoskeletal protein which maintains cell structure and form and 
facilitates endothelial cells’ ability to change shape during its many cellular tasks.  
There was also minimal fibronectin staining in control cells (Figure 6.5a (iv)).  In 
response to TGFβ 10ng/ml, HLMVECs appear to down regulate VE-Cadherin 
(Figure 6.5b (i)).  PECAM-1 staining was also altered being relocated from the cell 
surface to within the cytoplasm (Figure 6.5b (ii)).  Cells elongated (vimentin staining) 
(Figure 6.5b (iii)) with apparent increased fibronectin staining (Figure 6.5b (iv)).  In 
contrast and to act as an internal control to assess the quality of staining, fibroblasts 
were negative for the endothelial markers VE-Cadherin (Figure 6.5c (i)) and PECAM-
1 (Figure 6.5c (ii)).  Fibroblasts stained with vimentin showing dense spindle cells 
with bright cytoplasmic staining (Figure 6.5c (iii)) while there was dense deposition of 
fibronectin (Figure 6.5c (iv)).        
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 Figure 6.5: Confocal microscopy of cells at day 7 post TGFβ1 10ng/ml treatment compared with untreated 
HLMVECs and fibroblasts.  Control HLMVECs stained positively for the endothelial cell surface markers VE-
Cadherin (ai) and PECAM-1 (aii) and were also positive for the cytoskeletal protein vimentin (aiii).  Minimal 
fibronectin staining was shown in control HLMVECs (aiv).  In response to TGFβ 10ng/ml, HLMVECs down 
regulated VE-Cadherin (bi) and PECAM-1 (bii).  Cells demonstrated change in morphology to spindle cells 
(biii).  TGFβ1 treated cells showed increased fibronectin staining.  Fibroblasts stained similarly were 
negative for VE-Cadherin (ci) and PECAM-1 (cii) but showed bright dense packed spindle cells that were 
positive for vimentin (ciii) and increased fibronectin deposition (iv).   
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6.4.4 Endothelial cell surface marker expression in response to cigarette 
smoke extract 
LMVECs treated with 3% CSE for 1 hour and 24 hours were harvested at 7 days, 
together with untreated cells (controls), and were fixed and stained for the PECAM-1 
(endothelial marker) and vimentin, fibronectin and αsma (mesenchymal markers) as 
above with DAPI nuclear staining.  Similar to the previous experiment, untreated 
control HLMVECs at day 7 were cobblestone like and stained positively for PECAM-
1 (Figure 6.6a (i)) and for vimentin (Figure 6.6a (ii)).  Cells had very low staining for 
fibronectin (Figure 6.6a (iii)), but surprisingly were positive for α smooth muscle actin 
(Figure 6.6a (iv)).  In response to 3% CSE for 1 hour, LMVECs appeared to express 
reduced PECAM-1 (Figure 6.6b (i)) while acknowledging that overall cell 
number/viability seemed less as suggested by DAPI nuclear stain.  Cells became 
enlarged, spindle shaped and elongated and stained positively for vimentin (Figure 
6.6b (ii)) and also demonstrated apparent increased fibronectin staining (Figure 6.6b 
(iv)).  Cells treated with 3% CSE for 24 hours showed very reduced/absent PECAM-
1 staining (Figure 6.6c (i)) with reduced cell number/viability indicated by DAPI 
staining. Remaining cells appeared elongated and stained positively for vimentin 
(Figure 6.6c (ii)), fibronectin (Figure 6.6c (iii)) and α smooth muscle actin (Figure 6.6c 
(iv)).  Similar to the previous experiment, fibroblasts were negative for PECAM-1 
(Figure 6.6d (i)) with high positive staining for vimentin (Figure 6.6d (ii)), fibronectin 
(Figure 6.6d (iii)) and α smooth muscle actin (Figure 6.6d (iv)).                                    
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Figure 6.6: Confocal microscopy of cells at day 7 post 3% CSE treatment for 1 hour and 24 hours 
compared with untreated LMVECs and fibroblasts.  Control LMVECs stained positively for PECAM-1 
(ai) and were also positive for the cytoskeletal protein vimentin (aii).  Minimal fibronectin staining was 
shown in control LMVECs (aiii).  The cobblestone outline of control cells was demonstrated via 
positive α smooth muscle actin staining (aiv).   In response to3% CSE at 1 hour and 24 hours, there 
was marked loss of PECAM-1 (bi), (ci).  Cells stained positively for vimentin and became enlarged 
and elongated (bii), (cii) and similarly showed bright αSMA staining.  As in the similar experiment, 
Fibroblasts were negative for PECAM-1 (di) but showed bright dense packed spindle cells that were 
positive for vimentin (dii), increased fibronectin deposition (diii) and elongated αSMA positive cells 
(div).   
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6.4.5 Dual staining for CD31/ fibronectin in LMVECs treated with TGFβ1, 
CSE and TNFα with untreated dermal fibroblasts as a positive control. 
Following the observation that cells appeared to down regulate endothelial markers 
with possible upregulation of mesenchymal markers, LMVECs were dual stained for 
PECAM-1 (CD31) and fibronectin to investigate evidence of co-localisation of 
markers, as would be expected in transitional cells.  PECAM-1 (CD31) a mouse 
primary antibody was used with FITC (green) mouse secondary antibody.  
Fibronectin a rabbit antibody was used with a TRITC (red) rabbit secondary 
antibody.  Control cells displayed cell surface staining for PECAM-1 (green) with 
absent fibronectin staining (red) (Figure 6.7a).  Cells treated with TGFβ1 (10ng/ml for 
7 days) also demonstrated cells staining for positively for PECAM-1 (green) (Figure 
6.7b).  However some TGFβ1 treated cells appeared to lack PECAM-1 expression 
and instead expressed low levels of fibronectin (red) (Figure 6.7b).  One cell 
appeared to express both fibronectin and PECAM-1 which may be evidence of a 
transitional cell (arrow).   
 
Cells treated with 3% CSE for 1 hour (Figure 6.7c) and 24 hours (Figure 6.7d) at 7 
days had reduced cell surface expression of PECAM-1 (green).  Cells appeared to 
express increased fibronectin within the cytoplasm (red).  Interestingly the cells 
treated with CSE appeared more transitional than those treated with TGFβ1 (Figure 
6.7b), the archetypal orchestrator of phenotypic switch.      
 
In this experiment, some cells were also treated with TNFα.  Cells treated with TNFα 
alone markedly down regulated PECAM-1 (green) (Figure 6.7e-g).  Cells appeared 
elongated on phase contrast in keeping with reports in the literature [164] [165], but 
did not increase fibronectin expression or deposition.   The down regulation of CD31 
was more apparent in the TNFα treated cells than in either those treated with TGFB1 
(Figure 6.7b) or CSE (figure 6.7c-d).  No transitional cells were evident in this 
population. Control fibroblasts stained with the same dual staining protocol showed 
confluent fibronectin staining (red) and absent CD31 (green) (Figure 6.7h). 
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Figure 6.7: Dual staining of HLMVECs for PECAM-1/CD31(green, endothelial) and fibronectin (red, 
mesenchymal) detected via  Confocal microscopy at day 7 post TGFβ1 10ng/ml, TNFα 20ng/ml, 3% CSE 
treatment for 1 hour and 24 hours on day one compared with untreated cells and fibroblasts.  Control 
(untreated cells) stained positively for PECAM-1 but negatively for fibronectin (Figure 7.7a).  Cells treated 
with TGFβ1 10ng/ml showed some cells had absent PECAM-1 staining (green) with low levels of fibronectin 
staining (red).  Some cells appeared to have localisation of CD31 (green) and fibronectin (red) suggesting the 
possibility of transitional cells (arrow).  Cells treated with 3% CSE treatment for 1 hour and 24 hours on day 
had markedly reduced CD31 staining with increased fibronectin staining.  Cells treated with TNFα 20ng/ml 
showed down regulation of CD31 but with no similar increase in fibronectin.  Fibroblasts stained confluently 
with fibronectin (red) and had absent CD31 (green) staining.  
a) b) c) d) 
e) f) g) h) 
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6.4.6 Dual staining for CD31/αSMA in LMVECs treated with TGFβ1 and 
3% CSE for 1 hour, 24 hours, 48 hours and 72 hours at 7 days compared 
with untreated cells and dermal fibroblasts. 
 
Cellular plasticity was further investigated with dual staining via confocal microscopy 
using another more mature mesenchymal marker αSMA together with CD31.  αSMA 
a rabbit antibody was used with a TRITC (red) rabbit secondary antibody with the 
same PECAM-1 (CD31) (mouse primary antibody with FITC (green) mouse 
secondary antibody) as used in the previous experiment. 
 
Control fibroblasts stained with the same dual staining protocol showed elongated 
cells with strong αSMA (red) and absent CD31 (green) (Figure 6.8a).  Untreated 
LMVECs  displayed cell surface staining for PECAM-1 (green) with absent αSMA 
staining (red) (Figure 6.8b).  In this experiment the cells surface staining for CD31 on 
control cells was less clear than in previous experiments.   Cells treated with TGFβ1 
(10ng/ml for 7 days) also demonstrated cells staining for positively for PECAM-1 
(green) (Figure 6.8c).  However some TGFβ1 treated cells appeared to lack PECAM-
1 expression while expressing low levels of αSMA (red) (Figure 6.8d).  Some cells 
treated with 3% CSE for 1 hour (Figure 7.8e), 24 hours (Figure 7.8f), 48 hours 
(Figure 7.8g) and 72 hours (Figure 7.8h) at 7 days had reduced cell surface 
expression of PECAM-1 (green).  The most marked changes were witnessed in the 
cells treated for 72 hours.  Importantly, this was not a universal response with some 
cells continuing to express their native CD31 in a similar pattern to the untreated 
cells.  There was no clear evidence of cells expressing αSMA in response to CSE. 
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Figure 6.8: Dual staining of LMVECs for PECAM-1/CD31(green, endothelial) and αSMA (red, mesenchymal) 
detected via  Confocal microscopy at day 7 post TGFβ1 10ng/ml, 3% CSE treatment for 1 hour, 24 hours, 48 
hours and 72 hours compared with untreated cells and fibroblasts.  Fibroblasts demonstrated αSMA (red) in 
sheet like form with absent CD31 (green) staining (Figure 7.8a). Control (untreated cells) stained positively 
for PECAM-1 but negatively for αSMA (Figure 7.8b).  Cells treated with TGFβ1 10ng/ml showed some cells 
had reduced PECAM-1 staining (Figure 7.8c) with possible low levels of αSMA staining on some cells (Figure 
7.8d).  Cells treated with 3% CSE treatment for 1 hour (Figure 7.8e), 24 hours (Figure 7.8f), 48 hours (Figure 
7.8g) and 72 hours (Figure 7.8h) had reduced CD31 staining.  There was no clear evidence of increased 
αSMA staining in response to CSE   
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6.4.7 Examination of cell surface markers via flow cytometry 
Having identified possible change in cell surface markers, EnMT in response to 
TGFβ1 and CSE was further investigated via flow cytometry.  Cells were treated in 
triplicate at 70% confluence with TGFβ1 (1ng/ml and 10ng/ml) and CSE 3% for 1 
hour and 24 hours as previous.  Cells were harvested 7 days post treatment using 
cell dissociation solution and incubated with the cell surface markers CD31 
(endothelial) and CD90 (fibroblast), as used previously in the characterisation 
experiments (chapter 4).  Following incubation, cells were washed and centrifuged at 
1000rpm prior to resuspension in PBS and analysed via flow.   
 
All cells stained positively for CD31 and negatively for CD90 (data not shown).  
However there was a significant reduction in median fluorescence intensity in 
CD31staining (Figure 6.9) (ANOVA, p=0.028) that was not significant for TGFβ1but 
significant for CSE at 24 hours (p=0.047).  Although the cells were overall positive for 
the endothelial marker CD31, this data suggests a change in the cellular expression 
of this marker which may suggest loss of CD31.  CD90 was unchanged across all 
treatments with very low expression, this was however not unsurprising as CD90 is a 
mature fibroblast marker and such a marked phenotypic switch by 7 days would be 
unlikely.   
 
Following this experiment, I went on to examine CD31 and CD90 expression at days 
11 and 15 to examine whether changes in cell surface expression became more 
established at later time points (data not presented).  However this again showed all 
cells remained positive for CD31 and negative for CD90 with a reduction in the 
median fluorescence intensity observed for CD31 but with no change in CD90.      
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Figure 6.9:  Examination of cell surface expression in response to TGFβ1 and CSE via flow cytometry.  All 
cells were highly positively for CD31 and negative for CD90 however examination of median fluorescence 
intensity on the CD31 histograms identified a subtle but significant (p=0.028) leftward shift in the median 
fluorescence intensity between (6.9a) untreated and (6.9b) CSE treated cells.  This CD31 reduction was not 
significant in response to TGFβ1 but was in response to CSE at 24 hours (p=0.047) (Figure 6.9c).   
ANOVA  CD31 p=0.028 
  CD90 p=0.752 
p=0.047 
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6.4.8 Investigation of change in protein concentration of cell surface 
markers in response to TGFβ1 via western blotting 
 
Change in protein expression following treatment with TGFβ1 was thereafter 
investigated initially in commercial LMVECs (Promocell) but then repeated in 
emphysema cells and in normal cells.   
 
Cells were treated either with TGFβ1 5ng/ml or TGFβ1 10ng/ml in complete MV2 
media.  Some cells were also serum starved for 24 hours prior to treatment with 
10ng/ml TGFβ1.  Control cells had media changed at time zero.  Cells were 
harvested at 7days and lysed in phosphosafe extraction buffer prior to lysing via 
sonication at 4◦C.  Protein concentration of the cell lysates was determined via a 
BCA protein assay (Figure 6.10).   
 
20ug of protein was loaded for PECAM-1 (CD31), VE-Cadherin, VEGF KDR and 
αSMA.  5ug protein was loaded for fibronectin and vimentin.  Bis Tris 12% gels were 
ran at 100V and then transferred overnight at 100mAmps onto PVDF.  PVDF 
membranes were blocked in 5% marvel milk.  Primary antibodies were thereafter 
applied and left on a rocker at room temperature for a minimum 90 minutes at room 
temperature or at 4◦C overnight.  Membranes were washed and secondary 
antibodies applied.  Protein bands were detected using chemiluminescence and 
imaged.   
 
CD31, VEcadherin and VEGF KDR protein expression was unchanged in response 
to treatment TGFβ1 in LMVECs (Promocell) (Figure 6.11).  Fibronectin, Vimentin and 
αSMA was also unchanged following treatment (Figure 6.11).  Serum starvation of 
cells prior to treatment led to reduced vimentin, asma and fibronectin.  β actin was 
used as a loading control for each membrane and was unchanged across all 
treatments; a representative blot is also shown in figure 6.11. 
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This experiment was repeated multiple times in Promocell cells with the same result 
each time.  The experiment was also repeated in cells isolated from patient 15 with 
normal lungs (Figure 6.12) and in cells isolated from four patients with emphysema 
(Figure 6.13) and in patient 17 (idiopathic pulmonary arterial hypertension) (Figure 
6.14).   
 
Figure 6.10: Cell lysates were placed in phosphosafe extraction buffer and gently sonicated.  A BCA 
protein assay was then ran with standards prepared via serial dilution and plated in triplicate onto an 
elecsys optical plate.  Unknown samples (in this case cells 451.1 control, TGFβ1 5ng/ml, TGFβ1 
10ng/ml and Ss TGFβ1 10ng/ml) were also plated in triplicate.  The plate was incubated at 37◦C and 
read at 490nm after 30 minutes incubation.  A standard curve was constructed and protein 
concentration of unknown samples extrapolated from the curve.  Protein concentration (mg/ml) was 
determined and thereafter concentration to plate 20ug or 5ug for each western blot determined.   
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Figure 6.11: Normal LMVECs (Promocell) treated with TGFβ1 5ng/ml and 10ng/ml versus control 
(untreated cells) at 7 days.  One sample of cells was also serum starved (Ss) prior to treatment with 
TGFβ1 10ng/ml.  Western blots obtained showed CD31, VEcadherin and VEGF KDR protein 
expression was unchanged in response to treatment with TGFβ1.  There was no change in the 
mesenchymal markers fibronectin, vimentin and αSMA.  Serum starvation of cells prior to treatment led 
to reduced vimentin, asma and fibronectin, although endothelial markers were unchanged.  The cause 
of this is unclear.  βactin was used as a loading control and was unchanged across all treatments.   
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Figure 6.12: LMVECs isolated from excess normal tissue at lobectomy (patient 15) treated with TGFβ1 
5ng/ml and 10ng/ml versus control (untreated cells) at 7 days.  One sample of cells was also serum 
starved (Ss) prior to treatment with TGFβ1 10ng/ml.  Western blots obtained show the endothelial 
markers CD31, and VE-cadherin protein expression was unchanged in response to treatment with 
5ng/ml and 10ng/ml TGFβ1 at 7 days.  The mesenchymal markers fibronectin, vimentin and αSMA 
were also unchanged.  βactin acted as a loading control and was unchanged across all treatments.   
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Figure 6.13: LMVECs isolated from a patient with emphysema (patient 8) were treated with TGFβ1 
5ng/ml and 10ng/ml and compared with untreated (control cells) at 7 days.  One sample of cells was 
also serum starved (Ss) prior to treatment with TGFβ1 10ng/ml.  Western blots obtained show that 
CD31 and VE-cadherin protein expression (endothelial markers) were unchanged in response to 
treatment with 5ng/ml and 10ng/ml TGFβ1 at 7 days.  The mesenchymal markers fibronectin and 
vimentin were also unchanged.  βactin acted as a loading control and was unchanged across all 
treatments.   
 
168 
 
 
 
Figure 7.14: LMVECs isolated from patient with idiopathic pulmonary arterial hypertension (patient 17) 
treated with TGFβ1 5ng/ml and 10ng/ml versus control (untreated cells) at 7 days.  Limited markers 
were used in this exploratory experiment.  Western blots obtained show the endothelial marker VE-
cadherin protein expression was unchanged across the treatments at 7 days.  The mesenchymal 
markers fibronectin and vimentin were also unchanged across treatments.  βactin acted as a loading 
control. 
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In view of these persistently negative findings, A549 cells were treated similarly to 
the above experiments with TGFβ1 to investigate whether I could induce epithelial to 
mesenchymal transition as has been reported extensively by other researchers, 
including those in my own group.  The result shown in Figure 7.15 confirmed a 
positive control that epithelial cells but not endothelial cells undergo a possible 
phenotype switch in response to TGFβ1 as evidenced by down regulation of the 
endothelial marker E-cadherin with associated increased fibronectin and vimentin.  β 
actin was again used as a loading control and was unchanged, further validating 
these results. 
 
 
 
 
 
Figure 6.15: The epithelial cell line A549 was treated with TGFβ1 5ng/ml and 10ng/ml and compared 
with control (untreated cells) at 7 days.  Some cells were also treated after serum starvation (Ss) for 24 
hours prior to treatment.  Cellular protein expression was investigated via the epithelial cell marker E-
cadherin and the mesenchymal markers fibronectin and vimentin.  βactin was used as a loading 
control.Western blots show loss of the epithelial marker E-cadherin in response to treatment with 
TGFβ1 10ng/ml but not 5ng/ml.  Fibronectin and Vimentin were increased following TGFβ1 10ng/ml 
compared with untreated cells and those treated with TGFβ1 5ng/ml.  Response was similar in the 
serum starved cells treated with TGFβ1 10ng/ml and those treated with TGFβ1 10ng/ml without serum 
starvation.  A representative blot for β actin is shown.  A loading control was checked for each blot and 
confirmed equal loading further validating these results of loss of epithelial markers with acquisition of 
mesenchymal markers in response to TGFβ1 10ng/ml. 
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6.4.9 Investigation of change in protein concentration of cell surface 
markers in response to CSE via western blotting 
In view of the preliminary observations on confocal microscopy which suggested 
CSE may be a more potent stimulator of phenotypic change in endothelial cells, 
western blotting was performed on cell lysates prepared from cells treated with 3% 
CSE.  From the viability work, it was decided to investigate EnMT following treatment 
with 3% CSE for 1 hour and 24 hours at 7 days.  Initially experiments used LMVECs 
(Promocell) (Figure 6.16), but thereafter all work was repeated in cells isolated from 
patients with emphysema and in cells isolated from normal excess tissue obtained at 
lobectomy.  The endothelial and mesenchymal markers used in the TGFβ1 
stimulation experiments were used similarly in these experiments.  EnMT was also 
investigated at earlier time points, with cells treated with 3% CSE for 24, 48 and 72 
hours and EnMT investigated thereafter.   
 
LMVECs (Promocell) treated with TGFβ1 10ng/ml for 7 days or 3% CSE for 1 hour 
or 24 hours with cells harvested 7 days post exposure and compared with untreated 
cells showed no discernible change in CD31, fibronectin or vimentin (Figure 6.16).  
LMVECs (Promocell) treated with 3% CSE for 24, 48 and 72 hours showed no loss 
of CD31 (endothelial marker) and no upregulation of fibronectin, vimentin and aSMA 
(mesenchymal markers) (Figure 6.17).  This experiment was repeated in cells 
isolated from patients with emphysema (Figure 6.18-6.19), cells isolated from excess 
normal tissue (Figure 6.20) and using A549 cells (epithelial cell line) (Figure 6.21).  
There was no evidence of change in protein expression found in support of EnMT or 
EMT in response to CSE. 
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Figure 6.16: HLMVECs (Promocell) treated with TGFβ1 10ng/ml for 7 days or 3% CSE for 1 hour or 24 
hours with cells harvested at 7 days post exposure and compared with protein expression of untreated 
cells at 7 days.  Limited markers were used in this exploratory experiment.  There was no change in 
CD31 or vimentin or fibronectin in response to TGFβ1, 3% CSE for 1 hour and 24 hours.  βtubulin was 
used as a loading control. 
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Figure 6.17: HLMVECs (Promocell) were treated with 3% CSE for 24, 48 and 72 hours and 
compared with untreated cells (controls).  Protein expression was investigated via western blotting for 
the endothelial marker CD31 and for the mesenchymal markers fibronectin, vimentin and aSMA.  β 
actin was used as a loading control.  Western blots showed no change in CD31 expression on cells 
treated with 3% CSE across the 3 time points.  There was no increase in mesenchymal markers 
observed in response to CSE, indeed control cells expressed more fibronectin, vimentin and aSMA 
than treated cells.  Loading controls for each blot were confirmed using βactin, a representative blot is 
shown.  
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Figure 6.18: LMVECs isolated from emphysema lung tissue (patient 8) were treated with 3% CSE for 
24, 48 and 72 hours and compared with untreated cells (controls).  Protein expression was 
investigated via western blotting for the endothelial marker VE-cadherin and for the mesenchymal 
markers fibronectin, and vimentin.  There was no change in VE-cadherin or vimentin or fibronectin in 
response to 3% CSE for 24, 48, 72 hours.  βactin was used as a loading control. 
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Figure 6.19: LMVECs isolated from emphysema lung tissue (patient 4) were treated with 3% CSE for 
24, 48 and 72 hours and compared with untreated cells (controls).  Protein expression was 
investigated via western blotting for the endothelial marker CD31 and for the mesenchymal markers 
vimentin and aSMA.  There was no change in PECAM-1, aSMA or vimentin in response to 3% CSE 
for 24, 48, 72 hours.  βactin was used as a loading control. 
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Figure 6.20: LMVECs isolated from normal lung tissue (patient 15) were treated with 3% CSE for 24, 
48 and 72 hours and compared with untreated cells (controls).  Protein expression was investigated 
via western blotting for the endothelial marker VE-Cadherin and for the mesenchymal markers 
fibronectin, vimentin and aSMA.  There was no change in VE-cadherin or vimentin or aSMA in 
response to 3% CSE for 24, 48, 72 hours.  βactin was used as a loading control. 
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Figure 6.21: A549 cells were treated with 3% CSE for 24, 48 and 72 hours and compared with 
untreated cells (controls).  Protein expression was investigated via western blotting for the epithelial 
marker E-Cadherin and for the mesenchymal markers fibronectin and vimentin.  β actin was used as 
a loading control.  Western blots showed no change in E-cadherin expression on cells treated with 3% 
CSE across the 3 time points.  There was no increase in mesenchymal markers observed in response 
to CSE.  Loading controls for each blot were confirmed using βactin, a representative blot is shown.  
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6.4.10 Endothelial cell activation in response to cigarette smoke extract 
Endothelin-1, the potent vasoconstrictor peptide associated with cigarette smoke 
induced endothelial dysfunction in the systemic circulation, has been reported to be 
induced by TGFβ1 [160], [166].  Endothelin-1 release from cells treated with TGFβ1 
and CSE was therefore investigated via ELISA.   
 
Using a standard commercial ELISA kit, standards (0-100pg/ml) were titrated 
together with samples of media from endothelial cells treated with TGFβ1 5ng/ml and 
10ng/ml and 3% CSE for 24, 48 and 72 hours as in previous experiments.  Cells 
from 2 donors with emphysema (patient 7) and patient 8), from excess normal tissue 
(patient 15) and from Promocell were used for experiments.  A standard curve was 
constructed from the absorbance at 450nm (Figure 6.22) and then concentration of 
Endothelin-1 in media from cells treated (n=2 for TGFβ1 experiment, n=3 for CSE 
experiments) calculated and tabulated (Figure 6.23 & Figure 6.24).  Concentration of 
Endothelin-1 in media from commercial HLMVECs (Promocell) was too high and 
above the greatest standard concentration used (100pg/ml) and so these results 
were unable to be included.  It is difficult to interpret whether this reflects less ET1 in 
emphysema cells or whether lower cell viability and thus lower cell density 
accounted for this observation. 
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Figure 6.22: Standard curve using Endothelin-1 standards incubated with primary antibody and 
detected via enzyme linked immunoabsorbant assay (ELISA). 
179 
 
Cell supernatants showed a trend towards increase in endothelin-1 in response to 
treatment with TGFβ1 5ng/ml and 10ng/ml but this did not reach significance 
(p=0.078).   
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Figure 6.23: ELISA of cell supernatants to investigate endothelin-1 release in response to TGFβ1 in 
cells from normal tissue (patient 15 (451.1)) and from emphysema tissue (patient 7 (295A) and patient 
8 (300C).  Cell supernatants showed a trend towards increase in endothelin-1 in response to 
treatment with TGFβ1 5ng/ml and 10ng/ml but this did not reach significance (p=0.078), (all results 
n=2).    
 
P=0.078 
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Supernatants from cells treated with CSE did not show such a relationship with 
normal cells (patient 15) showing essentially unchanged levels of Endothelin-1, while 
there was a tendency to a reduction in endothelin-1 in (patient 8) but an increase in 
another (patient 7).  All results represent n=3, however due to the conflicting results 
no statistical analysis was performed and no further conclusions can be drawn from 
this experiment. 
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Figure 6.24: ELISA of cell supernatants to investigate endothelin-1 release in response to CSE in 
cells from normal tissue (patient 15) and from emphysema tissue (patient 7 and patient 8).  
Supernatants from cells treated with CSE showed no clear response, with normal cells (patient 15) 
showing essentially unchanged levels of Endothelin-1, while there was a tendency to a reduction in 
endothelin-1 in one emphysema donor (patient 8) but an increase in another (patient 7).  All results 
represent n=3.  No further conclusions should be drawn from this experiment unless repeated. 
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6.4.11 In vivo evidence of endothelial plasticity/ phenotype change 
To further investigate the existence of transitional cells and EnMT in the 
emphysematous lung, I attempted to perform dual staining for CD31 and aSMA via 
immunohistochemistry on paraffin embedded blocks from which emphysema lung 
from which cells were isolated.  In vivo evidence of EMT has been demonstrated in 
the post lung transplant airway via dual immunofluorescence [156] by colleagues in 
our institute and so I employed the same technique in order to investigate EnMT.  
Unlike airways, the alveolar bed has a very high autofluorescence due to elastin 
(Figure 6.25).  Figure 7.25a shows an arteriole (arrow), venule and surrounding 
alveolar bed with CD31 detected with a FITC secondary antibody.  Figure 6.25b 
shows the same section with no primary antibody applied i.e. no CD31, but with 
FITC secondary alone.  There is similar bright green staining suggesting 
autofluorescence.  This was further confirmed with no primary or secondary antibody 
applied with DAPI alone (Figure 6.25c) in which there was clear autofluorescence, 
rendering the stain uninterpretable.  No such difficulties were encountered with 
αSMA which gave a clear signal (red) with no autofluorescence (Figure 6.26).  In 
view of this, I therefore attempted to quench autofluorescence using pontamine sky 
blue.      
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Figure 6.25:CD31/αSMA immunohistochemistry on paraffin embedded blocks from emphysema lung 
tissue visualised via the FITC green channel.  CD31 with FITC secondary (a) allowed visualisation of 
an arteriole (arrow), venule and surrounding alveolar bed.  However the same section with FITC 
secondary alone applied (b) showed similar staining with visualisation of arteriole and supporting 
alveolar bed suggesting autofluorescence.  This was confirmed when no primary or secondary antibody 
was applied (DAPI alone) (c) in which there was clear autofluorescence, rendering the stain 
uninterpretable.       
Figure 6.26: CD31/αSMA immunohistochemistry on paraffin embedded blocks from emphysema lung 
tissue detected via the TRITC channel.  αSMA with TRITC secondary (a) allowed visualisation of an 
arteriole and surrounding alveolar bed.  The same section with TRITC secondary alone applied (b) 
showed no background autofluorescence. 
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Elastin and collagen are abundant in the lung and autofluoresce under ultraviolet 
light.  Elastin contains several fluorophores, one of which is a tricarboxylic amino 
acid with a pyridinium ring [167] which is similar to a fluorophore found in collagen.  
Studying the lung microvasculature therefore poses a problem as the internal elastic 
lamina of arterioles and the elastin associated with the alveolar bed emits a signal 
which is frequently more intense than any signal detected with the primary antibodies 
of study.  Supporting collagen around vessels and in the alveolar bed further 
compounds this.  Pontamine sky blue has been used to quench autofluorescence in 
a pre-treatment stage prior to antigen retrieval and immunostaining [168].  I therefore 
stained multiple sections of lung tissue in order to investigate whether I could 
achieve a clean CD31 immunofluorescent stain.   
 
HRP CD31 immunostaining requires pre-treatment with boric acid in order to bring 
out the microvasculature, thus adding further complexity.  The results are shown in 
figure 6.27.    Tissue pre-treated with boric acid prior to CD31 staining showed 
intense fluorescent green staining (a) in alveolar bed and external elastic lamina of 
vessels, consistent with the previous experiment and well documented 
autofluorescence.  Similarly pre-treatment with boric acid but with only FITC 
secondary antibody i.e. no CD31, showed high autofluorescence.  Pre-treatment of 
the section with pontamine sky blue followed by FITC secondary antibody alone (c) 
showed reduced but not complete attenuation of autofluorescence,  When tissue 
was pre-treated with pontamine sky blue and then boric acid as an antigen retrieval 
agent prior to antibody staining with CD31 followed by FITC secondary, there was 
very weak staining and no autofluorescence (d).  CD31 was only applied for 1 hour 
at room temperature and so it may be that a more prolonged incubation period i.e. 
overnight at 4◦C may have increased the signal.  This was confirmed by the same 
finding when incubated without primary antibody (e).  However when the section was 
pre-treated with pontamine sky blue and boric acid and stained for CD31 was viewed 
on the TRITC (red) channel, there was now intense autofluorescence detected (f).  
Thus pontamine sky blue fluoresces red, shifting the autofluorescence from green to 
red and so for such dual staining is unsuitable.  Due to such difficulties encountered 
trying to quench lung autofluorescence, I converted the stain to light microscopy 
immunocytochemistry.  
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Figure 6.27: CD31 immunostaining on paraffin embedded emphysema lung tissue.  Tissue pre-treated 
with boric acid (antigen retrieval agent) with CD31 showed intense fluorescent green staining (a) in 
alveolar bed and external elastic lamina of vessels.  However as before similar pre-treatment but 
without any primary antibody applied i.e. no CD31 produced similar staining suggesting 
autofluorescence.  Pre-treatment of paraffin embedded tissue with pontamine sky blue but no primary 
antibody (c) showed reduced but not complete attenuation of autofluorescence,  When tissue was pre-
treated with pontamine sky blue and then boric acid as an antigen retrieval agent prior to antibody 
staining with CD31 followed by FITC secondary, there was very weak staining but no autofluorescence 
(d).  CD31 was only applied for 1 hour at room temperature and so it may be that a more prolonged 
incubation period i.e. overnight at 4◦C may have increased the signal.  This was confirmed by the same 
finding when incubated without primary antibody (e).  However when the section was pre-treated with 
pontamine sky blue and boric acid and stained for CD31 was viewed on the TRITC (red) channel, there 
was now intense autofluorescence detected (f).    
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CD34 is an alternative marker of endothelial cells that has been used to investigate 
the lung microvasculature.  CD34 immunocytochemistry did not require antigen 
retrieval with boric acid and therefore in addition to CD31/αSMA, I also stained tissue 
for CD34/ αSMA due to concerns over the quality of CD31 on dual staining.  CD31 
and CD34 were detected via HRP/DAB (brown).  0.5% hydrogen peroxide was used 
to quench endogenous peroxidise.  αSMA was detected via ABC-AP kit with Vector 
red detection (red/pink).  Levamisole was used to quench the endogenous alkaline 
phosphatise (AP).  The CD31 stain was again very weak and difficult to interpret 
together with αSMA, however CD34 stained the microvasculature well together with 
αSMA and allowed interpretation.  Lung tissue sections were therefore 
immunostained for CD34/αSMA from normal excess tissue (Figure 6.28) and tissue 
obtained at transplantation for emphysema (Figure 6.29).  Sections were examined 
to determine the relationship between endothelial cells (CD34 positive cells) and 
matrix (αSMA positive cells), with evidence of transitional cells (co-localisation of 
CD34 and αSMA) sought.   
 
Normal excess paraffin embedded lung tissue immunostained for CD34 (brown) an 
endothelial marker and αSMA (red) a marker of matrix/mesenchymal cells 
demonstrated differentiation of brown/red immunostaining as shown in figures 6.28a) 
and b).  The vessel at higher power magnification 6.28b) illustrates the flat 
circumferential endothelial cells (brown) with associated supporting matrix cells (red) 
in close apposition but with clear distinction of red and brown.  Figure 6.28c) shows 
the alveolar bed of normal lung tissue.  The small alveolar capillaries (brown) can be 
clearly seen.  Figure 6.28d), at higher power supports this, with few αSMA positive 
cells.  No dual stained (transitional cells) were identified in sections of normal lung 
tissue. 
 
Emphysema lung tissue immunostained for CD34 (brown) and αSMA (red) shows 
the alveolar bed, with well-preserved capillaries (CD34+ brown cells) with a cluster of 
small vessels (CD34+ brown cells) (Figure 6.29a).  Lateral to these vessels is an 
area of thickened matrix with intense αSMA staining, with absent CD34 staining.  
Some peripheral fibrotic sprouts also stain positively for αSMA.  Two small 
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muscularised arterioles and the surrounding alveolar bed are captured in figure 
6.29b).  In this section there is intense αSMA of the vessels, but the CD34+ 
endothelial monolayer appears diminished.  Between the two vessels the alveolar 
bed is very thin, with loss of supporting structure including capillaries.  In this area 
there is a thickened septum with few very weakly positive CD34 cells but no dual 
stained cells.  Figure 6.29c) shows a thin septum and associated vessels.  The 
capillaries are relatively well preserved although in one part of the septum (arrow) 
there is low intensity CD34 (brown) staining with associated low intensity (αSMA) red 
staining, although these stains are not truly co-localised.  Figure 6.29d) shows the 
emphysematous alveolar bed, with marked regional loss of capillaries.  In this 
section there is a septum which appears to have flat cells typical of endothelial cells 
which stain red/brown (arrows).  These could represent transitional or activated 
endothelial cells. 
 
 
 
 
 
  
187 
 
 
 
 
 
Figure 7.26:Normal Tissue. Normal excess paraffin embedded lung tissue immunostained for CD34 (brown) an 
endothelial marker and αSMA (red) a marker of matrix/mesenchymal cells.  Figure a) shows a vessel and 
surrounding alveolar bed.  The vessel at higher power magnification b) illustrates clearly the flat circumferential 
endothelial cells (brown) with associated supporting matrix cells (red) in close apposition.  Importantly there is 
clear distinction of red and brown.  Figure c) shows the alveolar bed of normal lung tissue.  The small alveolar 
capillaries (brown) can be clearly seen with only low levels of αSMA.  Figure d), at higher power supports this, 
with few αSMA positive cells.  No dual stained i.e. transitional cells were identified in sections of normal lung 
tissue. 
 
Figure 7.28: Normal Tissue.  Normal excess paraffin embedded lung tissue immunostained for CD34 
(brown) an endothelial marker and αSMA (red) a marker of matrix/mesenchymal cells.  Figure a) shows 
a vessel and surrounding alveolar bed.  The vessel at higher power magnification b) illustrates clearly 
the flat circumferential endothelial cells (brown) with associated supporting matrix cells (red) in close 
apposition.  Importantly there is clear distinction of red and brown.  Figure c) shows the alveolar bed of 
normal lung tissue.  The small alveolar capillaries (brown) can be clearly seen with only low levels of 
αSMA.  Figure d), at higher power supports this, with few αSMA positive cells.  No dual stained i.e. 
transitional cells were identified in sections of normal lung tissue. 
X 20 X 30 
X 20 X 30 
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Figure 7.29: Emphysema Tissue.  Emphysema lung tissue immunostained for CD34 (brown), an 
endothelial marker, and αSMA (red), a marker of matrix/mesenchymal cells.  Figure a) shows the 
alveolar bed with a cluster of small vessels.  The microvasculature is well preserved, with no apparent 
loss of capillaries.  Just lateral to the vessels there is an area of thickened matrix with intense αSMA 
staining.  No cells in this region stain positively for CD34.  There are also some peripheral tissue 
sprouts which stain positively for αSMA.  Figure b) shows 2 small muscularised arterioles and alveolar 
bed.  In this section there is intense αSMA of the vessels, but the endothelial monolayer appears 
reduced.  Between the two vessels the alveolar bed is very thin with loss of supporting structure 
including capillaries with numerous reed-ghosts cells.  In this area there is a thickened septum with 
few very weakly positive CD34 cells but no dual stained cells.  Figure c) shows a thin, septum with 
associated vessels.  The capillaries are relatively well preserved although in one part of the septum 
(arrow) there is low intensity brown staining with low intensity red staining although not truly co-
localised to suggest transitional cells.  Figure d) shows peripheral lung tissue.  Again there is marked 
regional loss of capillaries.  In this section there is a long septum which appears to have flat cells 
typical of endothelial cells which stain a red/brown (arrows).  These may represent transitional or 
activated endothelial cells and may be evidence of in vivo EnMT. 
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7.5 Discussion 
Endothelial to mesenchymal transition (EnMT) has been reported by other 
researchers in large vessel endothelial cells, in animal models and in commercial 
lung microvascular endothelial cells.  In this chapter I have attempted to 
systematically investigate EnMT ex vivo and in vivo.  I have demonstrated 
morphological changes in cell structure that have been supported by change in cell 
surface markers on individual cells via confocal microscopy and reduction in 
endothelial surface expression via flow cytometry.  Following these preliminary 
supportive experiments I investigated dual staining for endothelial and mesenchymal 
markers on individual cells via confocal microscopy.  There was however no 
evidence of dual staining of cells.   
 
I therefore further investigated EnMT via protein expression on western blotting, 
examining both the response of cells to TGFβ1 and CSE.  These results however did 
not support a change in protein expression at 7 days, with no loss of endothelial 
markers or gain of mesenchymal markers.  To validate these findings, I repeated 
these experiments on multiple occasions and in different cells types (both 
commercial cells, and isolated emphysema cells and normal cells).  In the TGFβ1 
stimulation experiments, I also treated cells isolated from a patient with idiopathic 
pulmonary arterial hypertension (IPAH).  IPAH is a disease characterised by 
remodelling of the pulmonary arterioles, with proliferation and a resulting obstructive 
vasculopathy.  Cells isolated from patients with IPAH had a much shorter doubling 
time and produced a high cell yield at low passage.  Thus I hypothesised that EnMT 
may be most likely to be observed in such cells.  Once again there was no change in 
markers to suggest a phenotype change.  After such surprising and disappointing 
negative results I believed it important to prove that the technique and materials 
were sound as so treated A549 cells with TGFβ1 via the same protocol and showed 
that EMT occurred as reported by previous investigators.  No such phenotype 
change occurred however when A549 cells were treated with CSE. 
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Such results are interesting.  Cells clearly show areas of reduced CD31 expression 
however lack of measurable change on western blotting suggests that a full 
phenotypic switch has not occurred.  Such changes observed may be more in 
keeping with endothelial activation.  Endothelial cells play an important function in 
maintaining vascular homeostasis and generally exist in a quiescent form, with a 
monolayer of cells formed by tight adherens junctions and contact inhibition [14].  
This provides important anti-coagulant properties for the vessels and assists in 
laminar blood flow and leucocyte trafficking.  When disruption to this monolayer 
occurs, via mechanical injury, infection or chemical injury such as smoking, 
endothelial cells become activated in order to respond to this change in environment.  
This is an energy independent process which does not require protein 
synthesis[169].  Activation of endothelial cells may be transient but may become 
prolonged if there is a chronic insult or more potent injury.  Activated endothelial cells 
exhibit many of the qualities that mesenchymal cells display.  Activated endothelial 
cells are reported to lose their tight barrier function, to allow extravasation of fluid 
and migration of neutrophils into the area of injury.  This is archetypically seen in 
pneumonia, where there is oedema and expansion with inflammation of the alveolus.  
Activated endothelial cells also act as chemoattractants recruiting leucocytes to the 
area of injury may display proliferative and secretory actions as they respond to the 
injury.  Decrease in endothelial barrier function has been reported within 1-3 hours of 
treatment with TGFβ1 and VEGF in vitro with a possibly more rapid activation 
observed using in vivo models [170], [171].  Cells tend to remain in this activated 
state until the injury is removed or subsides.   
 
Endothelial cell activation is a normal physiological mechanism important for 
angiogenesis in both wound repair and has been studied in cancer biology 
specifically metastasis.  VEGF is an important activator of endothelial cells, with 
stimulation causing increased proliferation and migration with the ability to form small 
vessel sprouts [50].  Endothelin-1 also promotes proliferation and as shown in this 
chapter TGFβ1 stimulation increases ET-1 production, however TGFβ1 tends to 
inhibit cell growth [172].  Activated endothelial cells are also pro-coagulant, which is 
an important feature which facilitates protection against vascular injury [173].  While 
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not the focus of this study, it is important not to view endothelial cells in a one 
dimensional ex vivo model, rather relate their function to the three-dimensional 
characteristics including flow.  Thus endothelial cells must not be considered a 
passive monolayer of cells, but rather as a complex adapted system which maintains 
and restores vascular homeostasis.  Thus endothelial cells can behave with a more 
secretory phenotype which could be interpreted as a phenotypic switch, but rather as 
this data would support, it may simply represent endothelial cell activation.   
 
These observations are further supported by the observations that TNFα causes 
conformational changes and loss of endothelial cell surface markers, but no change 
in mesenchymal markers [164].  Mawatari et al were the first to examine the effect of 
human TNFα on cultured human microvascular endothelial cells from omental tissue 
removed at surgery [164].  They noted that “cobblestone like endothelial cells 
transformed into a disordered array of criss-crossed, elongated, spindle shaped 
cells” when incubated with TNFα and that this was accentuated when co-incubated 
with TNFα and epidermal growth factor (EGF).  Such description appears very close 
to the effects observed in these studies, and would suggest that what we are 
witnessing is an activation of endothelial cells in response to TGFβ1, TNFα and CSE 
rather than a true phenotypic switch. 
 
I initially planned to investigate change in function of the cells following stimulation 
particularly looking for evidence of change in matrix metalloproteinases and 
secretion of proteins such as collagen.  Due to the largely negative studies of EnMT 
this work was not pursued, although preliminary studies (work not shown) did not 
show any change in MMP 2 and MMP 9 via gelatine zymmography.  Similarly, 
western blotting of TCA precipitates for collagen I and collagen III did not show an 
increase compared to control cells. 
 
Dual staining for the endothelial marker CD34 and the mesenchymal marker aSMA 
on peripheral lung tissue was also conducted to look for in vivo evidence of EnMT.  
Normal tissue showed no evidence of endothelial cell injury and there were no dual 
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stained cells observed.  In emphysema tissue there were regions of alveolar 
endothelial cell loss and other regions in which there was expansion of the alveolar 
matrix with aSMA deposition.  Some of these areas were discrete but many of these 
alveolar changes were found in close apposition to each other.  Reed ghost cells are 
sclerotic casts of endothelial cells that are a marker of endothelial cell injury.  They 
were commonly observed in the alveolar bed of emphysema tissue.  Distal to these 
sclerotic casts, some of the alveolar bed appeared very thin and almost avascular.  
In some regions of the thin septa, flattened cells were seen typical of endothelial 
cells, but these cells were negative for endothelial cells and instead stained 
positively for aSMA.  No dual stained cells were easily identified in emphysema 
tissue.   
 
In these studies I did not find evidence of EnMT but did note change in cell surface 
expression and propose that EnMT should not be discounted, but rather questioned 
and further investigated in order to understand the response of microvascular 
endothelial cells to injury.  
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Chapter 7: Summary, Discussion and Future work 
7.1 Summary 
In this thesis I utilised severely emphysematous lungs obtained at transplantation to 
investigate the pathogenesis of emphysema.  The study was conducted to attempt to 
challenge the existing models of emphysema and allow close correlation between 
clinical characteristics, pathological findings and cell biology responses ex vivo.  This 
was logistically challenging, technically difficult and demanding work.  The potential 
gains from this model to improve our understanding of the pathophysiology of this 
complex disease were the impetus and reason for persisting with the construction of 
a new model and the investigation of the complex stress that is cigarette smoking.  
 
Returning to answer my original aims:   
 
 I attempted to establish a reliable and reproducible method to isolate 
and fully characterise microvascular endothelial cells from the excess 
emphysematous tissue obtained at lung transplantation 
Large numbers of microvascular endothelial cells were isolated from severely 
emphysematous explanted lungs with good success (71%).  These cells were 
fully characterised and proven to be of microvascular origin.  Cells were stable up 
to passage 7 and could be cryopreserved and later reanimated for use in future 
experimental work.  The methodology has been published and has been highly 
accessed.   
 
 To investigate whether these susceptible endothelial cells undergo 
apoptosis in response to cigarette smoke, in comparison with untreated 
cells and rates of apoptosis in cells isolated from normal individuals. 
Investigation of apoptosis was complex using these precious primary cells.   
Determining the concentration at which to stress cells in order to induce cell 
death via apoptosis and the time point at which to harvest cells and examine 
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them was complex and may have differed between donors as initial results were 
inconsistent as determined by annexin V staining on flow cytometry.  TUNEL 
staining of individual cells also did not confirm whether apoptosis was observed 
in response to cigarette smoke.  Live cell imaging was therefore employed.  This 
technique identified and reinforced the inherent problems of cellular 
autofluorescence while using cigarette smoke as an injury.  I attempted to control 
for this with the results suggesting that cells isolated from emphysema lung tissue 
may undergo apoptosis and earlier and at lower concentration than commercial 
normal lung microvascular endothelial cells.   This would be in keeping with my 
hypothesis that these cells are more susceptible to injury.  However due to 
autofluorescence such conclusions are not proven and need further investigation 
using methods which do not employ fluorescence as a method of detection of 
apoptosis.   
 
Further investigation of gene expression of these cells in response to cigarette 
smoking showed that cells from commercially available normal donors showed 
upregulation/ no change in VEGFr2 in response to cigarette smoke extract.  
Microvascular endothelial cells isolated from emphysema tissue in contrast 
showed a down regulation in VEGFr2 in response to cigarette smoking.  VEGFr2 
is the main receptor for human VEGF1 and is important for maintaining cell 
structure, function and defence.  Thus a downregulation in VEGFr2 in response 
to cigarette smoking appears to be a maladaptive response to injury in these 
susceptible cells. 
 
Unfortunately the controls used in these experiments were commercially 
available cells and not cells isolated from excess normal tissue as planned.  This 
was due to the time constraints of isolating and purifying large numbers of 
endothelial cells with sufficient donor numbers to allow repeat experiments to 
provide meaningful data.  Thus the focus was on isolating the microvascular 
endothelial cells from emphysema lung tissue and not from excess normal tissue 
as this was novel and unique exploratory work.  Each experiment however had 
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an internal control of being compared with untreated cells i.e. control and more 
than 1 normal donor was used for the experiments in normal cells.    
 
 To investigate characteristics of cells which are resistant to apoptosis. 
The characteristic of cells resistant to apoptosis was unfortunately not 
investigated and as such is beyond the scope of this thesis.  The properties of the 
cells which remain and are resistant to the insult of cigarette smoking should be 
the focus of further work to identify any protective mechanisms which they exhibit 
that could be exploited as a protective mechanism for therapeutic benefit.  
 
 To investigate endothelial plasticity in response to cigarette smoking, 
examining cell activation and phenotype via change in cellular 
expression and matrix production in response to cigarette smoke 
extract. 
Microvascular endothelial cells isolated from explanted severely emphysematous 
lung tissue were used to investigate endothelial plasticity in response to cigarette 
smoking.  Cells showed morphological changes and changes in cellular 
expression via confocal microscopy with elongation of cells, loss of contact 
inhibition, down regulation of endothelial markers.  Upregulation of mesenchymal 
markers was less clear.  There was however no change in protein expression of 
endothelial markers or mesenchymal markers on western blotting.  This raises 
the possibility that endothelial cells are activated in response to cigarette smoke 
extract, with change in cell morphology and expression, but without 
transcriptional change i.e. not a true phenotypic switch rather exhibiting cellular 
plasticity.  The same results were observed with both commercial normal cells 
and the cells isolated from emphysema lung tissue.  Preliminary studies 
confirmed that there was no change in matrix metalloproteinase production in 
response to CSE, however further work is required to examine change in function 
i.e. do activated endothelial cells exhibit a secretory function with attempts to lay 
down new matrix and assist with alveolar repair?   
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7.2 Implications of this study 
This study is to my knowledge the first study into the pathogenesis of emphysema 
using microvascular endothelial cells isolated from patients with severe emphysema 
who donated their explanted lung for research.  This ex vivo model which allows 
study of the microvascular hypothesis of COPD is unique as it is not only a human 
model using primary lung cells, the cells were isolated from individuals who had very 
severe disease, enough to warrant transplantation.  Thus biological mechanisms can 
be studied in response to the injurious stimulus, in this case cigarette smoke, which 
is believed to have precipitated the disease in cells that have been proven to be 
susceptible to the injury and which have taken part in the pathophysiology of the 
disease.  Although cell isolation was initially labour intensive, large numbers of cells 
were obtained that showed stability of phenotype up to passage 7 and could be 
cryopreserved for use in future experiments.  This study therefore challenges the 
current models used in lung science.  While some researchers might argue that 
proof of concept work must first be investigated in animal models or in stable cell 
lines or in normal cells, this study would argue and put forward that the information 
and results gained from studying these diseased cells is more relevant and closer to 
the in vivo response and is more likely to be translational.     
 
This thesis highlights two important mechanisms that may be relevant in 
emphysema, namely apoptosis and activation of endothelial cells in response to 
cigarette smoke.   
 
I attempted to systematically investigate apoptosis in this study however due to 
autofluorescence of cells in response to CSE no clear conclusions can be drawn.  
With attempts to control for autofluorescence (on live cell imaging) there was an 
apparent apoptosis of cells that occurred earlier and at lower dose of cigarette 
smoke extract in these cells isolated from individuals with severe emphysema.   
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However such preliminary findings need to be investigated further using methods to 
detect apoptosis that do not employ fluorescence.   
 
Endothelial cells appear to become activated in response to cigarette smoke.  
Endothelial activation is described more often in acute lung injury models and to my 
knowledge has not been reported in emphysema.  In this thesis I have not 
demonstrated a true endothelial to mesenchymal transition, but propose that I have 
demonstrated a degree of cellular plasticity, which remain of endothelial pedigree, 
but change shape and expression and may change function, although due to time 
constraints such studies of function were investigated briefly but not fully enough to 
be reported in this study.       
7.3 Limitations of this study 
One limitation of this study is the use of severe end stage emphysematous lung 
tissue to examine the pathogenesis of early emphysema and it could be suggested 
that using normal tissue from smokers may be a better model.  However I propose 
that very diseased cells are unlikely to survive the isolation process thus the isolated 
cells are likely to represent susceptible LMVECs from the disease in question.  I 
chose this model over the use of LMVECs isolated from cancer resection specimens 
or excess normal tissue obtained at surgery for other purposes as only 1 in 5 
individuals who smoke develop COPD so studying the disease in cells isolated from 
individuals who had developed the disease had potential advantages.  Furthermore 
each cell model has limitations including the use of cancer resection specimens (the 
surrounding tissue removed may have altered expression of VEGF) or excess 
normal tissue from lungs deemed unsuitable for transplantation (brain death causes 
a massive inflammatory response thus limiting the use of cells isolated from this 
model).  I propose that this model is relevant to studying the pathogenesis of COPD 
as even within severely damaged emphysematous lungs there is ongoing evidence 
of repair and active inflammation and that within severely damaged lung there are 
some areas of near normality but acknowledge its limitations. 
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This study was ambitious and novel, requiring a lot of preliminary work in order to 
achieve the model in which the cellular responses to cigarette smoke, namely 
apoptosis and endothelial to mesenchymal transition, could be studied.  Thus one of 
the inherent weaknesses of this study is the small number of repeats and small 
numbers of donors studied.  Additionally, as discussed before, many of the 
experiments using “normal control” cells from healthy lung tissue use commercially 
available cells rather than cells isolated in the same manner from excess tissue 
obtained at lobectomy as planned.  This was an unavoidable compromise of this 
thesis as I had to focus efforts on experimental work using primary cells rather than 
concentrating efforts on tissue banking sufficient cells in order to conduct multiple 
repeats on “normal cells”.  I am however unable to determine the effect of the cell 
isolation on the results as I have not been able to study similarly isolated cells from 
normal lungs.  While this is a limitation of this study, it should be acknowledged and 
emphasised that the novelty of this study is the investigation of responses of 
vulnerable cells from diseased individuals to the stimulus which caused the disease 
i.e. the response of microvascular endothelial cells from patients with emphysema to 
injury with cigarette smoke extract.  Thus although interesting and an important 
comparator to study normal cells, the information gained in this study from the 
response of the diseased cells alone compared to untreated affords important 
information which must not be disregarded or underestimated.  The results obtained 
from the commercially available normal cells should now be supported with repeat 
studies in cells isolated from excess normal tissue using the same methodology as 
described in this thesis. 
 
Similarly the number of samples tested for each experiment (n=) is relatively small 
throughout this thesis and reflects the precious nature of the microvascular 
endothelial cells isolated and also the difficulties in dealing with primary cells which 
can have slowed growth kinetics, which may in part reflect the underlying pathology.  
Thus it was not always possible to conduct each experiment in triplicate or more.  
Although this is conventional methodology, repeating the experiment in triplicate only 
demonstrates the ability to pipette exactly and treat/injure cells in a consistent 
manner, thus as long as results are in agreement, duplicate rather than triplicate 
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experiments are acceptable.  What is actually required but seldom reported is 
stressing different cell populations i.e. different donors at the same time with the 
same injury/stress.  In reality however, the ability to have all primary cells at the 
same level of confluence and same passage ready to treat on the same day is 
almost impossible.  Therefore one has to accept the limitations of work with primary 
cells and accept that the information gained from such experiments, although not as 
stringent as using a stable cell line population, is more insightful and meaningful as 
the cells reflect the in vivo situation more accurately. 
 
One of the major limitations of this study is the use of cigarette smoking as an injury.  
Cigarette smoke extract itself is a rather rudimentary stimulus.  It differs markedly in 
a number of ways from the true injury that occurs in vivo.  Firstly cigarette smoking 
tends to be a chronic injurious stimulus rather than the acute injury that is reported in 
this thesis.  This in itself makes it a challenging subject to research.  Cigarette smoke 
extract is in the liquid phase as opposed to the gaseous phase that is cigarette 
smoking.  This is a standard model that has been used for over 30 years and was 
the most standard and controlled way in which I could study cigarette smoking injury.  
The live cell imaging on cells was the closest I was able to achieve in terms of 
studying injury over time, although this was essentially still an acute injury.  It is 
unsurprising that apoptosis was difficult to detect and measure as clearly if 
microvascular endothelial cells underwent apoptosis in significant numbers in 
response to cigarette smoke, this would cause a chemical pneumonitis and not 
emphysema.    Similarly for cells to undergo measurable endothelial to mesenchymal 
transition acutely in response to cigarette smoke would cause large amounts of 
mesenchyme deposition with gross organ dysfunction.  This is an inherent problem 
in the study of chronic disease and surrogate models such as this and acute injury 
must be utilized with results extrapolated.   
 
Another limitation is the variability between emphysema donors and their cellular 
responses.  All patients who donated their lung for research had by definition very 
severe emphysema and fulfilled the criteria for transplantation.  However despite 
having severe airflow limitation and of similar functional class, the macroscopic 
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appearance of their lung tissue at times was quite heterogeneous and similarly the 
number of cells isolated and their responses in vivo differed.  This is an inherent 
limitation of studying patients in the real world and although may lead to greater 
spread of results, this limitation is offset by the valuable results that such studies 
bring.  Thus one must look for signals from such experiments and accept variability 
amongst results.    
 
Finally the disease COPD itself provides problems and limitations for researchers.  
Emphysema is one part of the disease COPD.  Various phenotypes found between 
patients with some patients exhibiting severe airflow obstruction with dynamic 
hyperinflation, while others have predominant bronchitic features with goblet cell 
hypertrophy and mucus hypersecretion.  Yet another group of patients have features 
of bronchiectasis, with chronic distal airway enlargement, scarring, impaired innate 
defences with colonization with pathogens which further damage lung anatomy and 
in turn affect physiology.  The patients in this study all had severe COPD with 
emphysema as characterized by hyperinflation, gas trapping and reduced diffusing 
capacity on pulmonary function testing.  How this study relates to patients with 
COPD with predominant small airways disease is uncertain and also to patients with 
extensive smoking history yet milder COPD.  Thus this study also highlights the 
problem with COPD classification and may suggest the need for further 
subclassification in research and clinical trials. 
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7.4 Future directions 
 
This model must now be continued to be used for the investigation of microvascular 
mechanisms in emphysema.  Indeed the cell isolation technique may be able to be 
refined and improved as newer techniques and equipment become available.  This 
may allow cells at even lower passage to be used in experimental work with cells 
reflecting even more closely the environment from which they were isolated.   
 
For the apoptosis arm of the study, apoptosis should be further investigated using 
techniques which do not employ the use of fluorescence.  If such studies confirm 
apoptosis in response to CSE, the characteristic of cells resistant to apoptosis 
should then be investigated as this may identify protective mechanisms which they 
exhibit that could be exploited as a protective mechanism for therapeutic benefit. 
 
Endothelial activation in emphysema must also be further investigated with a focus 
on change in function of the endothelial cells, focusing on secretion of matrix 
proteins and production of matrix metalloproteinases which are thought to play an 
important role in the pathogenesis of COPD and emphysema. 
 
Finally, ex vivo lung perfusion of explanted lungs could be used to incorporate a 
smoking model, whereby the same equipment used to recondition the lungs which 
the transplant recipient receives could be used to model smoking injury to the 
severely damaged emphysematous lung.  This study would be worthwhile as this 
thesis has highlighted that active attempts at repair are ongoing even in the most 
severely damaged emphysematous lungs and that some areas of near normality are 
also witnessed.  This would therefore allow three dimensional study with 
appreciation for dynamic volume stress and shear stress changes associated with 
blood flow and would have the additional benefit that the cigarette smoke injury 
would be in the gaseous phase and so again would be a close mimic of the in vivo 
situation. 
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